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LNK TRANSGENIC PLANTS
FIELD OF THE INVENTION
[0001] The present invention relates to the field of plant molecular biology, more
particularly to methods of expressing nucleic acids in plants.
BACKGROUND OF THE INVENTION
[0002] Light signaling pathways and the circadian clock interact to help organisms
synchronize physiological and developmental processes with periodic
environmental cycles. In plants, t e interaction between light signaling pathways
and the circadian clock plays a critical role in the process of day-length
measurement, which contributes to adjust the floral transition to the most
appropriate season of the year. The ability to genetically manipulate flowering
time in order to optimize the timing of developmental processes in crop plants is
critical to maximize crop yield under different growing conditions and in different
geographic regions.
SUMMARY OF THE INVENTION
[0003] The inventors have found that LINK1 and LINK2, hereinafter referred to as
LNK1 and LNK2, represent a new family of light and clock regulated morning
genes that control both the pace of circadian rhythms and the photoperiodic
regulation of flowering time. The invention relates in part to manipulating the
expression of members of a novel plant specific gene family that plays a key role
regulating floral transition and biomass production. In some embodiments, the
invention relates to nucleic acids, expression cassettes, vectors and transgenic
plants containing nucleic acids corresponding to LINK, hereinafter referred to as
LNK genes (night-light inducible and clock regulated genes) such as, the
homologous LNK1 and LNK2 genes of A . thaliana and orthologs of these genes, as
well as fragments and variants of these nucleic acid sequences and functional RNA
corresponding to, or polypeptides encoded by, these nucleic acids. The invention
also relates to the introduction and/or manipulation of these nucleic acids in plants
to regulate plant growth and development and the transgenic plants generated
thereby.
[0004] Accordingly, in one embodiment, the invention provides an isolated LNK1
nucleic acid comprising a nucleotide sequence selected from the group consisting
of: (a) the nucleotide sequence of SEQ ID NO:l; (b) a nucleotide sequence
comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides
of the nucleotide sequence of SEQ ID NO:l or t e complementary strand thereof;
(c) a nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 1 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK1 amino acid
sequence of SEQ ID NO:2; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to the amino acid sequence of SEQ ID NO:2; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO:2; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a), (b), (c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In further embodiments, the nucleic acids are transcribed to express a
functional RNA. The invention also encompasses expression cassettes and vectors
comprising nucleic acids of the invention.
[0005] In an additional embodiment, the invention provides an isolated LNK2
nucleic acid comprising a nucleotide sequence selected from the group consisting
of: (a) the nucleotide sequence of SEQ ID NO: 3; (b) a nucleotide sequence
comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides
of the nucleotide sequence of SEQ ID NO:3 or the complementary strand thereof;
(c) a nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 3 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to t e amino acid sequence of SEQ ID NO:4; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
t e amino acid sequence of SEQ ID NO:4; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a), (b), (c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In further embodiments, the nucleic acids are transcribed to express a
functional RNA. The invention also encompasses expression cassettes and vectors
comprising nucleic acids of the invention.
In additional embodiments, the invention provides a vector or expression
cassette comprising a LNK promoter sequence operably associated with a
nucleotide sequence of interest. In some embodiments the LNK1 promoter
sequence is a nucleotide sequence selected from the group consisting of: (a) the
nucleotide sequence of SEQ ID NO: 7; (b) a nucleotide sequence comprising at
least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 7 or the complementary strand thereof; (c) a
nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 7 or the complementary strand thereof; (d) a
nucleotide sequence comprising nucleotides 1 to 50, 50 to 100, 100 to 150, 150 to
200, 200 to 250; 250 to 300, 300 to 350, 350 to 400, 400 to 450, 450 to 500, 500 to
550; 550 to 600, 600 to 650, 650 to 700, 700 to 750, 750 to 800, 800 to 850; 850 to
900, 900 to 950, or 950 to 1000 the nucleotide sequence of SEQ ID NO: 7 or the
complementary strand thereof; (e) a nucleotide sequence having at least 95%
sequence identity to the nucleotide sequence of (a) - (c) or (d); (f) a nucleotide
sequence that hybridizes to the complete complement of t e nucleotide sequence
of (a) - (c) or (d) under stringent hybridization conditions. In some embodiments,
the nucleotide sequence of interest is in sense orientation relative to the promoter.
In alternative embodiments, the nucleotide sequence of interest is in antisense
orientation relative to the promoter. In further embodiments, the nucleotide
sequence of interest is transcribed to form a functional RNA. In particular
embodiments, the functional RNA is a LNK1 RNA antagonist.
In other embodiments the he invention provides a vector or expression
cassette comprising a LNK2 promoter sequence operably associated with a
nucleotide sequence of interest wherein the LNK2 promoter sequence is a
nucleotide sequence selected from the group consisting of: (a) the nucleotide
sequence of SEQ ID NO: 12; (b) a nucleotide sequence comprising at least 10, 15,
20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides of the nucleotide sequence
of SEQ ID NO: 12 or the complementary strand thereof; (c) a nucleotide sequence
comprising at least 100 consecutive nucleotides of the nucleotide sequence of SEQ
ID NO: 12 or the complementary strand thereof; (d) a nucleotide sequence
comprising nucleotides 1 to 50, 50 to 100, 100 to 150, 150 to 200, 200 to 250; 250
to 300, 300 to 350, 350 to 400, 400 to 450, 450 to 500, 500 to 550; 550 to 600, 600
to 650, 650 to 700, 700 to 750, 750 to 800, 800 to 850; 850 to 900, 900 to 950, or
950 to 1000 the nucleotide sequence of SEQ ID NO: 12 or the complementary
strand thereof; (e) a nucleotide sequence having at least 95% sequence identity to
the nucleotide sequence of (a) - (c) or (d); (f) a nucleotide sequence that hybridizes
to the complete complement of the nucleotide sequence of (a) - (c) or (d) under
stringent hybridization conditions. In some embodiments, the nucleotide sequence
of interest is in sense orientation relative to the promoter. In alternative
embodiments, the nucleotide sequence of interest is in antisense orientation
relative to the promoter. In further embodiments, nucleotide sequence of interest
is transcribed to form a functional RNA. In particular embodiments, the functional
RNA is a LNK RNA antagonist (e.g., a LNK1 and/or LNK2 antagonist).
[0008] The invention additionally encompasses transgenic plants containing LNK
nucleic acids of the invention. In one embodiment, t e invention provides a
transgenic plant stably transformed with an isolated nucleic acid comprising a
LNK1 nucleotide sequence selected from the group consisting of: (a) the
nucleotide sequence of SEQ ID NO: l ; (b) a nucleotide sequence comprising at
least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 1 or the complementary strand thereof; (c) a
nucleotide sequence comprising at least 100 consecutive nucleotides of t e
nucleotide sequence of SEQ ID NO: 1 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK1 amino acid
sequence of SEQ ID NO:2; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to the amino acid sequence of SEQ ID NO:2; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO:2; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a)-(c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In further embodiments, the nucleic acids are transcribed to express a
functional RNA. The invention also encompasses expression cassettes and vectors
comprising nucleic acids of the invention.
[0009] In one embodiment, the invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK1 polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNK1 amino acid
sequence of SEQ ID NO:2; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO:2; and (c) an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of the amino acid sequence of SEQ ID NO:2.
[0010] In additional embodiments, t e invention provides a transgenic plant stably
transformed with an isolated LNK2 nucleic acid comprising a nucleotide sequence
selected from the group consisting of: (a) the nucleotide sequence of SEQ ID
NO:3; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45,
50 or 75 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:3 or
the complementary strand thereof; (c) a nucleotide sequence comprising at least
100 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:3 or the
complementary strand thereof; (d) a nucleotide sequence encoding a polypeptide
comprising the LNK2 amino acid sequence of SEQ ID NO:4; (e) a nucleotide
sequence encoding an amino acid sequence that is at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of
SEQ ID NO: 4; (f) a nucleotide sequence encoding an amino acid sequence
comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or
more contiguous amino acid residues of the amino acid sequence of SEQ ID NO:4;
(g) a nucleotide sequence having at least 95% sequence identity to the nucleotide
sequence of (a)-(e) or (f); (h) a nucleotide sequence that hybridizes to the complete
complement of the nucleotide sequence of (a)-(c) or (d) under stringent
hybridization conditions; and (i) a nucleotide sequence that differs from the
nucleotide sequence of any of (a), (c), (d) or (e) due to the degeneracy of the
genetic code. In a further embodiment, the nucleic acids are operably associated
with a promoter. In some embodiments, the nucleic acids are in sense orientation
relative to the promoter. In alternative embodiments, the nucleic acids are in
antisense orientation relative to the promoter.
[0011] In one embodiment, the invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK2 polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO:4; and (c) an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of the amino acid sequence of SEQ ID NO:4.
[0012] The invention also encompasses a transgenic plant stably transformed with
both an isolated LNK1 and LNK2 nucleic acid of the invention.
[0013] In additional embodiments, t e invention provides a transgenic plant stably
transformed with a vector or expression cassette comprising a LNK promoter
sequence operably associated with a nucleotide sequence of interest. In some
embodiments the LNK1 promoter sequence is a nucleotide sequence selected from
t e group consisting of: (a) the nucleotide sequence of SEQ ID NO: 7; (b) a
nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75
consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 7 or the
complementary strand thereof; (c) a nucleotide sequence comprising at least 100
consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 7 or the
complementary strand thereof; (d) a nucleotide sequence having at least 95%
sequence identity to the nucleotide sequence of (a), (b) or (c); (d) a nucleotide
sequence that hybridizes to the complete complement of the nucleotide sequence
of (a), (b) or (c) under stringent hybridization conditions. In some embodiments,
the nucleotide sequence of interest is in sense orientation relative to the promoter.
In alternative embodiments, the nucleotide sequence of interest is in antisense
orientation relative to the promoter.
[0014] In other embodiments the LNK2 promoter sequence is a nucleotide
sequence selected from the group consisting of: (a) the nucleotide sequence of
SEQ ID NO: 12; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30,
35, 40, 45, 50 or 75 consecutive nucleotides of the nucleotide sequence of SEQ ID
NO: 12 or the complementary strand thereof; (c) a nucleotide sequence comprising
at least 100 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 12
or the complementary strand thereof; (d) a nucleotide sequence having at least
95% sequence identity to the nucleotide sequence of (a), (b) or (c); (d) a nucleotide
sequence that hybridizes to the complete complement of the nucleotide sequence
of (a), (b) or (c) under stringent hybridization conditions. In some embodiments,
the nucleotide sequence of interest is in sense orientation relative to the promoter.
In alternative embodiments, the nucleotide sequence of interest is in antisense
orientation relative to t e promoter.
[0015] In representative embodiments, t e transgenic plants of the invention
display altered growth and/or development compared to a wild-type control plant
grown under the same conditions. In some embodiments, the transgenic plants
display increased vegetative growth and/or biomass compared to wild-type control
plants. In additional embodiments, the transgenic plants produce biomass for a
longer period of time than wild-type control plants. In the case of seed plants, in
some embodiments, the transgenic plants display delayed flowering compared to
wild-type plants. In additional embodiments, the transgenic plants of the invention
have larger seed yield than wild-type plants. In further embodiments, the
transgenic plants of the invention have an increased tolerance to abiotic stress (e.g.,
high intensity light, low intensity light, drought (dehydration), high or low
temperature and/or salinity (e.g., salt) compared to a wild-type plant grown under
the same conditions.
[0016] In alternative embodiments, transgenic plants of the invention display
decreased vegetative growth and/or biomass compared to wild-type plants. In the
case of seed plants, in some embodiments, the transgenic plants display shortened
(i. e ., accelerated) flowering time compared to wild-type plants.
[0017] In some embodiments, the invention provides a method of modulating a
circadian response of a plant, the method comprising stably transforming a plant
cell with a LNK nucleic acid. One embodiment provides a method of modulating a
circadian response of a plan comprising, stably transforming a plant cell with a
LNK1 nucleic acid comprising a nucleotide sequence selected from the group
consisting of: (a) the nucleotide sequence of SEQ ID NO: l ; (b) a nucleotide
sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: l or the complementary
strand thereof; (c) a nucleotide sequence comprising at least 100 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: l or the complementary
strand thereof; (d) a nucleotide sequence encoding a polypeptide comprising the
LNK1 amino acid sequence of SEQ ID NO:2; (e) a nucleotide sequence encoding
an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:2; (f)
a nucleotide sequence encoding an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of t e amino acid sequence of SEQ ID NO: 2; (g) a nucleotide
sequence having at least 95% sequence identity to the nucleotide sequence of (a)-
(e) or (f); (h) a nucleotide sequence that hybridizes to t e complete complement of
the nucleotide sequence of (a)-(c) or (d) under stringent hybridization conditions;
and (i) a nucleotide sequence that differs from the nucleotide sequence of any of
(a), (c), (d) or (e) due to the degeneracy of the genetic code. In a further
embodiment, the nucleic acids are operably associated with a promoter. In some
embodiments, the nucleic acids are in sense orientation relative to the promoter. In
alternative embodiments, the nucleic acids are in antisense orientation relative to
the promoter. In additional embodiments, the method further comprises the steps
of (i) regenerating a stably transformed plant from the stably transformed plant
cell; and (ii) expressing the nucleotide sequence in the plant.
[0018] In some embodiments, the invention provides a method of modulating a
circadian response of a plant, comprising stably transforming a plant cell with for
example, a nucleic acid encoding a LNK1 polypeptide selected from the group
consisting of: (a) a polypeptide comprising the LNK1 amino acid sequence of SEQ
ID NO:2; (b) an amino acid sequence that is at least about 70%, 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ
ID NO:2; and (c) an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO:2. In a further embodiment, the nucleic
acids are operably associated with a promoter. In some embodiments, the nucleic
acids are in sense orientation relative to the promoter. In alternative embodiments,
the nucleic acids are in antisense orientation relative to the promoter. In additional
embodiments, the method further comprises the steps of (i) regenerating a stably
transformed plant from the stably transformed plant cell; and (ii) expressing the
nucleotide sequence in the plant.
[0019] In another embodiment, the invention provides a method of modulating a
circadian response of a plant, comprising stably transforming a plant cell with a
LNK2 nucleic acid comprising a nucleotide sequence selected from the group
consisting of: (a) the nucleotide sequence of SEQ ID NO: 3; (b) a nucleotide
sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (c) a nucleotide sequence comprising at least 100 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (d) a nucleotide sequence encoding a polypeptide comprising the
LNK2 amino acid sequence of SEQ ID NO:4; (e) a nucleotide sequence encoding
an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:4; (f)
a nucleotide sequence encoding an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of t e amino acid sequence of SEQ ID NO: 4; (g) a nucleotide
sequence having at least 95% sequence identity to the nucleotide sequence of (a)-
(e) or (f); (h) a nucleotide sequence that hybridizes to t e complete complement of
the nucleotide sequence of (a)-(c) or (d) under stringent hybridization conditions;
and (i) a nucleotide sequence that differs from the nucleotide sequence of any of
(a), (c), (d) or (e) due to the degeneracy of the genetic code. In a further
embodiment, the nucleic acids are operably associated with a promoter. In some
embodiments, the nucleic acids are in sense orientation relative to the promoter. In
alternative embodiments, the nucleic acids are in antisense orientation relative to
the promoter. In additional embodiments, the method further comprises the steps
of (i) regenerating a stably transformed plant from the stably transformed plant
cell; and (ii) expressing the nucleotide sequence in the plant.
In an additional embodiment, the invention provides a method of
modulating a circadian response of a plant, comprising stably transforming a plant
cell with for example, a nucleic acid encoding a LNK2 polypeptide selected from
the group consisting of: (a) a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO:4; and (c) an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of the amino acid sequence of SEQ ID NO:4. In further
embodiments, the nucleic acids are operably associated with a promoter. In some
embodiments, t e nucleic acids are in sense orientation relative to the promoter. In
alternative embodiments, the nucleic acids are in antisense orientation relative to
t e promoter. In additional embodiments, the method further comprises the steps
of (i) regenerating a stably transformed plant from the stably transformed plant
cell; and (ii) expressing the nucleotide sequence in the plant.
[0021] In an additional embodiment, the invention provides a method of
modulating a circadian response of a plant, comprising stably transforming a plant
cell with both a LNKl and LNK2 nucleic acid of the invention.
[0022] In additional embodiments, the invention provides a method of modulating
the flowering time of a plant comprising, stably transforming a plant cell with a
LNK nucleic acid. In additional embodiments, the invention provides a method of
modulating the flowering time of a plant comprising, stably transforming a plant
cell with a LNKl and/or LNK2 nucleic acid of the of the invention such as, a
nucleic acid described above or elsewhere herein. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In further embodiments, the method further comprises the steps of (i)
regenerating a stably transformed plant from the stably transformed plant cell; and
(ii) expressing the nucleotide sequence in the plant. In some embodiments, the
method produces a transgenic plant in which the flowering time of the plant is
accelerated. In other embodiments, the method produces a transgenic plant in
which the flowering time of the plant is delayed.
[0023] In additional embodiments, the invention provides a method of modulating
the biomass of a plant, the method comprising stably transforming a plant cell with
a LNK nucleic acid. In some embodiments, the invention provides a method of
modulating the biomass of a plant, the method comprising stably transforming a
plant cell with a LNKl and/or LNK2 nucleic acid of the of the invention such as, a
nucleic acid described above or elsewhere herein. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to t e promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to t e
promoter. In further embodiments, the method further comprises the steps of (i)
regenerating a stably transformed plant from the stably transformed plant cell; and
(ii) expressing the nucleotide sequence in the plant. In some embodiments, the
method produces a transgenic plant in which the biomass of the plant is increased.
In other embodiments, the method produces a transgenic plant in which the
biomass of the plant is decreased.
[0024] In some embodiments, the invention provides a method of increasing yield
of a plant comprising, stably transforming a plant cell with a LNK1 and/or LNK2
nucleic acid of the invention such as, a nucleic acid described above or elsewhere
herein. In a further embodiment, the nucleic acids are operably associated with a
promoter. In some embodiments, the nucleic acids are in sense orientation relative
to the promoter. In alternative embodiments, the nucleic acids are in antisense
orientation relative to the promoter. In further embodiments, the method further
comprises the steps of (i) regenerating a stably transformed plant from the stably
transformed plant cell; and (ii) expressing the nucleotide sequence in the plant. In
some embodiments, the method produces a transgenic plant in which the biomass
of the plant is increased. In other embodiments, the method produces a transgenic
plant in which the biomass of the plant is decreased.
[0025] In additional embodiments, the invention provides a method of increasing
yield of a plant comprising, stably transforming a plant cell with a LNK nucleic
acid. In particular embodiments, the invention provides a method of increasing
yield of a plant comprising, stably transforming a plant cell with a LNK1 nucleic
acid comprising a nucleotide sequence selected from the group consisting of: (a)
the nucleotide sequence of SEQ ID NO: 1; (b) a nucleotide sequence comprising at
least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 1 or the complementary strand thereof; (c) a
nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 1 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK1 amino acid
sequence of SEQ ID NO:2; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to t e amino acid sequence of SEQ ID NO:2; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
t e amino acid sequence of SEQ ID NO:2; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a)-(c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In additional embodiments, the method further comprises the steps of (i)
regenerating a stably transformed plant from the stably transformed plant cell; and
(ii) expressing the nucleotide sequence in the plant.
In other embodiments, the invention provides a method of increasing yield
of a plant comprising, stably transforming a plant cell with a LNK2 nucleic acid
comprising a nucleotide sequence selected from the group consisting of: (a) the
nucleotide sequence of SEQ ID NO: 3; (b) a nucleotide sequence comprising at
least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 3 or the complementary strand thereof; (c) a
nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 3 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to the amino acid sequence of SEQ ID NO:4; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO:4; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of t e nucleotide
sequence of (a)-(c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In additional embodiments, the method further comprises the steps of (i)
regenerating a stably transformed plant from the stably transformed plant cell; and
(ii) expressing the nucleotide sequence in the plant.
[0027] In additional embodiments, the invention provides a method of increasing
tolerance of a plant to an abiotic stress, the method comprising: stably
transforming a plant cell with a LNK nucleic acid. In some embodiments, the
invention provides a method of increasing tolerance of a plant to an abiotic stress,
the method comprising: stably transforming a plant cell with a LNK1 and/or LNK2
nucleic acid of the invention such as, a nucleic acid described above or elsewhere
herein. In a further embodiment, the nucleic acids are operably associated with a
promoter. In some embodiments, the nucleic acids are in sense orientation relative
to the promoter. In alternative embodiments, the nucleic acids are in antisense
orientation relative to the promoter. In further embodiments, the method further
comprises the steps of (i) regenerating a stably transformed plant from the stably
transformed plant cell; and (ii) expressing the nucleotide sequence in the plant. In
particular embodiments, the abiotic stress is a member selected from: high
intensity light, low intensity light, drought (dehydration), high temperature, low
temperature and high salinity (salt). In some embodiments, the method of the
invention is applied to increase tolerance of a plant to a severe abiotic stress. In
some embodiments, the method of the invention is applied to increase tolerance of
a plant to a mild abiotic stress.
[0028] In additional embodiments, the invention encompasses a method of
increasing the yield and/or tolerance of a plant to an abiotic stress comprising:
stably transforming a plant cell with a LNK nucleic acid. In some embodiments,
the invention provides a method of increasing the yield and/or tolerance of a plant
to an abiotic stress comprising: stably transforming a plant cell with a LNKl
and/or LNK2 nucleic acid of t e invention such as, a nucleic acid described above
or elsewhere herein. In further embodiments, the method further comprises t e
steps of (i) regenerating a stably transformed plant from the stably transformed
plant cell; and (ii) expressing the nucleotide sequence in the plant.
[0029] The invention also provided are expression cassettes, vectors, cells, plants
and plant parts comprising the isolated nucleic acids of the invention operably
associated with a LNK nucleotide sequence.
[0030] In some embodiments, the invention encompasses a vector or expression
cassette comprising an isolated LNK polynucleotide. In some embodiments, the
invention encompasses a vector or expression cassette comprising a LNKl and/or
LNK2 polynucleotide sequence of the invention operably associated with a
promoter sequence. In some embodiments the expression cassette contains a
sequence that encodes a selectable marker. Cells, plants and plant parts
transformed with these nucleic acids, vectors, and expression cassettes are also
encompassed by the invention. In particular embodiments, the transformed (i.e.,
transgenic) plants are monocots. In other embodiments, the transformed plants are
dicots. In particular embodiments, the cells, plants and/or plant parts correspond to
sunflower, wheat, maize, soybean, rice, alfalfa or Arabidopsis .
[0031] In further embodiments, the invention encompasses a vector or expression
cassette comprising an isolated LNK promoter sequence. In some embodiments,
the invention encompasses a vector or expression cassette comprising a LNKl
and/or LNK2 promoter sequence operably associated with a nucleotide sequence
of interest. In some embodiments, the nucleotide sequence of interest encodes a
protein. In further embodiments, the protein encoded by the polynucleotides
sequence of interest is a LNK polypeptide, such as LNKl or LNK2 or a
biologically active fragment or variant thereof. In other embodiments, the
nucleotide sequence of interest encodes a protein. In some embodiments the
expression cassette contains a polynucleotide sequence that is transcribed to form a
functional RNA. In particular embodiments, the functional RNA is an antagonist
of LNK, such as, an antagonist of LNKl or LNK2 expression. In some
embodiments the expression cassette contains a sequence that encodes a selectable
marker. Cells, plants and plant parts transformed with these nucleic acids, vectors,
and expression cassettes are also encompassed by the invention. In particular
embodiments, the transformed (i.e., transgenic) plants are monocots. In other
embodiments, t e transformed plants are dicots. In particular embodiments, t e
cells, plants and/or plant parts correspond to sunflower, wheat, maize, soybean,
rice, alfalfa or Arabidopsis .
[0032] As an additional aspect, the invention also encompasses products harvested
from the transgenic plants of the invention and processed products produced
therefrom.
[0033] The invention also provides seed produced from the plants of the invention
and seed comprising the isolated nucleic acids, vectors and expression cassettes of
the invention.
[0034] In further embodiments, the invention provides a method of introducing a
nucleic acid into a plant, plant part or plant cell, the method comprising
transforming the plant, plant part or plant cell with an isolated nucleic acid,
expression cassette or vector of the invention.
[0035] In additional embodiments, the invention encompasses a method of
expressing a nucleotide sequence of interest in a plant, the method comprising: (a)
stably transforming a plant cell with an expression cassette or vector of the
invention; (b) regenerating a stably transformed plant from the stably transformed
plant cell of (a); and (c) expressing the nucleotide sequence of interest in the plant.
In some embodiments, the nucleotide sequence is a LNK protein coding sequence.
In further embodiments, the nucleotide sequence of interest encodes LNK1, LNK2,
or a biologically active fragment thereof. In other embodiments, the nucleotide
sequence of interest is transcribed to form a functional RNA. In further
embodiments, the functional RNA is a LNK1 and/or LNK2 antagonist.
[0036] These and other aspects of the invention are set forth in more detail in the
description of the invention below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1. Describes the genomic approach used to characterize light and
clock interactions in the control of gene expression, which resulted in the
identification of LNK genes. (A) Experimental design. Plants were grown under
12h light/ 1 dark cycles for 14 days and then exposed or not to a lh light pulse in
t e middle of the night or subjective day on the 15th day. (B) Comparative genome-
wide expression analysis of t e effect of a light pulse given during subjective day
time (x-axis) vs night-time (y-axis). (C) Overlap between 87 genes that are
rhythmically expressed under multiple conditions, and 65 genes that showed a
stronger induction by light during night-time compared to subjective day-time. (D)
Microarray data corresponding to the relative response of LNK genes to a lh light
treatment given in the middle of the night or subjective day. (E) Relative
expression levels of LNKl and LNK2 measured by qRT-PCR. The analysis was
conducted in wild-type, phyAphyB and crycry2 plants grown under 12h light/12h
dark cycles and exposed or not to a lh light pulse in the middle of the night (n=3).
(nd= not detectable). Data represent average ± SEM. (F) Circadian expression of
LNKl and LNK2 genes. Expression was determined by qRT-PCR during the 2nd
and 3rd day under free running conditions. n=4. Data are average ± SEM.
[0038] Figure 2 . LNKl and LNK2 control hypocotyl elongation, photoperiodic
dependent flowering and circadian rhythms. (A) Hypocotyl length of wild-type
(WT), linkl, link2 and linkllink2 mutant seedlings grown under continuous white
light (LL) (n=6 replicates of 10 seedlings each). (B) Unkllink2 control the floral
transition in plants grown under long day (LD, 16h light/8h dark) conditions. (C
and D) Flowering time measured as the number of rosette leaves at bolting in LD
(C) and short day (D) conditions (SD, 8h light/ 16h dark). ANOVA followed by a
Tukey ' s multiple comparison test was used to evaluate the statistical significance
of differences observed between genotypes. Error bars indicate +SEM (***Ρ<0.001,
*P<0.05). (E and FD) Circadian rhythms of leaf movement in continuous light
(n=7). Plants were grown under LD cycles and then transferred to constant light
and temperature conditions. Error bars indicate + SEM. Open and lined boxes
indicate light and subjective night period, respectively.
[0039] Figure 3 . LNKl, a nuclear protein, positively regulates expression of
circadian genes with an afternoon phase. (A) LNKLYFP detection by confocal
microscopy in N . benthamiana leaves transiently expressing 35S:LNK1:YFP.
Arrowheads indicate nuclei expressing YFP. Scale bar= 50µ ι. (B) Phase
enrichment of circadian-regulated genes whose expression was down- or up-
regulated in linkl ;link2 mutant compared to WT plants, according to RNA-seq
data of plants grown under continuous light conditions. The phase over-
representation analysis was conducted with Phaser (http://phaser.mocklerlab.org/),
and was based on the phases of gene expression estimated from data obtained
using WT plants grown under LD conditions. Dashed line corresponds to p=0.01.
(C) Average normalized expression of 36 genes from the cluster with t e largest
number of genes whose expression was altered in linkl :link2 mutants compared to
WT plants grown under LD conditions. Normalized expression of FKF1 (D),
PRR5 (E) and ELF4 (F), three genes present in the cluster shown in (C). (C-F)
Plants grown under LD cycles were sampled every four hours, starting 2h after
lights on. n=3, Error bars indicate + SEM.
[0040] Figure 4 . LNK1 and LNK2 are necessary for the proper function of the
circadian clock. CCA1 (A), LHY (B), PRR9 (C), PRR7 (D), PRR5 (E) and TOC1
(F) mRNA expression measured by qRT-PCR in plants grown under 12h light/ 1
dark cycles and then transferred to continuous light. Values are expressed relative
to PP2A and normalized to the maximum value of each gene. Data represent
average + SEM (n=4). Open and lined boxes indicate subjective day and subjective
night periods, respectively.
[0041] Figure 5 . LNK1 and LNK2 are repressed by the TOC1/PRR1 family of
circadian clock components. (A-D) LNK1 (A and C) and LNK2 (B and D)
expression measured by qRT-PCR in continuous light relative to PP2A (n=4).
under 12h light/12h dark cycles and then transferred to continuous light. Error bars
indicate + SEM. Open and lined boxes indicate subjective day and subjective
night, respectively. (E) Model showing the proposed function of LNK1 and LNK2
in the circadian clock. Light regulates LNK1 and LNK2 expression in the morning,
which then act to promote, directly or indirectly, the expression of a subset of
afternoon genes, including the core clock gene PRR5. During the afternoon and
early evening, PRR9, PRR7, PRR5 and TOC1 bind to the LNK promoters
blocking their expression.
[0042] Figure 6 . Sequence alignment of LNK1 homologs in Arabidopsis thaliana.
The length of the sequence aligned is shown, and degree of similarity between
amino acids is highlighted (darker shading represents higher similarity).
[0043] Figure 7 . Cladogram displaying LNK1 homologs in a broad range of
species from embryophyta group. Arabidopsis thaliana LNK1 has three paralogs.
Where multiple homologs were identified within a single species, t e annotated
gene model code is provided (if more than one transcript was identified, the one
with higher score during the BLASTP was selected). Rc, Ricinus communis; Pp,
Physcomitrella patens; Solyc, Solanum lycopersicum; Carubv, Capsella rubella;
Os, Oryza sativa; Cs, Cucumis sativus; Medtr, Medicago truncatula; Sb, Sorghum
bicolor. Percentage bootstrap values are presented for each node.
[0044] Figure 8 . Temporal patterns of LNK1 and LNK2 expression under different
conditions. (A) DD_DDHC, plants grown under temperature cycles (12h 22°C/12h
12°C) and continuous darkness, and then transferred to constant temperature
conditions. Measurements correspond to the first 24h under constant temperature
and dark conditions. (B) LL23 LDHH, plants grown under 12h light/ 12h dark
cycles at constant temperature and then transferred to constant light and
temperature conditions for three days. Measurements correspond to the 2nd and 3rd
days under constant conditions. (C) COL LDHH, plants grown and measured
under 12h light/ 1 dark cycles at 22°C. (D) COL_SD, plants grown and measured
under 8h light/ 16h dark cycles at 22°C. Data was obtained from Mockler, T. C , T.
P. Michael, et al., (2007). The Diurnal Project: Diurnal and Circadian Expression
Profiling, Model-based Pattern Matching, and Promoter Analysis. Cold Spring
Harbor Symposia on Quantitative Biology 72:353-363.
[0045] Figure 9 . LNK1 and LNK2 expression in different mutant backgrounds. (A)
Scheme of LNK1 and LNK2 showing t e site of T-DNA insertions in the different
mutant alleles. (B) All mutant alleles have null expression of the full length
mRNA, evaluated using primers flanking the T-DNA insertion. Expression
upstream the T-DNA insertion was detectable in some alleles (data not shown).
Plants were grown in soil for 3 weeks in continuous light conditions. Samples
harvested were processed until cDNA synthesis. Transcript presence was
determined by PCR.
[0046] Figure 10. Hypocotyl length phenotypes in different linkl and Unk2 mutant
lines. Plants were grown for 4 days under different light conditions. (A) DD:
Continuous darkness. (B) LD: Long Day (C) LL: Continuous light. (D) SD: Short
Day. (E) Be: Continuous Blue light. (F) Rc: Continuous Red light. Hypocotyl
length under different light conditions is expressed relative to the hypocotyl length
of each genotype under continuous darkness. ANOVA followed by a Tukey ' s
multiple comparison test was used to evaluate statistical significance between
genotypes. Error bars indicate +SEM ("><0.001, **P<0.01, ><0.05).
[0047] Figure 11. Circadian rhythms of leaf movement in additional mutant alleles
of LNK1 and LNK2. (A and B) Circadian rhythm of leaf movement in continuous
light (n=6). Plants were grown in 16h light/8h dark cycles. Error bars indicate
+SEM. Open and lined boxes indicate light and subjective night period,
respectively.
[0048] Figure 12. Set of clusters obtained by high throughput sequencing. (A-I)
Clusters of genes with similar expression patterns detected using a correlation
based distance metric and a hierarchical clustering procedure followed by a hybrid
adaptive dendrogram cut step. Data sets represent the average of normalized
expression level for all genes within each cluster. Number of genes in each cluster
is indicated between parentheses. Plants were grown and harvested in 16h light/8h
dark cycles. Clusters obtained for genes down-regulated (A-E) or up-regulated (G-
I) in linkl ;link2 mutant. (F) Cluster formed by genes with a significant alteration in
the temporal pattern of expression but without significant differences in expression
levels between WT and linkl ;link2.
[0049] Figure 13. Expression levels of flowering time genes in WT and linkl ;link2
mutant plants: (A) FT, (B) SOC1. Plants were grown and harvested under 16h
light/8h dark cycles and data was obtained by high throughput RNA-sequencing.
CPM: Counts per Million.
[0050] Figure 14. Expression of CCA1 in the Unk2 mutant. CCA1 expression
levels are 4h delayed in Hnk2 mutant plants. mRNA expression measured by qRT-
PCR in plants grown under 12h light/12h dark cycles and transferred to LL
conditions. Values are expressed relative to PP2A and normalized to the maximum
value of each gene. Data represent average + SEM (n=4). Open and lined boxes
indicate light and subjective night period, respectively.
[0051] Figure 15. Phylogenetic tree for t e AtLNK genes, homolog genes in rice
{Oryza sativa) and orthologs in sorghum {Sorghum bicolor) and soy {Glycine max)
showing the evolutionary relationships for these taxa. The evolutionary history was
inferred using t e Neighbor-Joining method. In the bootstrap consensus tree
inferred from 1000 replicates, representing the evolutionary history of the taxa
analyzed, those branches corresponding to partitions reproduced in less than 50%
bootstrap replicates are collapsed. The evolutionary distances were computed
using the Poisson correction method and are in the units of the number of amino
acid substitutions per site. The rate variation among sites was modeled with a
gamma distribution (shape parameter = 0.05). The analysis involved 23 amino acid
sequences. All ambiguous positions were removed for each sequence pair. There
were a total of 1028 positions in the final dataset. Evolutionary analyses were
conducted in MEGA6.
[0052] Figure 16. Comparison of LNK gene regulation and function in rice and
Arabidopsis. Expression of OsUBQ, OsLNKl, OsLNK2 and OsLNK3 was
measured by qRT-PCR.
[0053] Figure 17. Molecular function of OsLNK2 in the control of the circadian
clock and in the regulation of flowering time in rice.
DETAILED DESCRIPTION OF THE INVENTION
[0054] The present invention is based, in part, on the discovery that LNK1 and/or
LNK2 represent of new family of light and clock regulated morning genes that
control both the pace of circadian rhythms and the photoperiodic regulation of
flowering time. The present invention will now be described in more detail with
reference to the accompanying examples and drawings in which certain
embodiments of the invention are shown. This invention may, however, be
embodied in different forms and should not be construed as limited to the
embodiments set forth herein. Rather, these embodiments are provided so that this
disclosure will be thorough and complete, and will fully convey the scope of the
invention to those skilled in the art.
[0055] Unless the context indicates otherwise, it is specifically intended that t e
various features of the invention described herein can be used in any combination.
[0056] Moreover, the present invention also contemplates that in some
embodiments of the invention, any feature or combination of features set forth
herein can be excluded or omitted. To illustrate, if the specification states that a
composition comprises components A, B and C, it is specifically intended that any
of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or
in any combination.
[0057] Unless otherwise defined, all technical and scientific terms used herein
have the same meaning as commonly understood by one of ordinary skill in the art
to which this invention belongs. The terminology used in the description herein is
for the purpose of describing particular embodiments only and is not intended to be
limiting of the invention.
[0058] All publications, patent applications, patents, and other references
mentioned herein are incorporated by reference in their entirety.
I . Definitions.
[0059] As used in the description of the invention and the appended claims, the
singular forms "a," "an" and "the" are intended to include the plural forms as well,
unless the context clearly indicates otherwise.
[0060] As used herein, "and/or" refers to and encompasses any and all possible
combinations of one or more of the associated listed items, as well as the lack of
combinations when interpreted in the alternative ("or").
[0061] The term "about," as used herein when referring to a measurable value such
as a dosage or time period and the like, is meant to encompass variations of ± 20%,
± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0 .1% of the specified amount.
[0062] The terms "comprise," "comprises" and "comprising" as used herein,
specify the presence of the stated features, integers, steps, operations, elements,
and/or components, but do not preclude the presence or addition of one or more
other features, integers, steps, operations, elements, components, and/or groups
thereof.
[0063] As used herein, the transitional phrase "consisting essentially of means
that the scope of a claim is to be interpreted to encompass the specified materials
or steps recited in the claim "and those that do not materially affect t e basic and
novel characteristic(s)" of the claimed invention. See, In re Herz, 537 F.2d 549,
551-52, 190 U.S.P.Q. 461,463 (CCPA 1976); see also MPEP §2111.03. Thus, the
term "consisting essentially of when used in a claim or the description of this
invention is not intended to be interpreted to be equivalent to "comprising."
[0064] As used herein, "LINK" or "LNK", refers to a family of night-light
inducible and clock regulated genes (LNK genes) that play a key role in the control
of daily and seasonal rhythms in plants. Unless otherwise specified, it is
understood that the term "LNK" may refer to LNK family members in A . thaliana
(such as LNK1 e.g., AT5G64170, represented by SEQ ID NOs:l-2 and 5-6),
LNK2 {e.g., AT3G54500, represented by SEQ ID NOs:3, 4, and 8-11), LNK3
(e.g., AT3G12320, represented by SEQ ID NOs:13 and 14), LNK4 (e.g.,
AT5G06980, represented by SEQ ID NOs:15 and 16), but also members from
other night-light inducible and clock regulated genes in other plant species,
including fragments and/or variants of these members, that display one or more
biological activities of a LNK family member as described herein.
[0065] As used herein "LNK agonist" refers to a nucleic acid or polypeptide that,
increases, enhances or up regulates one or more LNK biological activities
(including phenotypes), such as, a LNK biological activity described herein. For
example, a LNK agonist may lead to plants having one or more accelerated
circadian responses in agonist treated plants than in WT plants, shorter hypocotyls
than WT plants under continuous white light or red light, earlier flowering (i.e.,
accelerated flowering) in agonist treated plants than WT plants under long days
(LD; 16 hr light/8 hr dark), shorter circadian rhythm leaf movement in agonist
treated plants than in WT plants, increased FKF1, FT and/or SOC1 expression in
agonist treated plants or plant cells compared to WT plants or plant cells, and
increased PRR5 expression in agonist treated plants compared to WT plants or
plant cells.
[0066] As used herein "LNK antagonist" refers to a nucleic acid or polypeptide
that, reduces, inhibits or down regulates one or more LNK biological activities
(including phenotypes), such as, a LNK biological activity described herein. For
example, a LNK antagonist may lead to plants having an one or more delayed
circadian responses in antagonist treated plants than in WT plants, longer
hypocotyls than WT plants under continuous white light or red light; later
flowering in antagonist treated plants than WT plants under long days (LD; 16 hr
light/8 hr dark); longer circadian rhythm leaf movement than in WT plants;
reduced FKF1 FT and/or SOC1 expression in antagonist treated plants or plant
cells compared to WT plants or plant cells, and reduced PRR5 expression in
antagonist treated plants compared to WT plants or plant cells.
[0067] A "circadian response" is a physiological and/or developmental plant
process influenced by circadian rhythms and/or photoperiodism in plants. In some
embodiments, the circadian response is selected from the group consisting of: gene
transcription, leaf movement, photosynthetic ability, stomatal opening, hypocotyl
elongation, and a photoperiodic response such as, the control of flowering.
[0068] The term "biomass" refers to the amount of a plant body or a part thereof.
The term encompasses substances, foods, materials, fuels, resources and t e like
derived from these plants or plant parts. Specifically, increased biomass may refer
to hypertrophy of a subterranean stem (rhizom, corm, tuber, bulb), a terrestrial
stem, a flowering stem or a vine, hypertrophy of a seed, acceleration of elongation
of stem length, plant length, culm length or ear length, or enlargement of a source
plant organ such as a leaf.
[0069] As used herein, a "long-day" plant is a plant that only flowers after having
received more than 12 hours of light.
[0070] As used herein, a "short-day" plant is a plant that only flowers after having
received less than 12 hours of light.
[0071] An "abiotic stress" is a stressor from one or more outside, non-living
factors that adversely affects the productivity and/or the survival of the organism.
Abiotic stressors include, but are not limited to: high light intensity, low light
intensity, ozone, heat or high temperature, cold temperature, drought
(dehydration), flooding stress (e.g., due to waterlogging and/or submergence),
stress following the removal of a flooding stressor (e.g., dehydration in the period
following removal of a flooding stress such as desubmergence stress), salt stress
(e.g., high or excessive salt conditions), high winds, fire, poor pH (too alkaline
and/or too acidic), soil compaction and/or high radiation. Those skilled in t e art
will appreciate that an abiotic stress will depend on the preferred conditions for
that organism, and may well vary due to the presence of other biotic and/or abiotic
stressors.
[0072] Parameters for abiotic stress factors are species specific and even variety
specific and therefore vary widely according to the species/variety exposed to the
abiotic stress. Thus, while one species may be severely impacted by a salinity level
of 4.0 dS m , another species may not be affected until at least a salinity level of
6.0 dS m or even 10.0 dS m . See, for example, Blaylock, A.D. ("Soil salinity,
salt tolerance, and growth potential of horticultural and landscape plants," Univ.
Wyoming, Cooperative Extension Service, Bulletin B-988, February 1994) in
which different plants are categorized as sensitive, moderately sensitive,
moderately tolerant and tolerant depending on the level of soil salinity required to
affect plant growth. Thus, for example, the level of salinity that is excessive or
high for a sensitive plant species or variety is not the same level of salinity that is
excessive or high for a moderately sensitive plant or a tolerant plant. The same is
true for other types of abiotic stress such as drought (dehydration), waterlogging
and submergence stress. Thus, a level of drought that can be tolerated by a
sensitive plant species/variety is different from the level of drought that can be
tolerated by a plant species/variety that is more drought tolerant. Likewise, the
level of flooding (e.g., at the roots and/or the aerial parts of the plant) that can be
tolerated by a sensitive plant species/variety is different from that for a plant that is
more tolerant to excessive water (e.g., wet roots and/or submergence).
[0073] "Severe" abiotic stress results in death in control plants (e.g., plants not
expressing an LNK polypeptide of the invention), for example, at least about 10%,
20%, 30%, 40%, 50% or even more control plants die, whereas the plants of the
invention (e.g., expressing a LNK polypeptide of the invention) exhibit an
increased survival.
[0074] "Mild" abiotic stress is defined herein as conditions in which control plants
do not die but their production is very low (e.g., reduced by at least about 30%,
40%, 50% or more), whereas the plants of the invention exhibit increased
production as compared with and/or are less severely affected, as compared with
control plants.
[0075] "Normal" growth conditions are conditions in which the plants are not
exposed to significant biotic, abiotic, toxicological or nutritional stress, e.g.,
conditions in which the plants are well irrigated and exposed to normal salt
conditions. In particular embodiments, "normal" growth conditions are conditions
in which plants are exposed to no detectable (e.g., measurable) biotic, abiotic,
toxicological or nutritional stress.
[0076] Thus, an "increased tolerance to abiotic stress" (and similar terms) as used
herein, refers to the ability of a plant or part thereof exposed to abiotic stress and
transformed with an isolated or recombinant nucleic acid of the invention (e.g.,
encoding an LNK polypeptide of the invention) to withstand a given abiotic stress
better than a control plant or part thereof (e.g., a plant or part thereof that has been
exposed to the same abiotic stress but has not been transformed with an isolated or
recombinant nucleic acid molecule of the invention). Increased tolerance to abiotic
stress can be measured using a variety of parameters including, but not limited to,
the size and/or number of plants or parts thereof (e.g., leaf number and/or size),
productivity or yield (e.g., of seed), relative water content, electrolyte leakage,
stomata conductance, photosynthetic rate, internal CO2 concentration, transpiration
rate, chlorophyll fluorescence. Thus, in some embodiments of the invention, a
transformed plant or part thereof comprising an isolated or recombinant nucleic
acid molecule of the invention, thereby having increased tolerance to the abiotic
stress, would have, for example, greater growth (e.g., plant height) and/or survival
and/or yield as compared with a plant or part thereof exposed to the same stress,
but not having been transformed with an isolated or recombinant nucleic acid
molecule of the invention.
[0077] An "increased yield" (and similar terms) as used herein refers to an
enhanced or elevated production of a commercially and/or agriculturally important
plant, plant biomass, plant part (e.g., roots, tubers, seed, leaves, fruit), plant
material (e.g., an extract) and/or other product produced by the plant (e.g., a
recombinant polypeptide) by a plant or part thereof transformed with a nucleic acid
of the invention (e.g., encoding an LNK polypeptide of the invention) as compared
with a control plant or part thereof (e.g., a plant or part thereof that has been
exposed to the same growth conditions, but has not been transformed with a
nucleic acid molecule of the invention).
[0078] The term "modulate" (and grammatical variations) refers to an increase or
decrease.
[0079] As used herein, the terms "increase," "increases," "increased," "increasing"
and similar terms indicate an elevation of at least about 15%, 20% 25%, 50%,
75%, 100%, 150%, 200%, 300%, 400%, 500% or more.
[0080] As used herein, the terms "reduce," "reduces," "reduced," "reduction" and
similar terms such as, "decrease," "decreases," "decreased" and "decreasing" mean
a decrease of at least about 15%, 20%, 25%, 35%, 50%, 75%, 80%, 85%, 90%,
95%, 97% or more. In particular embodiments, the reduction results in no or
essentially no (i.e., an insignificant amount, e.g., less than about 10% or even 5%)
detectable activity or amount.
[0081] "Wild-type" as used herein, refers to a plant cell, seed, plant component,
plant tissue, plant organ or whole plant that has not been genetically modified or
treated in an experimental sense. Wild-type cells, seed, components, tissue, organs
or whole plants may be used as controls to compare levels of expression and the
extent and nature of trait modification with cells, tissue or plants of the same
species in which a transcription factor expression is altered, e.g., in that it has been
knocked out, overexpressed, or ectopically expressed.
[0082] As used herein, the term "heterologous" means foreign, exogenous,
non-native and/or non-naturally occurring.
[0083] As used here, "homologous" means native. For example, a homologous
nucleotide sequence or amino acid sequence is a nucleotide sequence or amino
acid sequence naturally associated with a host cell into which it is introduced, a
homologous promoter sequence is the promoter sequence that is naturally
associated with a coding sequence, and the like.
[0084] As used herein a "chimeric nucleic acid," "chimeric nucleotide sequence"
or "chimeric polynucleotide" comprises a promoter operably linked to a nucleotide
sequence of interest that is heterologous to the promoter (or vice versa). In
particular embodiments, the "chimeric nucleic acid," "chimeric nucleotide
sequence" or "chimeric polynucleotide" comprises a LNK coding sequence
operably associated with a heterologous promoter. In other embodiments, the
"chimeric nucleic acid," "chimeric nucleotide sequence" or "chimeric
polynucleotide" comprises a LNK nucleic acid sequence that is transcribed to form
a functional RNA and that is operably associated with a heterologous promoter. In
further embodiments, the LNK nucleic acid sequence is operably associated with a
homologous LNK promoter sequence.
[0085] A "promoter" is a nucleotide sequence that controls or regulates t e
transcription of a nucleotide sequence (e.g., a coding sequence or functional RNA)
that is operatively associated with the promoter. The coding sequence may encode
a polypeptide and/or a functional RNA Typically, a "promoter" refers to a
nucleotide sequence that contains a binding site for RNA polymerase II and directs
the initiation of transcription. In general, promoters are found 5', or upstream,
relative to the start of the coding region of the corresponding coding sequence or
functional RNA. The promoter region may comprise other elements that act as
regulators of gene expression. These include a TATA box consensus sequence, and
often a CAAT box consensus sequence (Breathnach et al, Annu. Rev. Biochem.
50:349 (1981)). In plants, the CAAT box may be substituted by the AGGA box
(Messing et al., (1983) in Genetic Engineering of Plants, T. Kosuge, C . Meredith
and A . Hollaender (eds.), Plenum Press, pp. 211-227). The promoter region,
including all the ancillary regulatory elements, typically contain between about
100 and 1000 nucleotides, but can be as long as 2 kb, 3 kb, 4 kb or longer in
length. Promoters according to the present invention can function as constitutive
and/or inducible regulatory elements.
[0086] As used herein, the LNK promoter sequence is the region of nucleic acid
sequence upstream (5') of a LNK (e.g., LNK1 and LNK2) coding sequence that is
responsible for spatial and temporal regulation of LNK transcription. As disclosed
herein, LNK1 and LNK2 are induced by light and expressed rhythmically with
peak expression in the morning or at noon. Transcription is circadian regulated, but
with an RNA maximum that is "later" in the 24-hour period than that of other
known circadian genes, such as CCAI and LHY (Wang and Tobin, 1998; Schaffer
et al., 1998). LNK-like circadian rhythm or cyclic transcriptional regulation refers
to this type of a relatively delayed transcription maximum. Because LNK
transcription reaches a maximal level at a different time point in the 24-hour
period, the LNK promoter will allow for altering the setting of the circadian clock.
For instance, by operable linking a LNK1 or LNK2 promoter sequence with a
coding sequence corresponding to another circadian-regulated gene, the circadian
set on this heterologously expressed protein will altered toward that of t e
respective LNK1 or LNK2.
[0087] Sequences as short as 50 or 100 nucleotides from within the 5' regulatory
region of LNK may also be employed as promoter sequences according to the
invention. The degree to which such a sequence provides for LNK-like circadian
rhythm or cyclic transcriptional regulation, when included in an expression vector,
can be determined using techniques known in the art. Thus, the term "biologically
active LNK1 promoter" or a "biologically active LNK2 promoter" refers to a 5'
regulatory region of the respective LNK gene, or a part or a variant of such a
region, that, when operably linked to the 5' end of a coding sequence and
introduced into a plant, results in LNK-like circadian rhythm or cyclic transcript
expression of the protein encoded by the coding sequence (i.e. , in the morning or at
noon).
[0088] A "functional" RNA includes any untranslated RNA that has a biological
function in a cell, e.g., regulation of gene expression. Such functional RNAs
include, but are not limited to, siRNA, shRNA, miRNA, antisense RNA,
ribozymes, and the like. In some embodiments, functional RNAs are operably
linked to a promoter in antisense orientation relative to the promoter.
[0089] By "operably linked" or "operably associated" as used herein, it is meant
that the indicated elements are functionally related to each other, and are also
generally physically related. For example, a promoter is operatively linked or
operably associated to a coding sequence (e.g., nucleotide sequence of interest) if it
controls the transcription of the sequence. Thus, the term "operatively linked" or
"operably associated" as used herein, refers to nucleotide sequences on a single
nucleic acid molecule that are functionally associated. Those skilled in the art will
appreciate that the control sequences (e.g., promoter) need not be contiguous with
the coding sequence, as long as they function to direct the expression thereof.
Thus, for example, intervening untranslated, yet transcribed, sequences can be
present between a promoter and a coding sequence, and the promoter sequence can
still be considered "operably linked" to t e coding sequence.
[0090] A "heterologous nucleotide sequence" or "heterologous nucleotide
sequence of interest" as used herein is a coding sequence that is heterologous to the
LNK nucleotide sequence (i.e., is not the native LNK sequence). The heterologous
nucleotide sequence can encode a polypeptide or a functional RNA. A
"heterologous promoter" is a promoter that is heterologous to the nucleotide
sequence with which it is operatively associated. For example, according to the
present invention, the LNK coding sequence can be operatively associated with a
heterologous promoter (e.g., a promoter that is not the native LNK promoter
sequence with which the LNK coding sequence is associated in its naturally
occurring state).
[0091] By the term "express," "expressing" or "expression" (or other grammatical
variants) of a nucleic acid coding sequence, it is meant that the sequence is
transcribed. In particular embodiments, the terms "express," "expressing" or
"expression" (or other grammatical variants) can refer to both transcription and
translation to produce an encoded polypeptide.
[0092] "Wild-type" nucleotide sequence or amino acid sequence refers to a
naturally occurring ("native") or endogenous nucleotide sequence (including a
cDNA corresponding thereto) or amino acid sequence.
[0093] The terms "nucleic acid," "polynucleotide" and "nucleotide sequence" can
be used interchangeably herein unless the context indicates otherwise. These terms
encompass both RNA and DNA, including cDNA, genomic DNA, partially or
completely synthetic (e.g., chemically synthesized) RNA and DNA, and chimeras
of RNA and DI'JA. The nucleic acid, polynucleotide or nucleotide sequence may
be double-stranded or single-stranded, and further may be synthesized using
nucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides).
Such nucleotides can be used, for example, to prepare nucleic acids,
polynucleotides and nucleotide sequences that have altered base-pairing abilities or
increased resistance to nucleases. The present invention further provides a nucleic
acid, polynucleotide or nucleotide sequence that is the complement (which can be
either a full complement or a partial complement) of a nucleic acid, polynucleotide
or nucleotide sequence of the invention (e.g., encodes a nucleic acid,
polynucleotide or nucleotide sequence comprising, consisting essentially of, or
consisting the complement of a LNK coding sequence of the invention). Nucleotide
sequences are presented herein by single strand only, in the 5' to 3' direction, from
left to right, unless specifically indicated otherwise. Nucleotides and amino acids
are represented herein in the manner recommended by t e IUPAC-IUB
Biochemical Nomenclature Commission, or (for amino acids) by either the one-
letter code, or the three letter code, both in accordance with 37 C.F.R. §1.822 and
established usage.
[0094] The nucleic acids and polynucleotides of the invention are optionally
isolated. An "isolated" nucleic acid molecule or polynucleotide is a nucleic acid
molecule or polynucleotide that, by the hand of man, exists apart from its native
environment and is therefore not a product of nature. An isolated nucleic acid
molecule or isolated polynucleotide may exist in a purified form or may exist in a
non-native environment such as, for example, a recombinant host cell. Thus, for
example, the term "isolated" means that it is separated from the chromosome
and/or cell in which it naturally occurs. A nucleic acid or polynucleotide is also
isolated if it is separated from the chromosome and/or cell in which it naturally
occurs and is then inserted into a genetic context, a chromosome, a chromosome
location, and/or a cell in which it does not naturally occur. The recombinant
nucleic acid molecules and polynucleotides of the invention can be considered to
be "isolated."
[0095] Further, an "isolated" nucleic acid or polynucleotide is a nucleotide
sequence (e.g., DNA or RNA) that is not immediately contiguous with nucleotide
sequences with which it is immediately contiguous (one on the 5' end and one on
the 3' end) in the naturally occurring genome of the organism from which it is
derived. The "isolated" nucleic acid or polynucleotide can exist in a cell (e.g., a
plant cell), optionally stably incorporated into the genome. According to this
embodiment, the "isolated" nucleic acid or polynucleotide can be foreign to the
cell/organism into which it is introduced, or it can be native to the cell/organism
(e.g., A . thaliana), but exist in a recombinant form (e.g., as a chimeric nucleic acid
or polynucleotide) and/or can be an additional copy of an endogenous nucleic acid
or polynucleotide. Thus, an "isolated nucleic acid molecule" or "isolated
polynucleotide" can also include a nucleotide sequence derived from and inserted
into the same natural, original cell type, but which is present in a non-natural state,
e.g., present in a different copy number, in a different genetic context and/or under
t e control of different regulatory sequences than that found in the native state of
t e nucleic acid molecule or polynucleotide.
[0096] In representative embodiments, the "isolated" nucleic acid or
polynucleotide is substantially free of cellular material (including naturally
associated proteins such as histones, transcription factors, and the like), viral
material, and/or culture medium (when produced by recombinant DNA
techniques), or chemical precursors or other chemicals (when chemically
synthesized). Optionally, in representative embodiments, the isolated nucleic acid
or polynucleotide is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, 95% or more pure.
[0097] As used herein, the term "recombinant" nucleic acid, polynucleotide or
nucleotide sequence refers to a nucleic acid, polynucleotide or nucleotide sequence
that has been constructed, altered, rearranged and/or modified by genetic
engineering techniques. The term "recombinant" does not refer to alterations that
result from naturally occurring events, such as spontaneous mutations, or from
non-spontaneous mutagenesis.
[0098] A "vector" is any nucleic acid molecule for the cloning of and/or transfer of
a nucleic acid into a cell. A vector may be a replicon to which another nucleotide
sequence may be attached to allow for replication of the attached nucleotide
sequence. A "replicon" can be any genetic element (e.g., plasmid, phage, cosmid,
chromosome, viral genome) that functions as an autonomous unit of nucleic acid
replication in the cell, i.e., capable of nucleic acid replication under its own
control. The term "vector" includes both viral and nonviral (e.g., plasmid) nucleic
acid molecules for introducing a nucleic acid into a cell in vitro, ex vivo, and/or in
vivo, and is optionally an expression vector. A large number of vectors known in
the art may be used to manipulate, deliver and express LNK polynucleotides of the
invention. Vectors may be engineered to contain sequences encoding selectable
markers that provide for t e selection of cells that contain the vector and/or have
integrated some or all of the nucleic acid of the vector into the cellular genome.
Such markers allow identification and/or selection of host cells that incorporate
and express t e proteins encoded by the marker. A "recombinant" vector refers to a
viral or non-viral vector that comprises one or more heterologous nucleotide
sequences (e.g., transgenes), e.g., two, three, four, five or more heterologous
nucleotide sequences.
[0099] Viral vectors have been used in a wide variety of gene delivery applications
in cells, as well as living animal subjects. Plant viral vectors that can be used
include, but are not limited to, Agrobacterium tumefaciens, Agrobacterium
rhizogenes and geminivirus vectors. Non-viral vectors include, but are not limited
to, plasmids, liposomes, electrically charged lipids (cytofectins), nucleic acid-
protein complexes, and biopolymers. In addition to a nucleic acid of interest, a
vector may also comprise one or more regulatory regions, and/or selectable
markers useful in selecting, measuring, and monitoring nucleic acid transfer results
(e.g., delivery to specific tissues, duration of expression, etc).
[00100] The term "fragment," as applied to a nucleic acid or polynucleotide, will be
understood to mean a nucleotide sequence of reduced length relative to the
reference or full-length nucleotide sequence and comprising, consisting essentially
of and/or consisting of contiguous nucleotides from the reference or full-length
nucleotide sequence. Such a fragment according to the invention may be, where
appropriate, included in a larger polynucleotide of which it is a constituent. In
some embodiments, such fragments can comprise, consist essentially of, and/or
consist of oligonucleotides having a length of at least about 8, 10, 12, 15, 16, 17,
18, 19, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300,
325, 350, 375, 400, 405, 410, 425, 450, 455, 460, 475, 500, 505, 510, 515 or 520
nucleotides or more from the reference or full-length nucleotide sequence, as long
as the fragment is shorter than the reference or full-length nucleotide sequence. In
representative embodiments, the fragment is a biologically active nucleotide
sequence, as that term is described herein.
[00101] A "biologically active" nucleotide sequence is one that substantially retains
at least one biological activity normally associated with the wild-type nucleotide
sequence, for example, the ability to drive transcription of an operatively
associated coding sequence. In particular embodiments, the "biologically active"
nucleotide sequence substantially retains all of t e biological activities possessed
by the unmodified sequence. By "substantially retains" biological activity, it is
meant that t e nucleotide sequence retains at least about 50%, 60%, 75%, 85%,
90%, 95%, 97%, 98%, 99%, or more, of the biological activity of the native
nucleotide sequence (and can even have a higher level of activity than the native
nucleotide sequence). For example, a biologically active promoter element is able
to control, regulate and/or enhance the expression of a nucleotide sequence
operably associated with the promoter. Methods of measuring expression of a
nucleotide sequence are well known in the art and include Northern blots, RNA
run-on assays and methods of measuring the presence of an encoded polypeptide
(e.g., antibody based methods or visual inspection in the case of a reporter
polypeptide).
[00102] Two nucleotide sequences are said to be "substantially identical" to each
other when they share at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%,
98%, 99% or even 100% sequence identity.
[0100] Two amino acid sequences are said to be "substantially identical" or
"substantially similar" to each other when they share at least about 60%, 70%,
75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or even 100% sequence identity or
similarity, respectively.
[0101] As used herein "sequence identity" refers to the extent to which two
optimally aligned polynucleotide or polypeptide sequences are invariant
throughout a window of alignment of components, e.g., nucleotides or amino
acids.
[0102] As used herein "sequence similarity" is similar to sequence identity (as
described herein), but permits the substitution of conserved amino acids (e.g.,
amino acids whose side chains have similar structural and/or biochemical
properties), which are well-known in the art.
[0103] As is known in the art, a number of different programs can be used to
identify whether a nucleic acid has sequence identity or an amino acid sequence
has sequence identity or similarity to a known sequence. Sequence identity or
similarity may be determined using standard techniques known in the art,
including, but not limited to, the local sequence identity algorithm of Smith &
Waterman, Adv. Appl. Math. 2:482 (1981), by the sequence identity alignment
algorithm of Needleman et al, J . Mol. Biol. 48:443 (1970), by the search for
similarity method of Pearson & Lipman, PNAS 85:2444 (1988), by computerized
implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in
the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science
Drive, Madison, WI), the Best Fit sequence program described by Devereux et al,
Nucl. Acid Res. 12:387-395 (1984), preferably using the default settings, or by
inspection.
[0104] An example of a useful algorithm is PILEUP. PILEUP creates a multiple
sequence alignment from a group of related sequences using progressive, pairwise
alignments. It can also plot a tree showing the clustering relationships used to
create the alignment. PILEUP uses a simplification of the progressive alignment
method of Feng et al., J . Mol. Evol. 35:351-360 (1987); the method is similar to
that described by Higgins etal, CABIOS 5:151-153 (1989).
[0105] Another example of a useful algorithm is the BLAST algorithm, described
in Altschul et al, J . Mol. Biol. 215:403-410, (1990) and Karlin et al, PNAS
90:5873-5787 (1993). A particularly useful BLAST program is the WU- BLAST-2
program which was obtained from Altschul et al, Methods in Enzymology,
266:460-480 (1996); http://blast.wustl/edu/blastl READMEhtml. WU-BLAST-2
uses several search parameters, which are preferably set to the default values. The
parameters are dynamic values and are established by the program itself depending
upon the composition of the particular sequence and composition of the particular
database against which the sequence of interest is being searched; however, the
values may be adjusted to increase sensitivity.
[0106] An additional useful algorithm is gapped BLAST as reported by Altschul et
al, Nucleic Acids Res. 25:3389-3402 (1997).
[0107] The CLUSTAL program can also be used to determine sequence similarity.
This algorithm is described by Higgins et al, Gene 73:237 (1988); Higgins et al,
CABIOS 5:151-153 (1989); Corpet et al, Nucleic Acids Res. 16:10881-90 (1988);
Huang et al, CABIOS 8:155-65 (1992); and Pearson et al, Meth. Mol. Biol.
24:307-331 (1994).
[0108] The alignment may include the introduction of gaps in the sequences to be
aligned. In addition, for sequences which contain either more or fewer nucleotides
than the nucleic acids disclosed herein, it is understood that in one embodiment,
t e percentage of sequence identity will be determined based on the number of
identical nucleotides acids in relation to the total number of nucleotide bases.
Thus, for example, sequence identity of sequences shorter than a sequence
specifically disclosed herein, will be determined using the number of nucleotide
bases in the shorter sequence, in one embodiment. In percent identity calculations
relative weight is not assigned to various manifestations of sequence variation,
such as, insertions, deletions, substitutions, etc.
[0109] Two nucleotide sequences can also be considered to be substantially
identical when the two sequences hybridize to each other under stringent
conditions. A non-limiting example of "stringent" hybridization conditions include
conditions represented by a wash stringency of 50% Formamide with 5x
Denhardt's solution, 0.5% SDS and lx SSPE at 42°C. "Stringent hybridization
conditions" and "stringent hybridization wash conditions" in the context of nucleic
acid hybridization experiments such as Southern and Northern hybridizations are
sequence dependent, and are different under different environmental parameters.
An extensive guide to the hybridization of nucleic acids is found in Tijssen
Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization
with Nucleic Acid Probes part I chapter 2 "Overview of principles of hybridization
and the strategy of nucleic acid probe assays" Elsevier, New York (1993). In some
representative embodiments, two nucleotide sequences considered to be
substantially identical hybridize to each other under highly stringent conditions.
Generally, highly stringent hybridization and wash conditions are selected to be
about 5°C lower than the thermal melting point (Tm) for the specific sequence at a
defined ionic strength and pH.
[0110] In some embodiments, LNK nucleotides of the invention hybridize with the
LNK nucleotide sequences of SEQ ID NO:l and/or SEQ ID NO:3 or the
complement thereof, under moderate stringency conditions. Exemplary moderate
stringency conditions include hybridization in 40-45% formamide, 1M NaCl, 1%
SDS at 37°C, and a wash in 0.5 to 1XSSC at 55-50°C.
[0111] In additional embodiments, LNK nucleotides of the invention hybridize
with the LNK nucleotide sequences of SEQ ID NO: 1 and/or SEQ ID NO: 3 or the
complement thereof, under low stringency conditions. A non-limiting example of
"low stringency" hybridization conditions includes hybridization with a buffer
solution of 30 to 35% formamide, 1M NaCl, 1% SDS at 37°C, and a wash in IX.
to 2XSSC at 50-55°C.
[0112] Homologs of t e disclosed Arabidopsis LNK proteins (e.g., LNK1, 2, 3 and
4) typically possess at least 60% sequence identity counted over full length
alignment with the amino acid sequence of Arabidopsis LNK proteins using the
NCBI Blast 2.0, gapped blastp set to default parameters. For comparisons of amino
acid sequences of greater than about 30 amino acids, the Blast 2 sequences
function is employed using the default BLOSUM62 matrix set to default
parameters, (gap existence cost of 11, and a per residue gap cost of 1). When
aligning short peptides (fewer than around 30 amino acids), the alignment should
be performed using the Blast 2 sequences function, employing the PAM30 matrix
set to default parameters (open gap 9, extension gap 1 penalties). Proteins with
even greater similarity to the reference sequence will show increasing percentage
identities when assessed by this method, such as at least 70%, at least 75%, at least
80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least
95% sequence identity. When less than the entire sequence is being compared for
sequence identity, homologs will typically possess at least 75% sequence identity
over short windows of 10-20 amino acids, and may possess sequence identities of
at least 85% or at least 90% or 95% or more depending on their similarity to the
reference sequence. Methods for determining sequence identity over such short
windows are described at the NCBI web-site, frequently asked questions page. One
of ordinary skill in the art will appreciate that these sequence identity ranges are
provided for guidance only; it is entirely possible that strongly significant
homologs could be obtained that fall outside of the ranges provided. The present
invention provides not only the peptide homologs that are described above, but
also nucleic acid molecules that encode such homologs. LNK proteins homologs
will typically also have one or more LNK protein biological activities described
herein.
[0113] As used herein, the term "polypeptide" encompasses both peptides and
proteins (including fusion proteins), unless indicated otherwise.
[0114] A "fusion protein" is a polypeptide produced when two heterologous
nucleotide sequences or fragments thereof coding for two (or more) different
polypeptides not found fused together in nature are fused together in the correct
translational reading frame.
[0115] The polypeptides of t e invention are optionally "isolated." An "isolated"
polypeptide is a polypeptide that, by the hand of man, exists apart from its native
environment and is therefore not a product of nature. An isolated polypeptide may
exist in a purified form or may exist in a non-native environment such as, for
example, a recombinant host cell. The recombinant polypeptides of the invention
can be considered to be "isolated."
[0116] In representative embodiments, an "isolated" polypeptide means a
polypeptide that is separated or substantially free from at least some of the other
components of the naturally occurring organism or virus, for example, the cell or
viral structural components or other polypeptides or nucleic acids commonly found
associated with the polypeptide. In particular embodiments, the "isolated"
polypeptide is at least about 1%, 5%, 10%, 25%, 50%, 60%, 70%, 75%, 80%,
85%, 90%, 95%, 97%, 98%, 99% or more pure (w/w). In other embodiments, an
"isolated" polypeptide indicates that at least about a 5-fold, 10-fold, 25-fold, 100-
fold, 1000-fold, 10,000-fold, or more enrichment of the protein (w/w) is achieved
as compared with the starting material. In representative embodiments, the isolated
polypeptide is a recombinant polypeptide produced using recombinant nucleic acid
techniques. In embodiments of the invention, the polypeptide is a fusion protein.
[0117] The term "fragment," as applied to a polypeptide, will be understood to
mean an amino acid sequence of reduced length relative to a reference polypeptide
or the full-length polypeptide (e.g., LNK) and comprising, consisting essentially
of, and/or consisting of a sequence of contiguous amino acids from the reference
or full-length polypeptide. Such a fragment according to the invention may be,
where appropriate, included as part of a fusion protein of which it is a constituent.
In some embodiments, such fragments can comprise, consist essentially of, and/or
consist of polypeptides having a length of at least about 50, 75, 100, 125, 150, 160,
165, 170, 171, 172, 173 or 174 amino acids from the reference or full-length
polypeptide, as long as t e fragment is shorter than the reference or full-length
polypeptide. In representative embodiments, the fragment is biologically active, as
that term is defined herein.
A "biologically active" polypeptide is one that substantially retains at least
one biological activity normally associated with the wild-type polypeptide or
alternatively, acts to reduce at least one biological activity normally associated
with the wild-type LNK polypeptide. For example, the ability to regulate the plant
circadian clock functions and/or photoperiodic responses, to regulate flowering
time and/or biomass production, to increase tolerance to abiotic stress and/or
increase yield. In another embodiment, a biologically active polypeptide is capable
of modulating PRR5 and/or ELF4 expression in a transgenic plant cell or plant that
recombinantly expresses the polypeptide. In additional embodiments, a
biologically active polypeptide is capable of modulating the expression of FKF1,
SOC1 and/or FT1 in a transgenic plant cell or plant that recombinantly expresses
the polypeptide. In some embodiments, the biologically active polypeptide is a
LNK agonist and leads to an increased expression of PRR5, ELF4 and/or FKF1
compared to a wild-type plant or plant cell. In alternative embodiments, the
biologically active polypeptide is a LNK antagonist and leads to a decreased
expression of PRR5, ELF4 and/or FKF1 compared to a wild-type plant or plant
cell. In particular embodiments, the "biologically active" polypeptide substantially
retains all of the biological activities possessed by the unmodified (wild-type)
LNK sequence. By "substantially retains" biological activity, it is meant that the
polypeptide retains at least about 50%, 60%, 75%, 85%, 90%, 95%, 97%, 98%,
99%, or more, of the biological activity of the native LNK polypeptide (and can
even have a higher level of activity than the native polypeptide). Methods of
measuring circadian rhythms, flowering time, biomass, yield, alterations in gene
expression profile, and tolerance to abiotic stress are known in the art, with non-
limiting and exemplary methods described in the Examples herein.
[0119] "Introducing" in the context of a plant cell, plant tissue, plant part and/or
plant means contacting a nucleic acid molecule with the plant cell, plant tissue,
plant part, and/or plant in such a manner that t e nucleic acid molecule gains
access to the interior of the plant cell or a cell of the plant tissue, plant part or
plant. Where more than one nucleic acid molecule is to be introduced, these
nucleic acid molecules can be assembled as part of a single polynucleotide or
nucleic acid construct, or as separate polynucleotide or nucleic acid constructs, and
can be located on the same or different nucleic acid constructs. Accordingly, these
nucleic acid molecules can be introduced into plant cells in a single transformation
event, in separate transformation events, or, e.g., as part of a breeding protocol.
[0120] The term "transformation" as used herein refers to the introduction of a
heterologous nucleic acid into a cell. Transformation of a cell may be stable or
transient. Thus, a transgenic plant cell, plant tissue, plant part and/or plant of the
invention can be stably transformed or transiently transformed. "Transient
transformation" in the context of a polynucleotide means that a polynucleotide is
introduced into the cell and does not integrate into the genome of the cell. As used
herein, "stably introducing," "stably introduced," "stable transformation" or "stably
transformed" (and similar terms) in the context of a polynucleotide introduced into
a cell, means that the introduced polynucleotide is stably integrated into the
genome of the cell (e.g., into a chromosome or as a stable- extra-chromosomal
element). As such, the integrated polynucleotide is capable of being inherited by
progeny cells and plants. "Genome" as used herein includes the nuclear and/or
plastid genome, and therefore includes integration of a polynucleotide into, for
example, the chloroplast genome. Stable transformation as used herein can also
refer to a polynucleotide that is maintained extrachromosomally, for example, as a
minichromosome .
[0121] As used herein, the terms "transformed" and "transgenic" refer to any plant,
plant cell, plant tissue (including callus), or plant part that contains all or part of at
least one recombinant or isolated LNK nucleic acid, polynucleotide or nucleotide
sequence of the invention. In representative embodiments, the recombinant or
isolated nucleic acid, polynucleotide or nucleotide sequence is stably integrated
into the genome of the plant (e.g., into a chromosome or as a stable extra-
chromosomal element), so that it is passed on to subsequent generations of the cell
or plant.
[0122] The term "plant part," as used herein, includes but is not limited to,
reproductive tissues (e.g., petals, sepals, stamens, pistils, receptacles, anthers,
pollen, flowers, fruits, flower bud, ovules, seeds, embryos, nuts, kernels, ears, cobs
and husks); vegetative tissues (e.g., petioles, stems, roots, root hairs, root tips, pith,
coleoptiles, stalks, shoots, branches, bark, apical meristem, axillary bud, cotyledon,
hypocotyls, and leaves); vascular tissues (e.g., phloem and xylem); specialized
cells such as epidermal cells, parenchyma cells, collenchyma cells, sclerenchyma
cells, stomates, guard cells, cuticle, mesophyll cells; callus tissue; and cuttings.
The term "Pplant part" also includes plant cells including plant cells that are intact
in plants and/or parts of plants, plant protoplasts, plant tissues, plant organs plant
cell tissue cultures, plant calli, plant clumps, and the like. As used herein, "shoot"
refers to t e above ground parts of a plant including t e leaves and stems. The term
"tissue culture" encompasses cultures of tissue, cells, protoplasts and callus.
[0123] As used herein, "plant cell" refers to a structural and physiological unit of
the plant, which typically comprise a cell wall but also includes protoplasts. A
plant cell of the present invention can be in the form of an isolated single cell,
tissue culture cell or can be a part of a higher-organized unit such as, for example,
a plant tissue (including callus) or a plant organ. Any plant (or groupings of plants,
for example, into a genus or higher order classification) can be employed in
practicing the present invention including angiosperms or gymnosperms, monocots
or dicots. In some embodiments, the plant cell is from a long-day plant. In
particular embodiments, the long-day plant is a member selected from the group
consisting of Arabidopsis thaliana, wheat, barley, spinach and poplar. In some
embodiments, the plant cell is from a short-day plant. In particular embodiments,
the short-day plant is a member selected from: rice, maize, soybean,
chrysanthemum, morning glory and cosmos.
[0124] Examples of transgenic plants and cells of the invention include, but are not
limited to, plants and cells belonging to Brassicaceae (e.g., Arabidopsis thaliana,
cabbage, rapeseed), Gramineae (e.g., rice, maize, barley, wheat, switchgrass, sugar
cane, sorghum), Solanaceae (e.g., tomato, eggplant, potato, tobacco), Leguminosae
(e.g., soybean, garden pea, bush bean), Convolvulaceae (e.g., sweet potato),
Compositae (e.g., sunflower), Euphorbiaceae (e.g., cassava, Jatropha), Rosaceae
(e.g., strawberry) and/or Salix (e.g., poplar), as well as, gymnosperms, ferns and
mosses.
[0125] Exemplary transgenic plants and plant cells of t e invention include, but
are not limited to, corn (Zea mays), canola (Brassica napus, Brassica rapa ssp ,
alfalfa (Medicago saliva), rice (Oryza sativa), rape (Brassica napus), rye (Secale
cereale), sorghum (Sorghum bicolor, Sorghum vulgare), sunflower (Helianthus
annuus), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana
tobacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), cotton
(Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot
esculenta), coffee (Cofea spp ), coconut (Cocos nucifera), pineapple (Ananas
comosus), citrus trees (Citrus spp ), cocoa (Theobroma cacao), tea (Camellia
sinensis), banana (Musa spp ), avocado (Persea americana), fig (Ficus casica),
guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea),
papaya (Carica papaya), cashew (Anacardium occidental), macadamia
(Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta
vulgaris), apple (Malus pumila), blackberry (Rubus), strawberry (Fragaria),
walnut (Juglans regia), grape (Vitis vinifera), apricot (Prunus armeniaca), cherry
(Prunus), peach (Prunus persica), plum (Prunus domestica), pear (Pyrus
communis), watermelon (Citrullus vulgaris), duckweed (Lemna), oats, barley,
vegetables, ornamentals, conifers, turfgrasses (e.g., for ornamental, recreational or
forage purposes), and/or biomass grasses (e.g., switchgrass and miscanthus).
[0126] Turfgrass and cells which may be employed in practicing t e present
invention, include but are not limited to zoysiagrasses, bentgrasses, fescue grasses,
bluegrasses, St. Augustinegrasses, bermudagrasses, bufallograsses, ryegrasses
and/or orchardgrasses.
[0127] In particular embodiments, the transgenic plants of the invention are a
member selected from wheat (Tritium aestivum), corn (Zea mays) and rice (Oryza
sativa). In an additional embodiment, the transgenic plants are alfalfa or sunflower.
In a particular embodiment, the transgenic plants are soybean (Glycine max).
[0128] Exemplary transgenic vegetables and cells of the invention include, but are
not limited to, Solanaceous species (e.g., tomatoes; Lycopersicon esculentum),
lettuce (e.g., Lactuea sativa), carrots (Caucus carota), cauliflower (Brassica
oleracea), celery (apium graveolens), eggplant (Solarium melongena), asparagus
(Asparagus officinalis), ochra (Abelmoschus esculentus), green beans (Phaseolus
vulgaris), lima beans (Phaseolus limensis), peas (Lathyrus spp ), members of the
genus Cucurbita such as Hubbard squash (C. Hubbard), Butternut squash (C.
moschata), Zucchini (C. pepo), Crookneck squash (C. crookneck), C.
argyrosperma, C. argyrosperma ssp sororia, C. digitata, C. ecuadorensis, C.
foetidissima, C. lundelliana, and C. martinezii, and members of t e genus Cucumis
such as cucumber (Cucumis sativus), cantaloupe (C. cantalupensis) and/or musk
melon (C. melo). Transgenic ornamentals and ornamental cells of the invention
include, azalea (Rhododendron spp.), hydrangea (Macrophylla hydrangea),
hibiscus (Hibiscus rosasanensis), roses (Rosa spp.), tulips (Tulipa spp.), daffodils
(Narcissus spp.), petunias (Petunia hybrida), carnation (dianthus caryophyllus),
poinsettia (Euphorbia pulcherima), and/or chrysanthemum.
[0129] Transgenic conifers and conifer cells of the invention, include, for example
pines such as loblolly pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa
pine (Pinus ponderosa), lodgepole pine (Pinus contorta), and Monterey pine
(Pinus radiata); Douglas-fir (Pseudotsuga menziesii); Western hemlock (Tsuga
canadensis); Sitka spruce (Picea glauca); redwood (Sequoia sempervirens); true
firs such as silver fir (Abies amabilis) and balsam fir (Abies balsamea); and cedars
such as Western red cedar (Thuja plicata) and/or Alaska yellow-cedar
(Chamaecyparis nootkatensis).
[0130] Also included as transgenic plants and cells of the invention are plants and
cells that serve primarily as laboratory models, such as, Arabidopsis.
II. LNK nucleic acids promoters and functional RNA
Antisense and Co-Suppression
[0131] As demonstrated in the Examples, LNK genes such as, LNK1 and LNK2
mediate gene expression that leads to the inhibition of hypocotyl elongation and
accelerated flowering. In some embodiments, the invention encompasses nucleic
acids that act as sense or anti-sense suppression of LNK (e.g., LNK1 and/or
LNK2) expression and that act as a LNK antagonist to for example, down-regulate
t e endogenous expression of a LNK polypeptide. Thus, in some embodiments,
LNK (e.g., LNK1 and/or LNK2) nucleic acids of the invention, including LNK
sense or LNK anti-sense sequences, are used to interfere with the expression of
endogenous homologous LNK nucleic acids in a transgenic plant or plant cell. A
variety of sense and anti-sense technologies that may routinely be applied in
preparing the compositions of the invention are known in the art. See, e.g.,
Lichtenstein and Nellen (1997) Antisense Technology: A Practical Approach IRL
Press at Oxford University Press, Oxford, U.K; Crowley et al, Cell 43:633-641
(1985); Rosenberg et al, Nature 313:703-706 (1985); Preiss et al, Nature 313:27-
32 (1985); Melton Proc. Natl. Acad. Sci. 82:144-148 (1985); Izant and Weintraub
Science 229:345-352 (1985); Kim and Wold, Cell 42:129-138 (1985); Smith et al,
Nature, 334: 724-726 (1988); and Smith et al, Plant Mol. Biol. 14:369-379 (1990).
(In general, sense or anti-sense sequences are introduced into a cell, where they are
optionally amplified, e.g., by transcription. Such sequences include both simple
oligonucleotide sequences and catalytic sequences such as ribozymes.
A reduction or elimination of expression (i.e., a "knock-down" or "knock
out") of a LNK protein or LNK homolog in a transgenic plant or plant cell, can be
obtained by introducing a LNK antisense expression cassette or expression vector
into a plant or plant cell as a cDNA. For antisense suppression, the regulatory
protein or homolog cDNA is arranged in reverse orientation (with respect to the
coding sequence) relative to the promoter sequence in the expression vector. The
introduced sequence need not be the full-length cDNA or gene, and need not be
identical to the LNK message or gene found in the plant or plant cell type to be
transformed. Typically, the antisense sequence need only be capable of hybridizing
to the target LNK gene or RNA. Thus, where the introduced sequence is of shorter
length, a higher degree of homology to the endogenous LNK coding sequence will
be needed for effective antisense suppression. While antisense sequences of
various lengths can be utilized, preferably, the introduced antisense sequence in the
vector/expression cassette will be at least 30 nucleotides in length, or at least 100
nucleotides. Transcription of an antisense construct as described results in the
production of RNA molecules that are the reverse complement of mRNA
molecules transcribed from the endogenous LNK gene in the plant cell.
Suppression of endogenous LNK expression can also be achieved using
RNA interference (RNAi) or microRNA-based methods (Llave et al, Science 297:
2053-2056 (2002); Tang et al, Genes Dev. 17: 49-63 (2003)). RNAi is a post-
transcriptional, targeted gene-silencing technique that uses double-stranded RNA
(dsRNA) to incite degradation of messenger RNA (mRNA) containing the same
sequence as the dsRNA (Constans, The Scientist 16:36 (2002)) Small interfering
RNAs, or siRNAs are produced in at least two steps: an endogenous ribonuclease
cleaves longer dsRNA into shorter, 21-23 nucleotide-long RNAs (Plasterk Science
296:1263-1265 (2002)). The siRNA segments then mediate t e degradation of the
target mRNA (Zamore, Nature Struct. Biol., 8:746-50 (2001)). RNAi has been
used for gene function determination in a manner similar to antisense
oligonucleotides (Constans, The Scientist 16:36(2002)). Expression vectors and
expression cassettes that express siRNAs in transiently and stably transfected cells
have been engineered to express small hairpin RNAs (shRNAs), which get
processed in vivo into siRNAs-like molecules capable of carrying out gene-specific
silencing (Brummelkamp et al., Science 296:550-553 (2002), and Paddison, et al,
Genes & Dev. 16:948-958 (2002)). Post-transcriptional gene silencing by double-
stranded RNA is discussed in further detail by Hammond et al, Nature Rev Gen 2 :
110-119 (2001), Fire et al, Nature 391:806-811 (1998) and Timmons and Fire
Nature 395:854 (1998). Vectors and expression cassettes in which RNA encoded
by a transcription factor or transcription factor homolog cDNA is over-expressed
can also be used to obtain co-suppression of a corresponding endogenous gene,
e.g., in the manner described in U.S. Pat. No. 5,231,020. Such co-suppression (also
termed sense suppression) does not require that the entire regulatory protein cDNA
be introduced into the plant cells, nor does it require that the introduced sequence
be exactly identical to t e endogenous LNK gene of interest. However, as with
antisense suppression, the suppressive efficiency will be enhanced as specificity of
hybridization is increased, e.g., as the introduced sequence is lengthened, and/or as
the sequence similarity between the introduced sequence and the endogenous
regulatory protein gene is increased.
[0134] In some embodiments, the invention includes LNK antagonist nucleic
acids, vectors and expression cassettes that express an untranslatable form of the
LNK protein mRNA, e.g., sequences comprising one or more stop codon, or
nonsense mutation) can also be used to suppress expression of an endogenous
LNK protein, thereby reducing or eliminating its activity and modulating one or
more traits. Methods for producing such constructs are known in t e art, see, e.g.,
U.S. Pat. No. 5,583,021. In some embodiments, the constructs contain LNK
nucleic acids comprising one or more premature stop codons introduced into LNK
coding sequence. In other embodiments, the expression of an endogenous LNK
gene is modified (i.e., decreased) by gene silencing using double-stranded RNA
(see, e.g., Sharp Genes and Development 13:139-141 (1999)). Another method for
abolishing or reducing the expression of a LNK gene is by insertion mutagenesis
using the T-DNA of Agrobacterium tumefaciens . After generating the insertion
mutants, the mutants can be screened to identify those containing the insertion in
one or more LNK genes (e.g., LNK1, LNK2 and both LNK1 and LNK2). Plants
containing a single transgene insertion event at the desired gene can be crossed to
generate homozygous plants for the mutation. Such methods are known in the art
(see e.g., Koncz et al, (1992) Methods in Arabidopsis Research, World Scientific
Publishing Co. Pte. Ltd., River Edge, N.J.).
LNK polypeptides and LNK coding sequences
[0135] In some embodiments, the invention provides LNK polypeptides. The term
"LNK polypeptide" is intended to encompass the LNK polypeptides specifically
described herein (e.g., SEQ ID NO:2 and SEQ ID NO:4) as well as equivalents
thereof, e.g., that have substantially identical or similar amino acid sequences to
the LNK polypeptides specifically described herein, and optionally biologically
active equivalents that have one or more of the biological activities of the LNK
polypeptides specifically described herein. The term "LNK polypeptide" also
encompasses fragments of full-length LNK polypeptides (e.g., SEQ ID NO:2 and
SEQ ID NO:4), and optionally biologically active fragments, and biologically
active equivalents thereof that have substantially identical or similar amino acid
sequences to a fragment of a full-length LNK polypeptide. Further, the term "LNK
polypeptide" includes sequences from A . thaliana or can be a homolog from any
other suitable plant species and also includes naturally occurring allelic variations,
isoforms, splice variants and the like. The LNK polypeptide sequences can further
be wholly or partially synthetic.
[0136] Biological activities associated with expression of LNK in a plant include,
but are not limited to: modulating circadian rhythms, photoperiodic responses and
plant phenotypes associated therewith; modulating the expression of key clock and
clock output genes, such as PRR5, ELF4 and/or FKF1; modulating flowering time
and/or biomass production; modulating response to seasonal changes in
photoperiod; and modulating tolerance to abiotic stress (e.g., high light intensity or
low light intensity). In some embodiments, the biologically active polypeptide is a
LNK agonist and leads to an increased expression of PRR5, ELF4 and/or FKF1
compared to a wild-type plant or plant cell. In alternative embodiments, the
biologically active polypeptide is a LNK antagonist and leads to a decreased
expression of PRR5, ELF4 and/or FKF1 compared to a wild-type control plant or
plant cell. In some embodiments, the biologically active polypeptide modulates
circadian rhythms in a transgenic plant that recombinantly expresses the LNK
polypeptide compared to a wild-type control plant. In additional embodiments, the
biologically active polypeptide is a LNK agonist and leads to an accelerated
flowering time and/or reduced biomass in a transgenic plant that recombinantly
expresses the polypeptide compared to a wild-type control plant. In alternative
embodiments, the biologically active polypeptide is a LNK antagonist and leads to
a delayed flowering time and/or increased biomass in a transgenic plant that
recombinantly expresses the polypeptide compared to a wild-type control plant.
[0137] In particular embodiments, the LNK polypeptide comprises, consists
essentially of, or consists of an isolated LNK1 polypeptide of SEQ ID NO:2 or an
equivalent thereof (including fragments and equivalents thereof).
[0138] In additional particular embodiments, the LNK polypeptide comprises,
consists essentially of, or consists of an isolated LNK2 polypeptide of SEQ ID
NO:4 or an equivalent thereof (including fragments and equivalents thereof).
[0139] Equivalents of the LNK polypeptides of the invention encompass those that
have substantial amino acid sequence identity or similarity, for example, at least
about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more amino acid
sequence identity or similarity with t e amino acid sequences specifically
disclosed herein (e.g., SEQ ID NO:2 or SEQ ID NO:4) or a fragment thereof,
optionally a biologically active fragment. Additional equivalents of the LNK
polypeptides of the invention encompass those that have substantial amino acid
sequence identity or similarity, for example, at least about 96%, 97%, 98%, 99%
or more amino acid sequence identity or similarity with the amino acid sequence of
SEQ ID NO: 10 or a fragment thereof, optionally a biologically active fragment.
[0140] Unless indicated otherwise, the LNK polypeptide can be a fusion protein.
For example, it may be useful to express the LNK polypeptides as a fusion protein
that can be recognized by a commercially available antibody (e.g., FLAG motifs)
or as a fusion protein that can otherwise be more easily purified (e.g., by addition
of a poly-His tail). Additionally, fusion proteins that enhance the stability of the
protein may be produced, e.g., fusion proteins comprising maltose binding protein
(MBP) or glutathione-S-transferase. As another alternative, the fusion protein can
comprise a reporter molecule. LNK is a transcription factor and LNK fusion
proteins can also be generated for use in yeast two-hybrid systems (e.g., GAL4-
LNK fusions), as is known in the art.
[0141] It will further be understood that the LNK polypeptides specifically
disclosed herein will typically tolerate substitutions in the amino acid sequence and
substantially retain biological activity. To routinely identify biologically active
LNK polypeptides of the invention other than those specifically disclosed herein,
amino acid substitutions may be based on any characteristic known in the art,
including the relative similarity or differences of the amino acid side-chain
substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and
the like. In particular embodiments, conservative substitutions (i.e., substitution
with an amino acid residue having similar properties) are made in the amino acid
sequence encoding the LNK polypeptide.
[0142] In making amino acid substitutions, the hydropathic index of amino acids
can be considered. The importance of the hydropathic amino acid index in
conferring interactive biologic function on a protein is generally understood in the
art (see, Kyte et al, J . Mol. Biol. 157:105 (1982)). It is accepted that the relative
hydropathic character of the amino acid contributes to the secondary structure of
t e resultant protein, which in turn defines the interaction of the protein with other
molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens,
and the like.
[0143] Each amino acid has been assigned a hydropathic index on the basis of its
hydrophobicity and charge characteristics (Kyte et a , Id.), and these are:
isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8);
cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine
(-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-
3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-
3.9); and arginine (-4.5). It is understood that certain amino acids may be
substituted for other amino acids having a similar hydropathic index or score and
still retain a similar biological activity. In making changes based upon the
hydropathic index, in certain embodiments, the substitution of amino acids whose
hydropathic indices are within +/- 2 is included. In certain embodiments, those
which are within +/-1 are included, and in certain embodiments, those within +/-
0.5 are included.
[0144] It is also understood in the art that the substitution of amino acids can be
made on the basis of hydrophilicity. U.S. Patent No. 4,554,101 states that the
greatest local average hydrophilicity of a protein, as governed by the
hydrophilicity of its adjacent amino acids, correlates with a biological property of
the protein. As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity
values have been assigned to amino acid residues: arginine (+3.0); lysine (±3.0);
aspartate (+3.0 ± 1); glutamate (+3.0 ± 1); serine (+0.3); asparagine (+0.2);
glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ±1); alanine (-0.5);
histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8);
isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). In
making changes based upon similar hydrophilicity values, in certain embodiments,
the substitution of amino acids whose hydrophilicity values are within +/-2 is
included, in certain embodiments, those which are within +/-1 are included, and in
certain embodiments, those within +/- 0.5 are included.
[0145] The LNK polypeptides of the present invention also encompass LNK
polypeptide fragments (optionally, biologically active LNK fragments), and
equivalents thereof (optionally, biologically active equivalents). The length of t e
LNK fragment is not critical. Illustrative functional LNK protein fragments
comprise at least about 50, 75, 100, 125, 150, 160, 165, 170, 17 1, 172, 173 or 174
amino acids of a LNK polypeptide.
[0146] In representative embodiments, the invention provides an isolated LNK
polypeptide comprising, consisting essentially of, or consisting of a LNK1 amino
acid sequence selected from the group consisting of: (a) the amino acid sequence
of SEQ ID NO:2; (b) an amino acid sequence having at least about 60%, 70%,
75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more amino acid sequence
identity or similarity with the amino acid sequence of SEQ ID NO:2, optionally
wherein the LNK polypeptide is biologically active; and (c) a fragment of at least
about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 155, 160, 17 1, 172, 173 or
174 amino acid residues of the amino acid sequence of (a) or (b) above, optionally
wherein the fragment is biologically active.
[0147] In representative embodiments, the invention provides an isolated LNK
polypeptide comprising, consisting essentially of, or consisting of a LNK2 amino
acid sequence selected from the group consisting of: (a) the amino acid sequence
of SEQ ID NO:4; (b) an amino acid sequence having at least about 60%, 70%,
75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more amino acid sequence
identity or similarity with the amino acid sequence of SEQ ID NO:4, optionally
wherein the LNK polypeptide is biologically active; and (c) a fragment of at least
about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 155, 160, 17 1, 172, 173 or
174 amino acid residues of the amino acid sequence of (a) or (b) above, optionally
wherein the fragment is biologically active.
[0148] The invention further provides antibodies and antibody fragments that
specifically bind to the LNK polypeptides of the invention. Anti-LNK antibodies
may be produced using standard procedures described in a number of texts,
including Harlow and Lane (1988). The determination that a particular agent binds
substantially only to a LNK protein (e.g., LNK1 and/or LNK2) may readily be
made by using or adapting techniques known in the art. One suitable in vitro assay
makes use of the Western blotting procedure (described in many standard texts,
including Harlow and Lane (1988)). Western blotting may be used to determine
that a given LNK protein binding agent, such as an anti-LNKl or LNK2
monoclonal antibody, binds substantially only to LNK1 and/or LNK2. The term
"antibody" or "antibodies" as used herein refers to all types of immunoglobulins,
including IgG, IgM, IgA, IgD, and IgE. The antibody can be monoclonal or
polyclonal and can be of any species of origin, including for example mouse, rat,
rabbit, horse, goat, sheep or human, or can be a chimeric, humanized or human
antibody. See, e.g., Walker et al, Molec. Immunol. 26:403-411 (1989). The
antibodies can be recombinant monoclonal antibodies produced according to the
methods disclosed in U.S. Patent No. 4,474,893 or 4,816,567. The antibodies can
also be chemically constructed according to t e method disclosed in U.S. Patent
No. 4,676,980.
[0149] Antibody fragments included within the scope of the present invention
include, for example, Fab, F(ab')2, and Fc fragments, and the corresponding
fragments obtained from antibodies other than IgG. Such fragments can be
produced by known techniques. For example, F(ab')2 fragments can be produced
by pepsin digestion of the antibody molecule, and Fab fragments can be generated
by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab
expression libraries can be constructed to allow rapid and easy identification of
monoclonal Fab fragments with the desired specificity (Huse et al., Science
254:1275-1281 (1989)).
[0150] Monoclonal antibodies according to the present invention can be produced
in a hybridoma cell line according to the technique of Kohler et al., Nature
265:495-97 (1975). For example, a solution containing the appropriate antigen can
be injected into a mouse and, after a sufficient time, the mouse sacrificed and
spleen cells obtained. The spleen cells are then immortalized by fusing them with
myeloma cells or with lymphoma cells, typically in the presence of polyethylene
glycol, to produce hybridoma cells. The hybridoma cells are then grown in a
suitable medium and the supernatant screened for monoclonal antibodies having
the desired specificity. Monoclonal Fab fragments can be produced in E . coli by
recombinant techniques known to those skilled in the art. See, e.g., Huse, Science
246:1275-1281 (1989).
[0151] Antibodies specific to a LNK polypeptide can also be obtained by phage
display techniques known in the art.
[0152] The invention also provides nucleic acids encoding LNK polypeptides,
optionally biologically active LNK polypeptides. The nucleic acid can be from any
plant species of origin (e.g., A . thaliana) or can be partially or completely
synthetic. In representative embodiments, the nucleic acid encoding t e LNK
polypeptide is an isolated nucleic acid.
[0153] Two nucleotide or amino acid sequences are orthologs of each other if they
share a common ancestral sequence and diverged when a species carrying that
ancestral sequence split into two species. Orthologous sequences are also
homologous sequences. LNK orthologs from other organisms, in particular other
plants, can be routinely identified using methods known in the art (e.g., orthologs
from species belonging to the Asteraceae family [also known as the Compositae
family], such as a species of lettuce). For example, PCR and other amplification
techniques and hybridization techniques can be used to identify such orthologs
based on their sequence similarity to the sequences set forth herein.
[0154] In representative embodiments, the invention encompasses polynucleotides
encoding the LNK polypeptides of the invention having substantial nucleotide
sequence identity with the polynucleotides specifically disclosed herein encoding
LNK (e.g., the LNK1 coding sequence in SEQ ID NO:l (i.e., nucleotides
302-2152), and the LNK2 coding sequence in SEQ ID NO:3 (i.e., nucleotides 324-
2333)), or fragments thereof, and which encode a LNK polypeptide (including
fragments), optionally a biologically active LNK polypeptide. In some
embodiments, the polynucleotides encoding the LNK polypeptides have
substantial nucleotide sequence identity with the coding sequence in SEQ ID NO: 1
or the coding sequence in SEQ ID NO: 3, or fragments thereof, and which encode a
LNK polypeptide (including fragments), optionally a biologically active LNK
polypeptide.
[0155] The invention also provides polynucleotides encoding the LNK
polypeptides of the invention, wherein the polynucleotide hybridizes to the
complete complement of the LNK nucleic acid sequences specifically disclosed
herein (e.g., SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO: 13 and SEQ ID NO: 15), or
fragments thereof, under stringent hybridization conditions as known by those
skilled in the art and encode a LNK polypeptide (including fragments), optionally
a biologically active LNK polypeptide. In some embodiments, the polynucleotide
hybridizes to nucleotides 300 to 500, 500 to 1000, 1000 to 1500, or 1500-2000 of
SEQ ID NO: l or SEQ ID NO: 3, or fragments thereof, under stringent
hybridization conditions and encode a LNK polypeptide (including fragments),
optionally a biologically active LNK polypeptide. Further, it will be appreciated by
those skilled in the art that there can be variability in the polynucleotides that
encode the LNK polypeptides of the present invention due to the degeneracy of the
genetic code. The degeneracy of the genetic code, which allows different
nucleotide sequences to code for the same protein, is well known in the art.
Moreover, plant or species-preferred codons can be used in the polynucleotides
encoding the LNK polypeptides of the invention, as is also known in the art.
[0156] The invention also provides polynucleotides encoding fragments of a
full-length LNK polypeptide, optionally biologically active fragments. Exemplary
polynucleotides encoding LNK fragments comprise at least about 50, 75, 100, 125,
150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 505,
510, 515 or 520 or more nucleotide bases of the coding polynucleotide sequence of
SEQ ID NO: l (i.e. , nucleotides 302-2152), or SEQ ID NO:3 (i. e. , nucleotides 324-
2333).
[0157] In exemplary, but non-limiting, embodiments, the invention provides a
nucleic acid (e.g., recombinant or isolated) comprising, consisting essentially of, or
consisting of a nucleotide sequence encoding a LNK polypeptide, the nucleotide
sequence selected from the group consisting of: (a) a nucleotide sequence
comprising the coding nucleotide sequence of SEQ ID NO: l (i. e. , nucleotides
302-2 152), or SEQ ID NO:3 (i.e. , nucleotides 324-2333); (b) a nucleotide
sequence comprising at least about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275,
300, 325, 350, 375, 400, 425, 450, 475, 500, 505, 510, 515 or 520 or more
consecutive nucleotides of the coding nucleotide sequence of SEQ ID NO: l or
SEQ ID NO: 3 (e.g., encoding a fragment, optionally a functional fragment of SEQ
ID NO:3); (c) a nucleotide sequence having at least about 60%, 70%, 75%, 80%,
85%, 90%, 95%, 97%, 98%, 99% or more sequence identity to the nucleotide
sequence of (a) or (b); (d) a nucleotide sequence that hybridizes to the complete
complement of the nucleotide sequence of (a) or (b) under stringent hybridization
conditions; and (e) a nucleotide sequence that differs from t e nucleotide sequence
of any of (a) to (d) due to t e degeneracy of the genetic code. In representative
embodiments, the nucleotide sequence encodes a biologically active LNK
polypeptide (including biologically active fragments of a full-length LNK
polypeptide).
[0158] In representative embodiments, the nucleotide sequence encodes the
polypeptide of SEQ ID NO: , or an equivalent polypeptide having substantial
amino acid sequence identity or similarity with SEQ ID NO:2 (optionally, a
biologically active equivalent). In representative embodiments, the nucleotide
sequence encodes an equivalent (optionally, a biologically active equivalent) of the
polypeptide of SEQ ID NO:2 and hybridizes to the complete complement of
coding sequence of SEQ ID NO: 1 under stringent hybridization conditions.
[0159] In additional representative embodiments, the nucleotide sequence encodes
the polypeptide of SEQ ID NO:4, or an equivalent polypeptide having substantial
amino acid sequence identity or similarity with SEQ ID NO:4 (optionally, a
biologically active equivalent). In representative embodiments, the nucleotide
sequence encodes an equivalent (optionally, a biologically active equivalent) of the
polypeptide of SEQ ID NO:4 and hybridizes to the complete complement of
coding sequence of SEQ ID NO: 3 under stringent hybridization conditions.
[0160] In further embodiments, the nucleotide sequence is a nucleic acid selected
from the group consisting of: (a) a nucleic acid encoding a polypeptide comprising
the LNK1 amino acid sequence of SEQ ID NO:2; (b) a nucleic acid encoding a
polypeptide having an amino acid sequence that is at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of
SEQ ID NO:2; (c) a nucleic acid encoding a polypeptide having an amino acid
sequence comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700,
800 or more contiguous amino acid residues of the amino acid sequence of SEQ
ID NO:2; (d) a nucleic acid encoding a polypeptide comprising the LNK2 amino
acid sequence of SEQ ID NO:4; (e) a nucleic acid encoding a polypeptide having
an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:4; (f)
a nucleic acid encoding a polypeptide comprising at least 50, 100, 150, 200, 250,
300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of t e
amino acid sequence of SEQ ID NO:4; (g) a nucleotide sequence comprising at
least 10, 15, 20, 25, 30, 35, 40, 45 or 50 consecutive nucleotides of t e nucleotide
sequence of SEQ ID NO:l or the complementary strand thereof; (h) a nucleotide
sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or 50 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (i) a nucleotide sequence comprising at least 100 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO:l or the complementary
strand thereof; (j) a nucleotide sequence comprising at least 100 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (k) a nucleotide sequence having at least 95% sequence identity to
the nucleotide sequence of (a)- (i) or (j); and (1) a nucleotide sequence that
hybridizes to the complete complement of the nucleotide sequence of (a)-(i) or (j)
under stringent hybridization conditions.
Accordingly, in one embodiment, the invention provides an isolated LNK3
nucleic acid comprising a nucleotide sequence selected from the group consisting
of: (a) the nucleotide sequence of SEQ ID NO: 13; (b) a nucleotide sequence
comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides
of the nucleotide sequence of SEQ ID NO: 13 or the complementary strand thereof;
(c) a nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 13 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK3 amino acid
sequence of SEQ ID NO: 14; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to the amino acid sequence of SEQ ID NO: 14; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO: 14; (g) a nucleotide sequence having at
least 95% sequence identity to t e nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a), (b), (c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to the
promoter. In further embodiments, the nucleic acids are transcribed to express a
functional RNA. The invention also encompasses expression cassettes and vectors
comprising LNK3 nucleic acids of the invention.
In an additional embodiment, the invention provides an isolated LNK4
nucleic acid comprising a nucleotide sequence selected from the group consisting
of: (a) the nucleotide sequence of SEQ ID NO: 15; (b) a nucleotide sequence
comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive nucleotides
of the nucleotide sequence of SEQ ID NO: 15 or the complementary strand thereof;
(c) a nucleotide sequence comprising at least 100 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 15 or the complementary strand thereof; (d) a
nucleotide sequence encoding a polypeptide comprising the LNK4 amino acid
sequence of SEQ ID NO: 16; (e) a nucleotide sequence encoding an amino acid
sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%
or 99% identical to the amino acid sequence of SEQ ID NO: 16; (f) a nucleotide
sequence encoding an amino acid sequence comprising at least 50, 100, 150, 200,
250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of
the amino acid sequence of SEQ ID NO: 16; (g) a nucleotide sequence having at
least 95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a
nucleotide sequence that hybridizes to the complete complement of the nucleotide
sequence of (a), (b), (c) or (d) under stringent hybridization conditions; and (i) a
nucleotide sequence that differs from the nucleotide sequence of any of (a), (c), (d)
or (e) due to the degeneracy of the genetic code. In a further embodiment, the
nucleic acids are operably associated with a promoter. In some embodiments, the
nucleic acids are in sense orientation relative to the promoter. In alternative
embodiments, the nucleic acids are in antisense orientation relative to t e
promoter. In further embodiments, the nucleic acids are transcribed to express a
functional RNA. The invention also encompasses expression cassettes and vectors
comprising LNK4 nucleic acids of the invention.
[0163] The invention further provides expression cassettes comprising a LNK
nucleic acid. In some embodiments the expression cassettes comprise a LNK
promoter sequence. In some embodiments the expression cassettes comprise a
nucleic acid encoding a LNK polypeptide or a nucleic acid that expresses a LNK
functional RNA. Thus, in some embodiments, t e invention provides expression
cassettes comprising a LNK nucleic acid encoding a LNK polypeptide operably
associated with a promoter. In some embodiments, the LNK nucleic acid is
operably associated with a heterologous promoter. In alternative embodiments, the
LNK nucleic acid is operably associated with endogenous LNK promoter
sequence.
[0164] In further embodiments, the expression cassettes comprise a LNK1 nucleic
acid operably associated with a promoter. In some embodiments, the LNK1
nucleic acid is in sense orientation relative to the promoter. In further
embodiments, the LNK1 nucleic acid encodes a polypeptide. In some
embodiments, the expression cassettes comprise a LNK1 nucleic acid in antisense
orientation relative to the promoter. In further embodiments, the LNK1 nucleic
acid expresses a functional RNA.
[0165] In further embodiments, the expression cassettes comprise a LNK2 nucleic
acid operably associated with a promoter. In some embodiments, the LNK2
nucleic acid is in sense orientation relative to the promoter. In further
embodiments, the LNK2 nucleic acid encodes a polypeptide. In some
embodiments, the expression cassettes comprise a LNK2 nucleic acid in antisense
orientation relative to the promoter. In further embodiments, the LNK2 nucleic
acid expresses a functional RNA.
[0166] In some embodiments, the expression cassettes comprise a LNK promoter
sequence operably associated with a nucleic acid of interest. In some
embodiments, the expression cassette comprises a LNK1 promoter. In other
embodiments, the expression cassette comprises a LNK2 promoter. In some
embodiments, the LNK1 nucleic acid is in nucleic acid encoding the LNK
polypeptide is operably associated with a LNK promoter sequence of t e invention.
In embodiments, the nucleic acid encoding the LNK polypeptide is operably
associated with a heterologous promoter.
[0167] The heterologous promoter can be any suitable promoter known in the art
(including bacterial, yeast, fungal, insect, mammalian, and plant promoters). In
particular embodiments, the promoter is a promoter for expression in plants. The
selection of promoters useable with the present invention can be made among
many different types of promoters. Thus, the choice of promoter depends upon
several factors, including, but not limited to, cell- or tissue-specific expression,
desired expression level, efficiency, inducibility and/or selectability. For example,
where expression in a specific tissue or organ is desired in addition to inducibility,
a tissue- specific promoter can be used (e.g., a root specific promoter). In contrast,
where expression in response to a stimulus is desired a promoter inducible by other
stimuli or chemicals can be used. Where continuous expression is desired
throughout the cells of a plant, a constitutive promoter can be chosen.
[0168] Non-limiting examples of constitutive promoters include cestrum virus
promoter (cmp) (U.S. Patent No. 7,166,770), an actin promoter (e.g., the rice actin
1 promoter; Wang et al, Mol. Cell. Biol. 12:3399-3406 (1992); as well as U.S.
Patent No. 5,641,876), Cauliflower Mosaic Virus (CaMV) 35S promoter (Odell et
al, Nature 313:810-812 (1985)), CaMV 19S promoter (Lawton et al, Plant Mol.
Biol. 9:315-324 (1987)), an opine synthetase promoter (e.g., nos, mas, ocs, etc;
(Ebert et al, PNAS 84:5745-5749 (1987)), Adh promoter (Walker et al, PNAS
84:6624-6629 (1987)), sucrose synthase promoter (Yang & Russell, PNAS
87:4144-4148 (1990)), and a ubiquitin promoter.
[0169] In some embodiments, the expression cassettes of the invention can further
comprise enhancer elements and/or tissue preferred elements in combination with
the promoter. In some embodiments, the expression cassette comprises a
constitutive S35 promoter operably associated with a polynucleotide sequence
encoding LNK having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
In some embodiments, the expression cassette comprises a constitutive S35
promoter operably associated with a polynucleotide sequence encoding LNK.
[0170] In some embodiments, the heterologous promoter is a promoter for
expression in a monocot plant. In further embodiments the heterologous promoter
is selected from: ZmUbil (Ubiquitin), Actl (Actin), OsTubAl, (Tubulin), OsCcl
(Cytochrome c), rubi3 (polyubiquitin), APX (ascorbate peroxidase), SCP1, PGD1
(phosphogluconate dehydrogenase), R1G1B (early drought induced protein) and
EIF5 (translation initiation factor).
[0171] In some embodiments, the heterologous promoter is a promoter for
expression in a dicot plant. In further embodiments the heterologous promoter is a
CsVMV (cassava vein mosaic virus) or ScBV (sugarcane bacilliform badnavirus)
promoter. In other embodiments, the heterologous promoter is an CaMV 35S
promoter.
[0172] Some non-limiting examples of tissue-specific promoters useable with t e
present invention include those driving the expression of seed storage proteins
(e.g., 13-conglycinin, cruciferin, napin phaseolin, etc), zein or oil body proteins
(such as oleosin), or proteins involved in fatty acid biosynthesis (including acyl
carrier protein, stearoyi- ACP desaturase and fatty acid desaturases (fad 2-1)), and
other nucleic acids expressed during embryo development (such as Bce4, see, e.g.,
Kridl et al, Seed Sci. Res. 1:209-219 (1991); as well as EP Patent No. 255378).
Thus, the promoters associated with these tissue-specific nucleic acids can be used
in the present invention.
[0173] Additional examples of tissue-specific promoters usable with the present
invention include, but are not limited to, the root-specific promoters RCc3 (Jeong
et al, Plant Physiol. 153:185-197 (2010)) and RB7 (U.S. Patent No. 5,459,252),
the lectin promoter (Lindstrom et al, Der. Genet. 11:160-167 (1990); and Vodkin
et al, Prog. Clin. Biol. Res. 138:87-98 (1983)), corn alcohol dehydrogenase 1
promoter (Dennis et al, Nucleic Acids Res. 12:3983-4000 (1984)), S-adenosyi-L-
methionine synthetase (SAMS) (Vander Mijnsbrugge et al, Plant and Cell
Physiology, 37(8): 1108-1 115 (1996)), corn light harvesting complex promoter
(Bansal et al, PNAS 89:3654-3658 (1992)), corn heat shock protein promoter
(O'Dell et al, EMBO J . 5:451-458 (1985); and Rochester et al, EMBO J . 5:451-
458 (1986)), pea small subunit RuBP carboxylase promoter (Cashmore, "Nuclear
genes encoding the small subunit of ribulose-l,5-bisphosphate carboxylase" pp.
29-39 In: Genetic Engineering of Plants, Hollaender ed., Plenum Press 1983; and
Poulsen et al, Mol. Gen. Genet. 205:193-200 (1986)), Ti plasmid mannopine
synthase promoter (Langridge et al, PNAS 86:3219-3223 (1989)), Ti plasmid
nopaline synthase promoter (Langridge et al, (1989), supra), petunia chalcone
isomerase promoter (van Tunen et al, EMBO J . 7:1257-1263 (1988)), bean
glycine rich protein 1 promoter (Keller et al, Genes Dev. 3:1639-1646 (1989)),
truncated CaMV 35S promoter (O'Dell et al, Nature 313:810-812 (1985)), potato
patatin promoter (Wenzler et al, Plant Mol. Biol. 13:347-354 (1989)), root cell
promoter (Yamamoto et al, Nucleic Acids Res. 18:7449 (1990)), maize zein
promoter (Kriz et al, Mol. Gen. Genet. 207:90-98 (1987); Langridge et al, Cell
34:1015-1022 (1983); Reina et al, Nucleic Acids Res. 18:6425 (1990); Reina et
al, Nucleic Acids Res. 18:7449 (1990); and Wandelt et al, Nucleic Acids Res.
17:2354 (1989)), globulin-1 promoter (Belanger et al, Genetics 129:863-872
(1991)), a-tubulin cab promoter (Sullivan et al, Mol. Gen. Genet. 215:431-440
(1989)), PEPCase promoter (Hudspeth et al, Plant Mol. Biol. 12:579-589 (1989)),
R gene complex-associated promoters (Chandler et al, Plant Cell 1:1175-1183
(1989)), and chalcone synthase promoters (Franken et al, EMBO J . 10:2605-2612
(1991)). Particularly useful for seed-specific expression is the pea vicilin promoter
(Czako et al, Mol. Gen. Genet. 235:33-40 (1992); as well as U.S. Patent No.
5,625,136). Other useful promoters for expression in mature leaves are those that
are switched on at the onset of senescence, such as the SAG promoter from
Arabidopsis (Gan etal, Science 270:1986-1988 (1995)).
[0174] In addition, promoters functional in plastids can be used. Non-limiting
examples of such promoters include the bacteriophage T3 gene 9 5' UTR and other
promoters disclosed in U.S. Patent No. 7,579,516. Other promoters useful with the
present invention include but are not limited to the S-E9 small subunit RuBP
carboxylase promoter and the Kunitz trypsin inhibitor gene promoter (Kti3).
[0175] In some embodiments, inducible promoters can be used with the present
invention. Examples of inducible promoters useable with the present invention
include, but are not limited to, tetracycline repressor system promoters, Lac
repressor system promoters, copper-inducible system promoters, salicylate-
inducible system promoters (e.g., the PRla system), glucocorticoid-inducible
promoters (Aoyama et al, Plant J . 11:605-612 (1997)), and ecdysone-inducible
system promoters. Other non-limiting examples of inducible promoters include
ABA- and turgor-inducible promoters, t e auxin-binding protein gene promoter
(Schwab et al, Plant J . 4:423-432 (1993)), the UDP glucose flavonoid glycosyl-
transferase promoter (Ralston et al, Genetics 119:185-197 (1988)), the IVIPI
proteinase inhibitor promoter (Cordero et al, Plant J . 6:141-150 (1994)), the
glyceraldehyde-3 -phosphate dehydrogenase promoter (Kohler et al, Plant Mol.
Biol. 29:1293-1298 (1995); Martinez et al, J . Mol. Biol. 208:551-565 (1989); and
Quigley et al, J . Mol. Evol. 29:412-421 (1989)) the benzene sulphonamide-
inducible promoters (U.S. Patent No. 5,364,780) and the glutathione S-transferase
promoters. Likewise, one can use any appropriate inducible promoter described in
Gatz et al, Current Opinion Biotechnol. 7:168-172 (1996) and Gatz et al, Annu.
Rev. Plant Physiol. Plant Mol. Biol. 48:89-108 (1997).
[0176] Other suitable promoters include promoters from viruses that infect t e
host plant including, but not limited to, promoters isolated from Dasheen mosaic
virus, Chlorella virus (e.g., the Chlorella virus adenine methyltransferase promoter;
Mitra et al, Plant Molecular Biology 26:85 (1994)), tomato spotted wilt virus,
tobacco rattle virus, tobacco necrosis virus, tobacco ring spot virus, tomato ring
spot virus, cucumber mosaic virus, peanut stump virus, alfalfa mosaic virus, and
the like.
[0177] The expression cassettes of the invention may further comprise a
transcriptional termination sequence. Any suitable termination sequence known in
the art may be used in accordance with the present invention. The termination
region may be native with the transcriptional initiation region, may be native with
the nucleotide sequence of interest, or may be derived from another source.
Convenient termination regions are available from the Ti-plasmid of A .
tumefaciens, such as the octopine synthetase and nopaline synthetase termination
regions. See also, Guerineau et al, Mol. Gen. Genet. 262:141 (1991); Proudfoot,
Cell 64:671 (1991); Sanfacon etal, Genes Dev. 5:141 (1991); Mogen etal, Plant
Cell 2:1261 (1990); Munroe et al, Gene 91:151 (1990); Ballas et al, Nucleic
Acids Res. 17:7891 (1989); and Joshi et al, Nucleic Acids Res. 15:9627 (1987).
Additional exemplary termination sequences are the pea RubP carboxylase small
subunit termination sequence and t e Cauliflower Mosaic Virus 35S termination
sequence. Other suitable termination sequences will be apparent to those skilled in
the art.
[0178] Further, in particular embodiments, the nucleotide sequence of interest
(e.g., heterologous nucleotide sequence of interest) is operably associated with a
translational start site. The translational start site can be derived from the LNK
coding sequence or, alternatively, can be the native translational start site
associated with a heterologous nucleotide sequence of interest, or any other
suitable translational start codon.
[0179] In illustrative embodiments, the expression cassette includes in the 5' to 3'
direction of transcription, a promoter, a nucleotide sequence of interest (e.g., a
heterologous nucleotide sequence of interest), and a transcriptional and
translational termination region functional in plants.
[0180] Those skilled in the art will understand that the expression cassettes of the
invention can further comprise enhancer elements and/or tissue preferred elements
in combination with the promoter. In some embodiments, the expression cassette
comprises a promoter sequence operably associated with the first intron of
Arabidopsis Cox5c2.
[0181] Further, in some embodiments, it is advantageous for the expression
cassette to comprise a selectable marker gene for the selection of transformed cells.
[0182] Selectable marker genes include genes encoding antibiotic resistance, such
as those encoding neomycin phosphotransferase II (NEO) and hygromycin
phosphotransferase (HPT), as well as genes conferring resistance to herbicidal
compounds. Herbicide resistance genes generally code for a modified target
protein insensitive to the herbicide or for an enzyme that degrades or detoxifies the
herbicide in the plant before it can act. See, DeBlock et al, EMBO J . 6:2513
(1987); DeBlock et al, Plant Physiol. 91:691 (1989); Fromm et al,
BioTechnology 8:833 (1990); Gordon-Kamm et al, Plant Cell 2:603 (1990). For
example, resistance to glyphosphate or sulfonylurea herbicides has been obtained
using genes coding for the mutant target enzymes, 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) and acetolactate synthase (ALS). Resistance to
glufosinate ammonium, boromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D)
have been obtained by using bacterial genes encoding phosphinothricin
acetyltransferase, a nitrilase, or a 2,4- dichlorophenoxyacetate monooxygenase,
which detoxify the respective herbicides.
[0183] Selectable marker genes that can be used according to the present invention
further include, but are not limited to, genes encoding: neomycin
phosphotransferase II (Fraley et al, CRC Critical Reviews in Plant Science 4:1
(1986)); cyanamide hydratase (Maier-Greiner et al, PNAS 88:4250 (1991));
aspartate kinase; dihydrodipicolinate synthase (Peri et al., BioTechnology 11:715
(1993)); the bar gene (Toki et al, Plant Physiol. 100: 1503 (1992); Meagher et al,
Crop Sci. 36:1367 (1996)); tryptophane decarboxylase (Goddijn et al, Plant Mol.
Biol. 22:907 (1993)); neomycin phosphotransferase (NEO; Southern et al, J . Mol.
Appl. Gen. 1:327 (1982)); hygromycin phosphotransferase (HPT orHYG; Shimizu
et al, Mol. Cell. Biol. 6:1074 (1986)); dihydrofolate reductase (DHFR; Kwok et
al, PNAS 83:4552 (1986)); phosphinothricin acetyltransferase (DeBlock et al,
EMBO J . 6:2513 (1987)); 2,2- dichloropropionic acid dehalogenase (Buchanan-
Wollatron et al, J . Cell. Biochem. 13D, 330 (1989)); acetohydroxyacid synthase
(United States Patent No. 4,761,373 to Anderson et al; Haughn et al, Mol. Gen.
Genet. 221:266 (1988)); 5-enolpyruvyl-shikimate-phosphate synthase (aroA;
Comai i al, Nature 317:741 (1985)); haloarylnitrilase (WO 87/04181 to Stalker et
al); acetyl-coenzyme A carboxylase (Parker et al, Plant Physiol. 92: 1220 (1990));
dihydropteroate synthase (sull; Guerineau et al, Plant Mol. Biol. 15:127 (1990));
and 32 kDa photosystem II polypeptide (psbA; Hirschberg et al, Science 222: 1346
(1983)).
[0184] Also included are genes encoding resistance to: chloramphenicol (Herrera-
Estrella et al, EMBO J . 2:987 (1983)); methotrexate (Herrera-Estrella et al,
Nature 303:209 (1983); Meijer etal, Plant Mol. Biol. 16:807 (1991)); hygromycin
(Waldron et al, Plant Mol. Biol. 5:103 (1985); Zhijian et al, Plant Science
108:219 (1995); Meijer etal, Plant Mol. Bio. 16:807 (1991)); streptomycin (Jones
et al, Mol. Gen. Genet. 210:86 (1987)); and spectinomycin (Bretagne- Sagnard et
al, Transgenic Res. 5:131 (1996)); bleomycin (Hille et al, Plant Mol. Biol. 7:171
(1986)); sulfonamide (Guerineau et al, Plant Mol. Bio. 15:127 (1990); bromoxynil
(Stalker et al, Science 242:419 (1988)); 2,4-D (Streber et al, Bio/Technology
7:8 11 (1989)); phosphinothricin (DeBlock e t al, EMBO J . 6:25 13 (1987));
spectinomycin (Bretagne-Sagnard et al., Transgenic Research 5 : 13 1 (1996)).
[0185] Other selectable marker genes include the pat gene (for bialaphos and
phosphinothricin resistance), t e ALS gene for imidazolinone resistance, t e HPH
or HYG gene for hygromycin resistance, the Hml gene for resistance to the He-
toxin, and other selective agents used routinely and known to one of ordinary skill
in the art. See generally, Yarranton, Curr. Opin. Biotech. 3:506 (1992);
Chistopherson et al, PNAS 89: 63 14 (1992); Yao et al, Cell 7 1:63 (1992);
Reznikoff, Mol. Microbial. 6:24 19 (1992); Barkley et al, THE OPERON 177-220
(1980); Hu et al, Cell 48:555 (1987); Brown et al, Cell 49:603 (1987); Figge et
al, Cell 52:7 13 (1988); Deuschle et al, PNAS 86:5400 (1989); Fuerst et al,
PNAS 86:2549 (1989); Deuschle et al, Science 248:480 (1990); Labow et al,
Mol. Cell. Biol. 10:3343 (1990); Zambretti et al, PNAS 89:3952 (1992); Baim et
al, PNAS 88:5072 (199 1); Wyborski et al, Nuc. Acids Res. 19:4647 (199 1);
Hillenand-Wissman, Topics in Mol. and Struct. Biol. 10: 143 (1989); Degenkolb et
al, Antimicrob. Agents Chemother. 35: 159 1 (199 1); Kleinschnidt et al,
Biochemistry 27: 1094 (1988); Gatz et al, Plant J . 2:397 (1992); Gossen et al,
PNAS 89:5547 (1992); Oliva et al, Antimicrob. Agents Chemother. 36:9 13
(1992); Hlavka., HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 78
(1985); and Gill et al, Nature 334:72 1 (1988).
[0186] The nucleotide sequence of interest can additionally be operably linked to a
sequence that encodes a transit peptide that directs expression of an encoded
polypeptide of interest to a particular cellular compartment. Transit peptides that
target protein accumulation in higher plant cells to the chloroplast, mitochondrion,
vacuole, nucleus, and the endoplasmic reticulum (for secretion outside of the cell)
are known in the art. Transit peptides that target proteins to the endoplasmic
reticulum are desirable for correct processing of secreted proteins. Targeting
protein expression to the chloroplast (for example, using the transit peptide from
the RubP carboxylase small subunit gene) has been shown to result in the
accumulation of very high concentrations of recombinant protein in this organelle.
The pea RubP carboxylase small subunit transit peptide sequence has been used to
express and target mammalian genes in plants (U.S. Patent Nos. 5,7 17,084 and
5,728,925). Alternatively, mammalian transit peptides can be used to target
recombinant protein expression, for example, to t e mitochondrion and
endoplasmic reticulum. It has been demonstrated that plant cells recognize
mammalian transit peptides that target endoplasmic reticulum (U.S. Patent Nos.
5,202,422 and 5,639,947).
[0187] Further, the expression cassette can comprise a 5' leader sequence that acts
to enhance expression (transcription, post-transcriptional processing and/or
translation) of an operably associated nucleotide sequence of interest. Leader
sequences are known in the art and include sequences from: picornavirus leaders,
e.g., EMCV leader (Encephalomyocarditis 5' noncoding region; Elroy-Stein et al.,
PNAS USA, 86:6126 (1989)); potyvirus leaders, e.g., TEV leader (Tobacco Etch
Virus; Allison et al., Virology, 154:9 (1986)); human immunoglobulin heavy-
chain binding protein (BiP; Macajak and Sarnow, Nature 353:90 (1991));
untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV
RNA 4; Jobling and Gehrke, Nature 325: 622 (1987)); tobacco mosaic virus leader
(TMV; Gallie, MOLECULAR BIOLOGY OF RNA, 237-56 (1989)); and maize
chlorotic mottle virus leader (MCMV; Lommel et al, Virology 81:382 (1991)).
See also, Della-Cioppa etal, Plant Physiology 84:965 (1987).
[0188] The heterologous nucleotide sequence(s) of interest in the expression
cassette can be any nucleotide sequence(s) of interest and can be obtained from
prokaryotes or eukaryotes (e.g., bacteria, fungi, yeast, viruses, plants, mammals) or
the heterologous nucleotide sequence can be synthesized in whole or in part.
Further, the heterologous nucleotide sequence can encode a polypeptide or can be
transcribed to produce a functional RNA. In particular embodiments, the
functional RNA can be expressed to improve an agronomic trait in the plant (e.g.,
drought resistance, heat resistance, salt resistance, disease resistance, insect and
other pest resistance [e.g., Bacillus thuringiensis endotoxin], herbicide resistance,
and the like), to confer male sterility, to improve fertility and/or enhance
nutritional quality (e.g., enzymes that enhance nutritional quality). The nucleotide
sequence may be used in the sense orientation or antisense orientation relative to
the promoter to achieve suppression of endogenous plant genes, as is known by
those skilled in the art (see, e.g., U.S. Patent Nos. 5,283,184; and 5,034,323).
[0189] The heterologous nucleotide sequence can encode a polypeptide that
imparts a desirable agronomic trait to the plant (as described above), confers male
sterility, improves fertility and/or improves nutritional quality. Other suitable
polypeptides include enzymes that can degrade organic pollutants or remove heavy
metals. Such plants, and the enzymes that can be isolated therefrom, are useful in
methods of environmental protection and remediation. Alternatively, the
heterologous nucleotide sequence can encode a therapeutically or pharmaceutically
useful polypeptide or an industrial polypeptide (e.g., an industrial enzyme). Such
polypeptides include, but are not limited to antibodies and antibody fragments,
cytokines, hormones, growth factors, receptors, enzymes and the like.
[0190] Heterologous nucleotide sequences of interest suitable to confer tolerance
to the herbicide glyphosate include, but are not limited to the Agrobacterium strain
CP4 glyphosate resistant EPSPS gene (aroA:CP4) as described in U.S. Patent No.
5,633,435 or t e glyphosate oxidoreductase gene (GOX) as described in U.S.
Patent No. 5,463,175. Other heterologous nucleotide sequences include genes
conferring resistance to herbicides that act to inhibit the action of acetolactate
synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., mutant forms
of t e acetolactate synthase (ALS) gene that lead to such resistance, in particular
the S4 and/or Hra mutations), genes coding for resistance to herbicides that act to
inhibit the action of glutamine synthase, such as phosphinothricin or basta (e.g.,
the bar gene). The bar gene encodes resistance to the herbicide basta, the nptll gene
encodes resistance to the antibiotics kanamycin and geneticin, and the ALS gene
encodes resistance to the herbicide chlorsulfuron.
[0191] Suitable heterologous nucleotide sequences that confer insect tolerance
include those which provide resistance to pests such as rootworm, cutworm,
European Corn Borer, and the like. Exemplary nucleotide sequences include, but
are not limited to, a Bacillus insect control protein gene (see, e.g., WO 99/31248;
U.S. Patent Nos. 5,689,052; 5,500,365; 5,880,275); Bacillus thuringiensis toxic
protein genes (see, e.g., U.S. Patent Nos. 5,366,892; 5,747,450; 5,737,514;
5,723,756; 5,593,881; 6,555,655; 6,541,448; and 6,538,109; Geiser, et al, Gene
48: 109 (1986)); and lectins (Van Damme et al, Plant Mol. Biol. 24:825 (1994)).
[0192] Alternatively, t e heterologous nucleotide sequence can encode a reporter
polypeptide (e.g., an enzyme), including but not limited to Green Fluorescent
Protein, beta-galactosidase, luciferase, alkaline phosphatase, the GUS gene
encoding beta- glucuronidase, and chloramphenicol acetyltransferase.
[0193] Where appropriate, the heterologous nucleic acids may be optimized for
increased expression in a transformed plant, e.g., by using plant preferred codons.
Methods for synthetic optimization of nucleic acid sequences are available in the
art. The nucleotide sequence can be optimized for expression in a particular host
plant or alternatively can be modified for optimal expression in monocots or
dicots. See, e.g., EP 0 359 472, EP 0 385 962, WO 91/16432; Perlak et al, PNAS
88, 3324 (1991), and Murray et al, Nucl. Acids Res. 17:477 (1989), and the like.
Plant preferred codons can be determined from the codons of highest frequency in
the proteins expressed in that plant. Additional sequence modifications are known
to enhance gene expression in a cellular host. These include elimination of
sequences encoding spurious polyadenylation signals, exon-intron splice site
signals, transposon-like repeats, and other such well-characterized sequences
which may be deleterious to gene expression. The G-C content of the sequence
may be adjusted to levels average for a given cellular host, as calculated by
reference to known genes expressed in the host cell. When possible, the sequence
is modified to avoid predicted hairpin secondary mRNA structures.
[0194] The invention further provides vectors comprising the LNK nucleic acids
of the invention and expression cassettes of the invention, including expression
vectors, transformation vectors and vectors for replicating and/or manipulating the
nucleotide sequences in the laboratory. The vector can be a plant vector, animal
(e.g., insect or mammalian) vector, bacterial vector, yeast vector or fungal vector.
Generally, according to the present invention, the vector is a plant vector, a
bacterial vector, or a shuttle vector that can replicate in either host under
appropriate conditions. Bacterial and plant vectors are well-known in the art.
Exemplary plant vectors include plasmids (e.g., pUC or the Ti plasmid), cosmids,
phage, bacterial artificial chromosomes (BACs), yeast artificial chromosomes
(YACs) and plant viruses.
III. Transgenic plants, plant parts and plant cells.
[0195] The invention also provides transgenic plants, plant parts and plant cells
comprising the nucleic acids, expression cassettes and vectors of the invention.
[0196] Accordingly, as one aspect, the invention provides a cell comprising a LNK
nucleic acid, expression cassette, or vector of the invention. The cell can be
transiently or stably transformed with t e nucleic acid, expression cassette or
vector. Further, t e cell can be a cultured cell, a cell obtained from a plant, plant
part, or plant tissue, or a cell in situ in a plant, plant part or plant tissue. Cells can
be from any suitable species, including plant {e.g., Arabidopsis thaliana and
Helianthus annuus), bacterial, yeast, insect and/or mammalian cells. In
representative embodiments, the cell is a plant cell or bacterial cell.
[0197] The invention also provides a plant part (including a plant tissue culture)
comprising a nucleic acid, expression cassette, or vector of the invention. The plant
part can be transiently or stably transformed with the nucleic acid, expression
cassette or vector. Further, the plant part can be in culture, can be a plant part
obtained from a plant, or a plant part in situ. In representative embodiments, the
plant part comprises a transgenic cell of the invention, as described in the
preceding paragraph.
[0198] Seed comprising the LNK nucleic acid, expression cassette, or vector of the
invention are also provided. Optionally, the nucleic acid, expression cassette or
vector is stably incorporated into the genome of the seed.
[0199] The invention also contemplates a transgenic plant comprising a LNK
nucleic acid, expression cassette, or vector of the invention. The plant can be
transiently or stably transformed with the LNK nucleic acid, expression cassette or
vector. In representative embodiments, the plant comprises a cell or plant part of
the invention, as described in the preceding paragraphs. In some embodiments, the
transgenic plant has an altered circadian rhythm compared to a non-transgenic
control wild-type plant. In additional embodiments, the transgenic plant has an
altered PRR5, ELF4 and/or FKF1 expression profile compared to a non-transgenic
control wild-type plant. In some embodiments, the transgenic plant has an
accelerated flowering time and/or decreased biomass compared to a non-transgenic
control wild-type plant. In alternative embodiments, the transgenic plant has a
delayed flowering time and/or increased biomass compared to a non-transgenic
control wild-type plant. In additional embodiments, the transgenic plant has
increased yield compared to a non-transgenic control wild-type plant. In a further
embodiment, the transgenic plant has an increased tolerance to an abiotic stress
(e.g., high intensity light, low intensity light, drought, high temperature, low
temperature and/or high salinity (e.g., salt)) compared to a non-transgenic control
wild-type plant.
In some embodiments, the invention encompasses a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK polypeptide. In
additional embodiments, the invention encompasses a transgenic plant stably
transformed with an isolated nucleic acid comprising a LNK1 nucleotide sequence
selected from t e group consisting of: (a) the nucleotide sequence of SEQ ID
NO: l ; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45,
50 or 75 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: l or
the complementary strand thereof; (c) a nucleotide sequence comprising at least
100 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: l or the
complementary strand thereof; (d) a nucleotide sequence encoding a polypeptide
comprising the LNK1 amino acid sequence of SEQ ID NO:2; (e) a nucleotide
sequence encoding an amino acid sequence that is at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of
SEQ ID NO:2; (f) a nucleotide sequence encoding an amino acid sequence
comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or
more contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2;
(g) a nucleotide sequence having at least 95% sequence identity to the nucleotide
sequence of (a)-(e) or (f); (h) a nucleotide sequence that hybridizes to the complete
complement of the nucleotide sequence of (a)-(c) or (d) under stringent
hybridization conditions; and (i) a nucleotide sequence that differs from the
nucleotide sequence of any of (a), (c), (d) or (e) due to the degeneracy of the
genetic code. In a further embodiment, the nucleic acids are operably associated
with a promoter. In some embodiments, the nucleic acids are in sense orientation
relative to the promoter. In alternative embodiments, the nucleic acids are in
antisense orientation relative to the promoter.
[0201] In additional embodiments, t e invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNKl polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNKl amino acid
sequence of SEQ ID NO:2; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO:2; and (c) an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of the amino acid sequence of SEQ ID NO:2.
[0202] The invention also encompasses a transgenic plant stably transformed with
an isolated LNK2 nucleic acid comprising a nucleotide sequence selected from the
group consisting of: (a) the nucleotide sequence of SEQ ID NO:3; (b) a nucleotide
sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45, 50 or 75 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (c) a nucleotide sequence comprising at least 100 consecutive
nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the complementary
strand thereof; (d) a nucleotide sequence encoding a polypeptide comprising the
LNKl amino acid sequence of SEQ ID NO:4; (e) a nucleotide sequence encoding
an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:4; (f)
a nucleotide sequence encoding an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of t e amino acid sequence of SEQ ID NO: 4; (g) a nucleotide
sequence having at least 95% sequence identity to the nucleotide sequence of (a)-
(e) or (f); (h) a nucleotide sequence that hybridizes to the complete complement of
the nucleotide sequence of (a)-(c) or (d) under stringent hybridization conditions;
and (i) a nucleotide sequence that differs from the nucleotide sequence of any of
(a), (c), (d) or (e) due to the degeneracy of the genetic code. In a further
embodiment, the nucleic acids are operably associated with a promoter. In some
embodiments, the nucleic acids are in sense orientation relative to the promoter. In
alternative embodiments, the nucleic acids are in antisense orientation relative to
the promoter.
[0203] In additional embodiments, t e invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK2 polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO:4; and (c) an amino acid sequence comprising at least 50,
100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino
acid residues of the amino acid sequence of SEQ ID NO:4.
[0204] The invention also encompasses a transgenic plant stably transformed with
both an isolated LNK1 and LNK2 nucleic acid of the invention. In particular
embodiments, the nucleic acid sequence encodes the LNK1 polypeptide sequence
of SEQ ID NO:2 and/or the LNK2 polypeptide sequence of SEQ ID NO:4.
[0205] In additional embodiments, t e invention encompasses transgenic plant
stably transformed with an isolated nucleic acid comprising a nucleotide sequence
selected from the group consisting of: (a) the nucleotide sequence of SEQ ID
NO:l; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45
or 50 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:l or the
complementary strand thereof; (c) a nucleotide sequence comprising at least 100
consecutive nucleotides of the nucleotide sequence of SEQ ID NO:l or the
complementary strand thereof; (d) the nucleotide sequence of SEQ ID NO:3; (e) a
nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or 50
consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the
complementary strand thereof; (f) a nucleotide sequence comprising at least 100
consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 3 or the
complementary strand thereof; (g) a nucleotide sequence having at least 95%
sequence identity to the nucleotide sequence of (a), (c), (d) or (f); (h) a nucleotide
sequence that hybridizes to the complete complement of the nucleotide sequence
of (a), (c), (d) or (f) under stringent hybridization conditions; and (i) a nucleotide
sequence that differs from the nucleotide sequence of any of (a), (c), (d) or (f)-(h)
due to the degeneracy of the genetic code.
[0206] In particular embodiments, the transgenic plant comprises at least 10, 15,
20, 25 or 30 consecutive nucleotides of the LNK1 nucleotide sequence of SEQ ID
NO:l, or the complementary strand thereof. In additional particular embodiments,
t e transgenic plants comprises at least 10, 15, 20, 25 or 30 consecutive
nucleotides of t e LNK2 nucleotide sequence of SEQ ID NO:3, or the
complementary strand thereof.
[0207] In some embodiments, the transgenic plants are transformed with a vector
comprising a LNK nucleic acid. In some embodiments, the vector comprises a
LNK1 nucleic acid such as described herein. In some embodiments, the vector
comprises a LNK2 nucleic acid such as described herein.
[0208] In one embodiment, the invention provides a transgenic plant stably
transformed with an isolated nucleic acid comprising a LNK3 nucleotide sequence
selected from the group consisting of: (a) the nucleotide sequence of SEQ ID
NO: 13; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45,
50 or 75 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 13 or
the complementary strand thereof; (c) a nucleotide sequence comprising at least
100 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 13 or the
complementary strand thereof; (d) a nucleotide sequence encoding a polypeptide
comprising the LNK3 amino acid sequence of SEQ ID NO: 14; (e) a nucleotide
sequence encoding an amino acid sequence that is at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of
SEQ ID NO: 14; (f) a nucleotide sequence encoding an amino acid sequence
comprising at least 50, 100, 150, 200 or 250 contiguous amino acid residues of the
amino acid sequence of SEQ ID NO: 14; (g) a nucleotide sequence having at least
95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a nucleotide
sequence that hybridizes to the complete complement of the nucleotide sequence
of (a)-(c) or (d) under stringent hybridization conditions; and (i) a nucleotide
sequence that differs from the nucleotide sequence of any of (a), (c), (d) or (e) due
to the degeneracy of the genetic code. In a further embodiment, the nucleic acids
are operably associated with a promoter. In some embodiments, the nucleic acids
are in sense orientation relative to the promoter. In alternative embodiments, the
nucleic acids are in antisense orientation relative to the promoter. In further
embodiments, the nucleic acids are transcribed to express a functional RNA. The
invention also encompasses expression cassettes and vectors comprising nucleic
acids of the invention.
[0209] In one embodiment, the invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK3 polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNK3 amino acid
sequence of SEQ ID NO: 14; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO: 14; and (c) an amino acid sequence comprising at least
50, 100, 150, 200 or 250 contiguous amino acid residues of the amino acid
sequence of SEQ ID NO: 14.
[0210] In additional embodiments, t e invention provides a transgenic plant stably
transformed with an isolated LNK4 nucleic acid comprising a nucleotide sequence
selected from the group consisting of: (a) the nucleotide sequence of SEQ ID
NO: 15; (b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45,
50 or 75 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 15 or
the complementary strand thereof; (c) a nucleotide sequence comprising at least
100 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 15 or the
complementary strand thereof; (d) a nucleotide sequence encoding a polypeptide
comprising the LNK4 amino acid sequence of SEQ ID NO: 16; (e) a nucleotide
sequence encoding an amino acid sequence that is at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of
SEQ ID NO: 16; (f) a nucleotide sequence encoding an amino acid sequence
comprising at least 50, 100, 150, 200 or 250 contiguous amino acid residues of the
amino acid sequence of SEQ ID NO: 16; (g) a nucleotide sequence having at least
95% sequence identity to the nucleotide sequence of (a)-(e) or (f); (h) a nucleotide
sequence that hybridizes to the complete complement of the nucleotide sequence
of (a)-(c) or (d) under stringent hybridization conditions; and (i) a nucleotide
sequence that differs from the nucleotide sequence of any of (a), (c), (d) or (e) due
to the degeneracy of the genetic code. In a further embodiment, the nucleic acids
are operably associated with a promoter. In some embodiments, the nucleic acids
are in sense orientation relative to the promoter. In alternative embodiments, the
nucleic acids are in antisense orientation relative to the promoter.
[0211] In one embodiment, the invention provides a transgenic plant stably
transformed with an isolated nucleic acid encoding a LNK4 polypeptide selected
from the group consisting of: (a) a polypeptide comprising the LNK4 amino acid
sequence of SEQ ID NO: 16; (b) an amino acid sequence that is at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid
sequence of SEQ ID NO: 16; and (c) an amino acid sequence comprising at least
50, 100, 150, 200 or 250 contiguous amino acid residues of the amino acid
sequence of SEQ ID NO: 16.
[0212] The invention also encompasses a transgenic plant stably transformed with
both an isolated LNK3 and LNK4 nucleic acid of the invention. In particular
embodiments, the nucleic acid sequence encodes the LNK3 polypeptide sequence
of SEQ ID NO: 14 and/or the LNK4 polypeptide sequence of SEQ ID NO: 16.
[0213] In additional embodiments, the transgenic plants are transformed with an
expression cassette comprising a LNK nucleic acid. In some embodiments, the
expression cassette comprises a LNK promoter sequence operably associated with
a nucleic acid sequence of interest. In a further embodiment the expression
cassette comprises a LNK coding sequence or is transcribed to form a functional
LNK RNA. In further embodiments, the expression cassette comprises a LNK
nucleic acid coding sequence or a LNK nucleic acid that is transcribed to form a
functional RNA, operably associated with a promoter. In some embodiments, the
promoter is an endogenous LNK promoter sequence. In alternative embodiments,
t e promoter is a heterologous promoter sequence. In further embodiments, the
expression cassette comprises a selectable marker.
[0214] In further embodiments, the transgenic plants are transformed with an
expression cassette comprising a LNKl nucleic acid. In some embodiments, the
expression cassette comprises a LNKl promoter sequence operably associated
with a nucleic acid sequence of interest. In a further embodiment the expression
cassette comprises a LNKl coding sequence or is transcribed to a functional LNKl
RNA. In further embodiments, the expression cassette comprises a LNKl nucleic
acid coding sequence or a LNKl nucleic acid that is transcribed to a functional
RNA, operably associated with a promoter. In some embodiments, the promoter is
an endogenous LNKl promoter sequence. In alternative embodiments, the
promoter is a heterologous promoter. In further embodiments, the expression
cassette comprises a selectable marker.
[0215] In additional embodiments, the transgenic plants are transformed with an
expression cassette comprising a LNK2 nucleic acid. In some embodiments, the
expression cassette comprises a LNK2 promoter sequence operably associated
with a nucleic acid sequence of interest. In a further embodiment the expression
cassette comprises a LNK2 coding sequence or is transcribed to a functional LNK2
RNA. In further embodiments, the expression cassette comprises a LNK2 nucleic
acid coding sequence or a LNK nucleic acid that is transcribed to a functional
RNA, operably associated with a promoter. In some embodiments, the promoter is
an endogenous LNK2 promoter sequence. In alternative embodiments, the
promoter is a heterologous promoter. In further embodiments, the expression
cassette comprises a selectable marker.
[0216] The invention also encompasses a crop comprising a plurality of the
transgenic plants of the invention, as described herein. Non-limiting examples of
the types of crops comprising a plurality of transgenic plants of the invention
include an agricultural field, a golf course, a residential lawn or garden, a public
lawn or garden, a road side planting, an orchard, and/or a recreational field (e.g., a
cultivated area comprising a plurality of the transgenic plants of the invention).
[0217] Products harvested from the plants of the invention are also provided. Non-
limiting examples of a harvested product include a seed (e.g., sunflower seeds and
grain), a leaf, a stem, a shoot, a fruit, flower, root, biomass (e.g., for biofuel
production) and/or extract.
[0218] In some embodiments, a processed product produced from the harvested
product is provided. Non-limiting examples of a processed product include a
protein (e.g., a recombinant protein), an extract, a medicinal product (e.g.,
artemicin as an antimalarial agent), a fiber or woven textile, a fragrance, dried
fruit, a biofuel (e.g., ethanol), a tobacco product (e.g., cured tobacco, cigarettes,
chewing tobacco, cigars, and the like), an oil (e.g., sunflower oil, corn oil, canola
oil, and the like), a nut butter, a seed butter (e.g., sunflower butter), a flour or meal
(e.g., wheat flour, corn meal) and/or any other animal feed (e.g., soy, maize,
barley, rice, alfalfa) and/or human food product (e.g., a processed wheat, maize,
rice or soy food product). Further, processed product can be cut, dried, cooked,
canned, frozen, dehydrated, powdered, ground and/or mixed with other
ingredients.
III. Methods of transforming plants and plant cells
[0219] The invention also provides methods of delivering (i.e., introducing) a
nucleic acid, expression cassette or vector of the invention to a target plant or plant
cell (including callus cells or protoplasts), plant parts, seed, plant tissue (including
callus), and the like. The invention further comprises host plants, cells, plant parts,
seeds, tissue culture (including callus) transiently or stably transformed with t e
nucleic acids, expression cassettes or vectors of the invention. In representative
embodiments, the methods of the invention comprise transforming the plant, plant
part or plant cell with a nucleic acid, expression cassette, or vector comprising an
LNK coding sequence operably associated with a promoter. In other embodiments,
the methods of the invention comprise transforming the plant, plant part or plant
cell with a nucleic acid, expression cassette, or vector comprising an LNK
nucleotide sequence transcribed to form a functional RNA in operable association
with a promoter.
[0220] Also provided by the invention are seed produced from the inventive
transgenic plants. Optionally, the seed comprise a nucleic acid, expression cassette
or vector of the invention stably incorporated into the genome.
[0221] Methods of introducing nucleic acids, transiently or stably, into plants,
plant tissues, cells, protoplasts, seed, callus and the like are known in the art.
Stably transformed nucleic acids can be incorporated into the genome. Exemplary
transformation methods include biological methods using viruses and
Agrobacterium, physicochemical methods such as electroporation, floral dip
methods, polyethylene glycol, ballistic bombardment, microinjection, and the like.
Other transformation technology includes the whiskers technology that is based on
mineral fibers (see 'e.g., U.S. Patent No. 5,302,523 and 5,464,765) and pollen tube
transformation. In one form of direct transformation, the vector is microinjected
directly into plant cells by use of micropipettes to mechanically transfer the
recombinant DNA (Crossway, Mol. Gen. Genetics 202: 179 (1985)).
[0222] In another protocol, the genetic material is transferred into t e plant cell
using polyethylene glycol (Krens et al, Nature 296:72 (1982)).
[0223] In still another method, protoplasts are fused with minicells, cells,
lysosomes, or other fusible lipid-surfaced bodies that contain the nucleotide
sequence to be transferred to the plant (Fraley et al., PNAS 79: 1859 (1982)).
[0224] Nucleic acids may also be introduced into the plant cells by electroporation
(Fromm et al, PNAS 82:5824 (1985)). In this technique, plant protoplasts are
electroporated in the presence of nucleic acids comprising the expression cassette.
Electrical impulses of high field strength reversibly permeabilize biomembranes
allowing the introduction of the nucleic acid. Electroporated plant protoplasts
reform the cell wall, divide and regenerate. One advantage of electroporation is
that large pieces of DNA, including artificial chromosomes, can be transformed by
this method.
[0225] Ballistic transformation typically comprises the steps of: (a) providing a
plant material as a target; (b) propelling a microprojectile carrying the
heterologous nucleotide sequence at the plant target at a velocity sufficient to
pierce the walls of the cells within the target and to deposit the nucleotide
sequence within a cell of the target to thereby provide a transformed target. The
method can further include the step of culturing the transformed target with a
selection agent and, optionally, regeneration of a transformed plant. As noted
below, the technique may be carried out with the nucleotide sequence as a
precipitate (wet or freeze-dried) alone, in place of the aqueous solution containing
the nucleotide sequence.
[0226] Any ballistic cell transformation apparatus can be used in practicing the
present invention. Exemplary apparatus are disclosed by Sandford et al,
Particulate Science and Technology 5:27 (1988)), Klein et al, Nature 327:70
(1987)), and in EP 0 270 356. Such apparatus have been used to transform maize
cells (Klein et al, PNAS 85:4305 (1988)), soybean callus (Christou et al, Plant
Physiol. 87:671 (1988)), McCabe et al, BioTechnology 6:923 (1988), yeast
mitochondria (Johnston et al, Science 240:1538 (1988)), and Chlamydomonas
chloroplasts (Boynton et al, Science 240:1534 (1988)).
[0227] Alternately, an apparatus configured as described by Klein et al, (Nature
70:327 (1987)) may be utilized. This apparatus comprises a bombardment
chamber, which is divided into two separate compartments by an adjustable-height
stopping plate. An acceleration tube is mounted on top of the bombardment
chamber. A macroprojectile is propelled down the acceleration tube at t e stopping
plate by a gunpowder charge. The stopping plate has a borehole formed therein,
which is smaller in diameter than the microprojectile. The macroprojectile carries
t e microprojectile(s), and the macroprojectile is aimed and fired at the borehole.
When the macroprojectile is stopped by the stopping plate, the microprojectile(s) is
propelled through the borehole. The target is positioned in the bombardment
chamber so that a microprojectile(s) propelled through the bore hole penetrates the
cell walls of the cells in the target and deposit the nucleotide sequence of interest
carried thereon in the cells of the target. The bombardment chamber is partially
evacuated prior to use to prevent atmospheric drag from unduly slowing the
microprojectiles. The chamber is only partially evacuated so that the target tissue is
not desiccated during bombardment. A vacuum of between about 400 to about 800
millimeters of mercury is suitable.
[0228] In alternate embodiments, ballistic transformation is achieved without use
of microprojectiles. For example, an aqueous solution containing the nucleotide
sequence of interest as a precipitate may be carried by the macroprojectile (e.g., by
placing the aqueous solution directly on the plate-contact end of the
macroprojectile without a microprojectile, where it is held by surface tension), and
the solution alone propelled at the plant tissue target (e.g., by propelling the
macroprojectile down the acceleration tube in the same manner as described
above). Other approaches include placing the nucleic acid precipitate itself ("wet"
precipitate) or a freeze-dried nucleotide precipitate directly on the plate-contact
end of the macroprojectile without a microprojectile. In the absence of a
microprojectile, it is believed that the nucleotide sequence must either be propelled
at the tissue target at a greater velocity than that needed if carried by a
microprojectile, or the nucleotide sequenced caused to travel a shorter distance to
the target (or both).
[0229] It particular embodiments, the nucleotide sequence is delivered by a
microprojectile. The microprojectile can be formed from any material having
sufficient density and cohesiveness to be propelled through t e cell wall, given the
particle's velocity and the distance t e particle must travel. Non-limiting examples
of materials for making microprojectiles include metal, glass, silica, ice,
polyethylene, polypropylene, polycarbonate, and carbon compounds (e.g.,
graphite, diamond). Non-limiting examples of suitable metals include tungsten,
gold, and iridium. The particles should be of a size sufficiently small to avoid
excessive disruption of the cells they contact in the target tissue, and sufficiently
large to provide the inertia required to penetrate to the cell of interest in the target
tissue. Particles ranging in diameter from about one-half micrometer to about three
micrometers are suitable. Particles need not be spherical, as surface irregularities
on the particles may enhance their carrying capacity.
[0230] The nucleotide sequence may be immobilized on the particle by
precipitation. The precise precipitation parameters employed will vary depending
upon factors such as the particle acceleration procedure employed, as is known in
the art. The carrier particles may optionally be coated with an encapsulating agents
such as polylysine to improve the stability of nucleotide sequences immobilized
thereon, as discussed in EP 270356 (column 8).
[0231] Alternatively, plants may be transformed using Agrobacterium tumefaciens
or Agrobacterium rhizogenes. Agrobacterium-mediated nucleic acid transfer
exploits the natural ability of A . tumefaciens and A . rhizogenes to transfer DNA
into plant chromosomes. Agrobacterium is a plant pathogen that transfers a set of
genes encoded in a region called T-DNA of the Ti and Ri plasmids of A .
tumefaciens and A . rhizogenes, respectively, into plant cells. The typical result of
transfer of the Ti plasmid is a tumorous growth called a crown gall in which the T-
DNA is stably integrated into a host chromosome. Integration of the Ri plasmid
into the host chromosomal DNA results in a condition known as "hairy root
disease". The ability to cause disease in the host plant can be removed by deletion
of the genes in the T-DNA without loss of DNA transfer and integration. The DNA
to be transferred is attached to border sequences that define the end points of an
integrated T-DNA.
[0232] Transfer by means of engineered Agrobacterium strains has become routine
for many dicotyledonous plants. Some difficulty has been experienced, however,
in using Agrobacterium to transform monocotyledonous plants, in particular,
cereal plants. However, Agrobacterium mediated transformation has been achieved
in several monocot species, including cereal species such as rye, maize (Rhodes et
al, Science 240:204 (1988)), and rice (Hiei etal, Plant J . 6:271 (1994)).
[0233] While the following discussion will focus on using A . tumefaciens to
achieve gene transfer in plants, those skilled in t e art will appreciate that this
discussion also applies to A . rhizogenes. Transformation using A . rhizogenes has
developed analogously to that of A . tumefaciens and has been successfully utilized
to transform, for example, alfalfa, Solarium nigrum L., and poplar (U.S. Patent No.
5,777,200). As described by U.S. Patent No. 5, 773,693, it is preferable to use a
disarmed A . tumefaciens strain, however, the wild-type A . rhizogenes may be
employed. An illustrative strain of A . rhizogenes is strain 15834.
[0234] In particular protocols, the Agrobacterium strain is modified to contain the
nucleotide sequences to be transferred to t e plant. The nucleotide sequence to be
transferred is incorporated into the T-region and is typically flanked by at least one
T-DNA border sequence, optionally two T-DNA border sequences. A variety of
Agrobacterium strains are known in the art particularly, and can be used in the
methods of the invention. See, e.g., Hooykaas, Plant Mol. Biol. 13:327 (1989);
Smith et al, Crop Science 35:301 (1995); Chilton, PNAS 90, 3119 (1993);
Mollony et al, Monograph Theor. Appl. Genet NY 19, 148 (1993); Ishida et al,
Nature Biotechnol. 14:745 (1996); and Komari etal, The Plant J . 10:165 (1996).
[0235] In addition to the T-region, the Ti (or Ri) plasmid contains a vir region. The
vir region is important for efficient transformation, and appears to be species-
specific.
[0236] Two exemplary classes of recombinant Ti and Ri plasmid vector systems
are commonly used in the art. In one class, called "cointegrate," the shuttle vector
containing the gene of interest is inserted by genetic recombination into a
non-oncogenic Ti plasmid that contains both the cis-acting and trans-acting
elements required for plant transformation as, for example, in the PMLJ1 shuttle
vector of DeBlock et al, EMBO J . 3:1681 (1984), and the non-oncogenic Ti
plasmid pGV2850 described by Zambryski e t al, EMBOJ. 2:2 143 ( 1983). In the
second class or "binary" system, the gene of interest is inserted into a shuttle vector
containing the cis-acting elements required for plant transformation. The other
necessary functions are provided in trans by the non-oncogenic Ti plasmid as
exemplified by the pBIN19 shuttle vector described by Bevan, Nucleic Acids
Research 12: 87 11 (1984), and the non-oncogenic Ti plasmid PAL4404 described
by Hoekma, e t al, Nature 303 :179 (1983).
[0237] Binary vector systems have been developed where the manipulated
disarmed T-DNA carrying t e heterologous nucleotide sequence of interest and t e
vir functions are present on separate plasmids. In this manner, a modified T-DNA
region comprising foreign DNA (the nucleic acid to be transferred) is constructed
in a small plasmid that replicates in E . coll This plasmid is transferred
conjugatively in a tri-parental mating or via electroporation into A . tumefaciens
that contains a compatible plasmid with virulence gene sequences. The vir
functions are supplied in trans to transfer the T-DNA into the plant genome. Such
binary vectors are useful in the practice of the present invention.
[0238] In particular embodiments of the invention, super-binary vectors are
employed. See, e.g., U.S. Patent No. 5,59 1,615 and EP 604662. Such a super-
binary vector has been constructed containing a DNA region originating from the
hypervirulence region of the Ti plasmid pTiBo542 (Jin et al, J . Bacterial.
169:44 17 (1987)) contained in a super-virulent A . tumefaciens A28 1 exhibiting
extremely high transformation efficiency (Hood et al, Biotechnol. 2:702 ( 1984);
Hood et al, J . Bacterial. 168: 1283 (1986); Komari et al, J . Bacterial. 166: 88
(1986) ; Jin e t al, J . Bacterial. 169:44 17 ( 1987); Komari, Plant Science 60:223
(1987) ; ATCC Accession No. 37394.
[0239] Exemplary super-binary vectors known to those skilled in the art include
pTOK162 (Japanese patent Appl. (Kokai) No. 4-222527, EP 504,869, EP 604,662,
and United States Patent No. 5,59 1,616) and pTOK233 (Komari, Plant Cell
Reports 9:303 (1990); Ishida et al, Nature Biotechnology 14:745 (1996)). Other
super- binary vectors may be constructed by the methods set forth in the above
references. Super-binary vector pTOK162 is capable of replication in both E . coli
and in A . tumefaciens . Additionally, the vector contains the virB, virC and virG
genes from the virulence region of pTiBo542. The plasmid also contains an
antibiotic resistance gene, a selectable marker gene, and the nucleic acid of interest
to be transformed into the plant. The nucleic acid to be inserted into the plant
genome is typically located between the two border sequences of the T region.
Super-binary vectors of the invention can be constructed having t e features
described above for pTOK162.
[0240] The T-region of the super-binary vectors and other vectors for use in the
invention are constructed to have restriction sites for the insertion of the genes to
be delivered. Alternatively, the DNA to be transformed can be inserted in the T-
DNA region of the vector by utilizing in vivo homologous recombination. See,
Herrera-Esterella et al, EMBO J . 2:987 (1983); Horch et al, Science 223:496
(1984). Such homologous recombination relies on the fact that the super-binary
vector has a region homologous with a region of bpR322 or other similar plasmids.
Thus, when the two plasmids are brought together, a desired gene is inserted into
the super-binary vector by genetic recombination via the homologous regions.
[0241] In plants stably transformed by Agrobacteria-mediated transformation, the
nucleotide sequence of interest is incorporated into the plant nuclear genome,
typically flanked by at least one T-DNA border sequence and generally two T-
DNA border sequences.
[0242] Plant cells may be transformed with Agrobacterici by any means known in
the art, e.g., by co-cultivation with cultured isolated protoplasts, or transformation
of intact cells or tissues. The first uses an established culture system that allows for
culturing protoplasts and subsequent plant regeneration from cultured protoplasts.
Identification of transformed cells or plants is generally accomplished by including
a selectable marker in the transforming vector, or by obtaining evidence of
successful bacterial infection.
[0243] Protoplasts, which have been transformed by any method known in the art,
can also be regenerated to produce intact plants using known techniques.
[0244] Plant regeneration from cultured protoplasts is described in Evans et al,
Handbook of Plant Cell Cultures, Vol. 1 : (MacMillan Publishing Co. New York,
1983); and Vasil I . R . (ed.), Cell Culture and Somatic Cell Genetics of Plants,
Acad. Press, Orlando, Vol. I, 1984, and Vol. II, 1986). Essentially all plant species
can be regenerated from cultured cells or tissues, including but not limited to, all
major species of sugar-cane, sugar beet, cotton, fruit trees, and legumes.
[0245] Means for regeneration vary from species to species of plants, but generally
a suspension of transformed protoplasts or a petri plate containing transformed
explants is first provided. Callus tissue is formed and shoots may be induced from
callus and subsequently root. Alternatively, somatic embryo formation can be
induced in the callus tissue. These somatic embryos germinate as natural embryos
to form plants. The culture media will generally contain various amino acids and
plant hormones, such as auxin and cytokinins. It is also advantageous to add
glutamic acid and proline to the medium, especially for such species as corn and
alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on
t e history of t e culture. If these three variables are controlled, then regeneration
is usually reproducible and repeatable.
[0246] The regenerated plants are transferred to standard soil conditions and
cultivated in a conventional manner. The plants are grown and harvested using
conventional procedures.
[0247] Alternatively, transgenic plants may be produced using the floral dip
method (See, e.g., Clough et al, Plant J. 16:735-743 (1998), which avoids the need
for plant tissue culture or regeneration. In one representative protocol, plants are
grown in soil until the primary inflorescence is about 10 cm tall. The primary
inflorescence is cut to induce the emergence of multiple secondary inflorescences.
The inflorescences of these plants are typically dipped in a suspension of
Agrobacterium containing the vector of interest, a simple sugar (e.g., sucrose) and
surfactant. After the dipping process, the plants are grown to maturity and the
seeds are harvested. Transgenic seeds from these treated plants can be selected by
germination under selective pressure (e.g., using the chemical bialaphos).
Transgenic plants containing the selectable marker survive treatment and can be
transplanted to individual pots for subsequent analysis. See, Bechtold, et al,
Methods Mol Biol. 82:259-266 (1998); Chung et al, Transgenic Res 9:471-476
(2000); Clough et al, A . Plant J. 16:735-743 (1998); Mysore et al, Plant J. 21:9-
16 (2000); Tague et al, Transgenic Res. 10:259-267 (2001); Wang et al, Plant
Cell Rep. 22:274-281 (2003); Ye etal, Plant J. 19:249-257 (1999).
[0248] The particular conditions for transformation, selection and regeneration can
be optimized by those of skill in the art. Factors that affect the efficiency of
transformation include the species of plant, the target tissue or cell, composition of
t e culture media, selectable marker genes, kinds of vectors, and light/dark
conditions. Therefore, these and other factors may be varied to determine what an
optimal transformation protocol is for any particular plant species. It is recognized
that not every species will react in the same manner to the transformation
conditions and may require a slightly different modification of the protocols
disclosed herein. However, by altering each of the variables, an optimum protocol
can be derived for any plant species.
[0249] In some embodiments, the invention encompasses a method of expressing a
LNK polypeptide in a plant, plant part or plant cell. In representative
embodiments, the method comprises transforming the plant, plant part or plant cell
with a nucleic acid, expression cassette, or vector of the invention comprising a
nucleotide sequence encoding the LNK polypeptide. The plant can be transiently
or stably transformed. In further embodiments, the method further comprises the
steps of (i) regenerating a stably transformed plant from the stably transformed
plant cell; and (ii) expressing the nucleotide sequence in the plant. In some
embodiments, the expressed polypeptide is a LNK1 polypeptide as described
herein. In additional embodiments, the expressed polypeptide is a LNK2
polypeptide as described herein. In further embodiments, the nucleic acid,
expression cassette, or vector expresses both a LNK1 and LNK2 polypeptide as
described herein.
[0250] The invention additionally provides a method of expressing a LNK nucleic
acid in a plant, plant part or plant cell. In representative embodiments, the method
comprises transforming the plant, plant part or plant cell with a nucleic acid,
expression cassette, or vector operably associated with a LNK polynucleotide
sequence of the invention. In further embodiments, the method further comprises
the steps of (i) regenerating a stably transformed plant from the stably transformed
plant cell; and (ii) expressing the nucleotide sequence in the plant. In particular
embodiments, the transcription of the LNK polynucleotide produces a functional
RNA. In further embodiments, the functional RNA is a member selected from:
siR A, shR A, miR A, antisense RNA and a ribozyme. In particular
embodiments, t e functional RNA is a LNK antagonist. In some embodiments, t e
polynucleotide encodes a LNK polypeptide of the invention. In additional
embodiments, the LNK polypeptide is a LNK agonist. In alternative embodiments,
the LNK polypeptide is a LNK antagonist.
[0251] The invention additionally provides a method of expressing a LNK1
nucleic acid in a plant, plant part or plant cell. In representative embodiments, the
method comprises transforming the plant, plant part or plant cell with a LNK1
nucleic acid, expression cassette, or vector operably associated with a LNK
polynucleotide sequence of the invention. In further embodiments, the method
further comprises the steps of (i) regenerating a stably transformed plant from the
stably transformed plant cell; and (ii) expressing the nucleotide sequence in the
plant. In representative embodiments, the method comprises transforming the
plant, plant part or plant cell with a nucleic acid, expression cassette, or vector
operably associated with a LNK1 polynucleotide sequence of the invention. In
particular embodiments, the transcription of the LNK1 polynucleotide produces a
functional RNA. In further embodiments, the functional RNA is a member
selected from: siRNA, shRNA, miRNA, antisense RNA and a ribozyme. In
particular embodiments, the functional RNA is a LNK1 antagonist. In some
embodiments, the polynucleotide encodes a LNK1 polypeptide of the invention. In
additional embodiments, the LNK1 polypeptide is a LNK1 agonist. In alternative
embodiments, the LNK1 polypeptide is a LNK1 antagonist.
[0252] The invention additionally provides a method of expressing a LNK2
nucleic acid in a plant, plant part or plant cell. In representative embodiments, the
method comprises transforming the plant, plant part or plant cell with a nucleic
acid, expression cassette, or vector operably associated with a LNK2
polynucleotide sequence of the invention. In further embodiments, the method
further comprises the steps of (i) regenerating a stably transformed plant from the
stably transformed plant cell; and (ii) expressing the nucleotide sequence in the
plant. In representative embodiments, the method comprises transforming the
plant, plant part or plant cell with a nucleic acid, expression cassette, or vector
operably associated with a LNK2 polynucleotide sequence of the invention. In
particular embodiments, the transcription of the LNK2 polynucleotide produces a
functional RNA. In further embodiments, the functional RNA is a member
selected from: siRNA, shRNA, miRNA, antisense RNA and a ribozyme. In
particular embodiments, the functional RNA is a LNK2 antagonist. In some
embodiments, t e polynucleotide encodes a LNK2 polypeptide of the invention. In
additional embodiments, the LNK2 polypeptide is a LNK2 agonist. In alternative
embodiments, t e LNK2 polypeptide is a LNK2 antagonist.
[0253] In some embodiments, the invention provides a method of modulating a
circadian response in a plant, comprising: stably transforming a plant cell with a
nucleic acid, expression cassette, or vector operably associated with a LNK
polynucleotide sequence of the invention; (b) regenerating a stably transformed
plant from the stably transformed plant cell of (a); and (c) expressing the LNK
polynucleotide sequence in the plant (e.g., in an amount effective to modulate a
circadian response of the plant). In some embodiments the resulting transgenic
plant displays a modulated (i.e., altered) expression of PRR5, ELF4 and/or FKF1.
In some embodiments, the resulting transgenic plant displays and increased
expression of LNK protein. In some embodiments, the resulting transgenic plant
displays and increased expression of PRR5, ELF4 and/or FKF1. In alternative
embodiments, the resulting transgenic plant displays a decreased (i.e., reduced)
expression of LNK protein. In other embodiments, the resulting transgenic plant
displays a decreased expression of PRR5, ELF4 and/or FKF1. In some
embodiments, the LNK polynucleotide is a LNK agonist. In alternative
embodiments, the LNK polynucleotide is a LNK antagonist.
[0254] In some embodiments, the invention provides a method of modulating a
circadian response in a plant, the method comprising: (a) stably transforming a
plant cell with a nucleic acid, expression cassette, or vector encoding an LNK
polypeptide of the invention; (b) regenerating a stably transformed plant from the
stably transformed plant cell of (a); and (c) expressing the nucleotide sequence of
the nucleic acid in the plant (e.g., in an amount effective to modulate a circadian
response of the plant). In some embodiments the resulting transgenic plant displays
a modulated expression of PRR5, ELF4 and/or FKF1 . In some embodiments, the
resulting transgenic plant displays and increased expression of LNK protein. In
some embodiments, t e resulting transgenic plant displays and increased
expression o{PRR5, ELF4 and/or FKFl. In alternative embodiments, t e resulting
transgenic plant displays a decreased (/.e. , reduced) expression of LNK protein. In
other embodiments, the resulting transgenic plant displays a decreased expression
of PRR5, ELF4 and/or FKFl. In some embodiments, the LNK polypeptide is a
LNK agonist. In alternative embodiments, the LNK polypeptide is a LNK
antagonist.
[0255] In some embodiments, the invention provides a method of modulating the
adjustment of daily and/or seasonal rhythms in a plant, the method comprising: (a)
stably transforming a plant cell with a nucleic acid, expression cassette, or vector
encoding an LNK polypeptide of the invention; (b) regenerating a stably
transformed plant from the stably transformed plant cell of (a); and (c) expressing
the nucleotide sequence of the nucleic acid in the plant (e.g., in an amount
effective to alter daily and/or seasonal rhythms in a plant). In some embodiments
the resulting transgenic plant displays a modulated (i.e., altered) expression of
PRR5, ELF4 and/or FKFl. In some embodiments, the resulting transgenic plant
displays and increased expression of LNK protein. In some embodiments, the
resulting transgenic plant displays and increased expression of PRR5, ELF4 and/or
FKFl. In alternative embodiments, the resulting transgenic plant displays a
decreased (i.e., reduced) expression of LNK protein. In other embodiments, the
resulting transgenic plant displays a decreased expression of PRR5, ELF4 and/or
FKFl. In some embodiments, the LNK polypeptide is a LNK agonist. In
alternative embodiments, the LNK polypeptide is a LNK antagonist.
[0256] In additional embodiments, the invention provides a method of modulating
the adjustment of daily and/or seasonal rhythms in a plant, wherein the method
comprises: (a) stably transforming a plant cell with a nucleic acid, expression
cassette, or vector operably associated with a LNK polynucleotide sequence of the
invention; (b) regenerating a stably transformed plant from the stably transformed
plant cell of (a); and (c) expressing the nucleotide sequence in the plant (e.g., in an
amount effective in an amount effective to alter daily and/or seasonal rhythms in a
plant). In some embodiments the resulting transgenic plant displays a modulated
(i.e., altered) expression of PRR5, ELF4 and/or FKFl. In some embodiments, the
resulting transgenic plant displays and increased expression of LNK protein. In
some embodiments, t e resulting transgenic plant displays and increased
expression οΐ Ρ , ELF4 and/or FKF1. In alternative embodiments, t e resulting
transgenic plant displays a decreased (/.e. , reduced) expression of LNK protein. In
other embodiments, the resulting transgenic plant displays a decreased expression
of PRR5, ELF4 and/or FKF1. In some embodiments, the LNK polynucleotide is a
LNK agonist. In alternative embodiments, the LNK polynucleotide is a LNK
antagonist. In particular embodiments, transcription of the LNK polynucleotide
produces a functional RNA. In further embodiments, the functional RNA is a
member selected from: siRNA, shRNA, miRNA, antisense RNA, and a ribozyme
[0257] In additional embodiments, the invention provides a method of increasing
the yield from a plant, the method comprising: (a) stably transforming a plant cell
with a nucleic acid, expression cassette, or vector operably associated with a LNK
polynucleotide sequence of the invention; (b) regenerating a stably transformed
plant from the stably transformed plant cell of (a); and (c) expressing the
nucleotide sequence in the plant (e.g., in an amount effective to increase the yield
from the plant). Still further, the invention provides a method of the prolonging
(e.g., increasing) the life span and/or delaying development of a plant, the method
comprising: (a) stably transforming a plant cell with a nucleic acid, expression
cassette, or vector operably associated with a LNK polynucleotide sequence of the
invention; (b) regenerating a stably transformed plant from the stably transformed
plant cell of (a); and (c) expressing the nucleotide sequence in the plant (e.g., in an
amount effective to prolong the life span and/or delay the development of a plant).
In particular embodiments, transcription of the LNK polynucleotide produces a
functional RNA. In further embodiments, the functional RNA is a member
selected from: siRNA, shRNA, miRNA, antisense RNA, and a ribozyme. In
particular embodiments, the functional RNA is a LNK antagonist.
[0258] In some embodiments, the invention provides a method of increasing the
yield from a plant, the method comprising: (a) stably transforming a plant cell with
a nucleic acid, expression cassette, or vector encoding an LNK polypeptide of the
invention; (b) regenerating a stably transformed plant from the stably transformed
plant cell of (a); and (c) expressing the nucleotide sequence in the plant (e.g., in an
amount effective to increase the yield from the plant). Still further, t e invention
provides a method of the prolonging (e.g., increasing) t e life span and/or delaying
development of a plant, the method comprising: (a) stably transforming a plant cell
with a nucleic acid, expression cassette, or vector encoding an LNK polypeptide of
the invention; (b) regenerating a stably transformed plant from the stably
transformed plant cell of (a); and (c) expressing the nucleotide sequence in the
plant (e.g., in an amount effective to prolong the life span and/or delay the
development of a plant). In some embodiments, the resulting transgenic plant
displays a decreased (i.e., reduced) expression of LNK protein. In other
embodiments, the resulting transgenic plant displays a decreased expression of
PRR5, ELF4 and/or FKF1. In particular embodiments, the LNK polypeptide is a
LNK antagonist.
[0259] In additional embodiments, the invention provides a method of delaying the
flowering time of a plant, the method comprising: (a) stably transforming a plant
cell with a nucleic acid, expression cassette, or vector operably associated with a
LNK polynucleotide sequence of the invention; (b) regenerating a stably
transformed plant from the stably transformed plant cell of (a); and (c) expressing
the nucleotide sequence in the plant (e.g., in an amount effective to delay the
flowering time of a plant). In particular embodiments, transcription of the LNK
polynucleotide produces a functional RNA. In further embodiments, the
functional RNA is a member selected from: siRNA, shRNA, miRNA, antisense
RNA, and a ribozyme. In particular embodiments, the functional RNA is a LNK
antagonist.
[0260] In some embodiments, the invention provides a method of delaying the
flowering time of a plant, the method comprising: (a) stably transforming a plant
cell with a nucleic acid, expression cassette, or vector encoding an LNK
polypeptide of the invention; (b) regenerating a stably transformed plant from the
stably transformed plant cell of (a); and (c) expressing the nucleotide sequence in
the plant (e.g., in an amount effective to delay the flowering time of the plant). In
particular embodiments, the LNK polypeptide is a LNK antagonist.
[0261] In some embodiments, the invention provides a method of increasing the
biomass of a plant, the method comprising: (a) stably transforming a plant cell
with a nucleic acid, expression cassette, or vector encoding an LNK polypeptide of
t e invention; (b) regenerating a stably transformed plant from t e stably
transformed plant cell of (a); and (c) expressing the nucleotide sequence in the
plant (e.g., in an amount effective to increase the biomass of the plant). In
particular embodiments, the LNK polypeptide is a LNK antagonist.
[0262] In some embodiments, the invention provides a method of accelerating the
flowering time of a plant, the method comprising: (a) stably transforming a plant
cell with a nucleic acid, expression cassette, or vector encoding an LNK
polypeptide of the invention; (b) regenerating a stably transformed plant from the
stably transformed plant cell of (a); and (c) expressing the nucleotide sequence in
the plant (e.g., in an amount effective to accelerate the flowering time of the plant).
In particular embodiments, the LNK polypeptide is a LNK agonist.
[0263] The invention also encompasses a method of increasing tolerance of a plant
to abiotic stress, the method comprising: (a) stably transforming a plant cell with a
nucleic acid, expression cassette, or vector encoding an LNK polypeptide of the
invention; (b) regenerating a stably transformed plant from the stably transformed
plant cell of (a); and (c) expressing the nucleotide sequence in the plant (e.g., in an
amount effective to increase the tolerance of the plant to an abiotic stress). The
method optionally includes the further step of exposing the plant to the abiotic
stress (e.g., growing the plant under the abiotic stress conditions). Abiotic stress is
as described elsewhere herein. In representative embodiments of the foregoing
methods, the abiotic stress comprises drought, salt stress, submergence stress
and/or waterlogging stress, and/or stress after removal of a submergence stressor
(e.g., desubmergence stress).
[0264] In some embodiments, the methods of the invention can be used to increase
the yield of a plant and/or increase tolerance of a plant to abiotic stress. In further
embodiments, the abiotic stress comprises drought, salt stress, waterlogging stress,
submergence stress, and/or desubmergence stress. Thus, in some embodiments, the
transgenic plants of the invention are grown under the abiotic stress conditions.
Alternatively, in additional embodiments, the transgenic plants are grown under
normal cultivation conditions.
[0265] In one embodiment, the invention provides a method of increasing yield
and/or increasing tolerance of a plant to abiotic stress, the method comprising: (a)
stably transforming a plant cell with an isolated nucleic acid encoding a
polypeptide selected from the group consisting of (i) a polypeptide comprising the
LNKl amino acid sequence of SEQ ID NO:2; (ii) an amino acid sequence that is at
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to
t e amino acid sequence of SEQ ID NO:2; and (iii) an amino acid sequence
comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or
more contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.
In a further embodiment, the invention further includes regenerating a stably
transformed plant from the stably transformed plant cell; and expressing the
nucleotide sequence in the plant.
[0266] In one embodiment, the invention provides a method of increasing yield
and/or increasing tolerance of a plant to abiotic stress, the method comprising: (a)
stably transforming a plant cell with an isolated nucleic acid encoding a
polypeptide selected from the group consisting of (i)a polypeptide comprising the
LNK2 amino acid sequence of SEQ ID NO:4; (ii) an amino acid sequence that is at
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to
the amino acid sequence of SEQ ID NO:4; and (iii) an amino acid sequence
comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800 or
more contiguous amino acid residues of the amino acid sequence of SEQ ID NO:4.
In a further embodiment, the invention further includes regenerating a stably
transformed plant from the stably transformed plant cell; and expressing the
nucleotide sequence in the plant.
[0267] Having described the present invention, the same will be explained in
greater detail in the following examples, which are included herein for illustration
purposes only, and which are not intended to be limiting to the invention.
EXAMPLE 1
EXPERIMENTAL PROCEDURES
Plant Material
[0268] All the Arabidopsis lines used in Examples 1 and 2 were Columbia
ecotype. linkl-1 (SALK_024353), linkl-2 (SALK_063322), linkl-3
(GABI_044A09), Unk2-1 (GABI_484F07), Unk2-2 (SALK_1 16103) and Unk2-3
(SALK_141609) mutants were obtained from the Arabidopsis Biological Research
Center (ABRC) and the Gabi Kat T-DNA insertion collections, respectively. The
linkl ;link2 double mutant was obtained by crossing the simple mutants linkl-1
(At5g64170) and Unk2-1 (At3g54500). The clock and photoreceptor mutants used
in this study were prr7-3;prr9-l (31), tocl -101(42), phyA-21 1;phyB-9(43) and
cryl-bl04;cry2-l(44).
Growth Conditions and physiological measurements
[0269] For flowering time experiments, seeds were stratified for four days in the
dark at 4°C and then transferred to soil. The plants were grown at 22 °C under long
days (LD, 16h light/8h dark cycles; 70 µ ιοΐ rr V of white light), short day
(SD, 16h light/8 h dark cycles; 140 µ ιοΐ m V of white light) or continuous
light (LL, 50 umoles m V of white light), depending on the experiment.
Flowering time was estimated by counting the number of rosette leaves at the time
of bolting. For hypocotyl length measurements, wild-type, linkl, Unk2 and
Hnkl;link2 seedlings were grown on 0.8% agar under complete darkness,
continuous white light (LL), short day (8h light/ 16 h dark) photoperiods,
continuous red (100 µ ιοΐ rrfV1) or continuous blue light (10 µ ιοΐ m V ),
and the final length of the hypocotyls was measured after 4 days. Light effects on
hypocotyl elongation were calculated normalizing hypocotyl length under each
light regime relative to hypocotyl length of the same genotypes under constant
dark conditions. For leaf movement analysis, plants were grown under 12h
light/ 1 dark cycles, transferred to continuous 20µ ι white fluorescent light at 22
°C, and the position of t e first pair of leaves was recorded every two hours for 6
days using digital cameras and determined using Image J software.
Expression analysis of LNK genes in link mutants:
[0270] Plants were grown in soil for 3 weeks and then samples from 4 plants per
genotype were collected to reduce biological variation. RNA was obtained using
TRIzol reagent (Invitrogen). Resuspended g of RNA was treated with RQ1
RNase-Free DNase (Promega) and subjected to retrotranscription with M-MLV
(Invitrogen) and oligo-dT according manufacturer's instructions. The transcripts
abundance of LNKs genes was determinate by PCR in the different mutant lines.
Subcellular localization of LNK 1
[0271] Subcellular localization of LNK1 was analyzed infecting three-week old
Nicotiana benthamiana leaves with Agrobacterium tumefaciens GV3101 carrying
the 35S:LNK1:YFP construct as described by (45). The 35S:ZN^7:YFP construct
was assembled using the coding region of t e At5g64l70.2 gene model, according
to the Arabidopsis Information Resource (TAIRIO), through Gateway technology
(Invitrogen) using the pEarly gate 101 as destination vector (46). The leaves were
infected from the abaxial side using a syringe without needle, and 3.5 days later
different discs of infected leaves were analyzed. Imaging was completed using a
LSM 5 Pascal Axioplan2 confocal microscope equipped with an argon ion
(488nm) excitation laser system and a X20 objective lens. Image manipulation was
completed with LSM image browser software. Similar localization patterns were
observed in different infected leaves.
qRT-PCR
[0272] For time-course analysis, 15 day-old plants were grown under 12h
light/ 1 dark cycles at 22°C and then transferred for three days to continuous
white light at 22°C. Samples were collected every 4h for two days, starting 24h
after the plants were transferred to constant conditions. Total RNA was obtained
from these samples using TRIzol reagent (Invitrogen). g of RNA was treated
with RQ1 RNase-Free DNase (Promega) and subjected to retrotranscription with
M-MLV (Invitrogen) and oligo-dT according to manufacturer's instructions.
Synthesized cDNAs were amplified with FastStart Universal SYBR Green Master
(Roche) using the Mx3000P Real Time PCR System (Agilent Technologies)
cycler. PP2A transcript was used as house -keeping gene. Primer sequences and
PCR conditions are available upon request.
Phylogenetic Analysis:
Gene homology search was performed using t e protein sequence of
Arabidopsis thaliana LNK1 (splice variant 2) as query in BLASTP tool
(worldwideweb at phytozome.net/). Protein sequences were aligned using Clustal
Omega program. A maximum likelihood phylogenetic tree was constructed using
SeaView Version 4 (Gouy, M . et al, 2010). Bootstrap analysis with 1000
replicates was performed. Gouy, M., G RNA-seq reads were estimated using
Illumina Pipeline version 1.3. Reads were quality-filtered using the standard
Illumina process and demultiplexed with 2 allowed barcode mismatches. Sequence
files were generated in FASTQ format. Table 1 provides a summary table of main
read count statistics. Sequence data was made available from GEO repository
(accession number: GSE43865). The TopHat suite [Trapnell C, Pachter L,
Salzberg S . "TopHat: discovering splice junctions with RNA-Seq". Bioinformatics
doi:10.1093/bioinformatics/btpl20] was used to map reads to the A . thaliana
TAIR10 reference genome [The Arabidopsis Genome Initiative 2000]. Along with
the pre-built A . thaliana index, the reference genome was downloaded from
ENSEMBL (December 2012). Default values for TopHat parameters were used
with the exception of maximun intron length parameter, that was set to a value of
5000 nt following estimated values reported in [Hong et al, D . Mol. Biol. Evol.
23:2392-2404 (2006)]. Transcript abundances were estimated using Cufflink
[Trapnell et al., "Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks", Nature Protocols 7:562-578 (2012)]
with default parameter setting.
Table 1
Microarray analysis
[0274] Total RNA was extracted from aerial tissue of 15 day-old wild-type plants
grown under 12h light/ 1 h dark cycles at 22°C. Triplicate samples were collected
after a lh white light treatment (70 µιηοΐ m-2s-l) in t e middle of the night or
subjective day, and control samples kept in darkness were collected at the same
time. Each biological replicate consisted of 10-12 plants, to reduce biological
variation. Total RNA was processed and hybridized to Affymetrix GeneChip
Arabidopsis ATH1 Genome Arrays, according to the manufacturer's instructions.
Data were analyzed using MA 10, and ANOVA was used to identify differentially
expressed genes (q-value < 0.0005; fold change >2). Genes were then classified in
six groups, depending on whether they were induced or repressed by light, and
whether the effect of light was proportionally larger, smaller or relatively similar
during the night compared to the subjective day.
[0275] Growth conditions, cDNA library preparation and high-throughput
sequencing protocols
[0276] Seeds were sown onto solid Murashige and Skoog medium containing
0.8% agarose, stratified for four days in the dark at 4°C, and then grown at 22°C in
continuous light or long day conditions (16h light and 8h dark cycles) depending
on the experiment. Nine-day-old seedlings were harvested and total RNA was
extracted with RNeasy Plant Mini Kit (QIAGEN) following the manufacturer's
protocols. To estimate the concentration and quality of samples, NanoDrop 2000c
(Thermo Scientific) and Agilent 2100 Bioanalyzer (Agilent Technologies) with
Agilent RNA 6000 NanoKit were employed, respectively. Libraries were prepared
following the TruSeq™ RNA Sample Preparation Guide (Illumina). Briefly, 3 µg
of total RNA were polyA-purified, fragmented and first-strand cDNA synthesized
by reverse transcriptase (Superscript II-Invitrogen) and random hexamers. This
was followed by RNA degradation and second strand cDNA synthesis. End repair
process and addition of a single 'A' nucleotide to the 3' ends allowed ligation of
multiple indexing adapters. Then, an enrichment step of 12 cycles of PCR was
performed. Library validation included quality control and quantification. Samples
were pooled to create 17-multiplexed DNA libraries and they were single-end
sequenced with an Illumina Genome Analyzer II kit on the Illumina GAIIx
platform, providing lOObp sequences.
RNA-seq reads processing
[0277] RNA-seq reads were estimated using Illumina Pipeline version 1.3. Reads
were quality-filtered using the standard Illumina process and demultiplexed with 2
allowed barcode mismatches. Sequence files were generated in FASTQ format.
Table 1 provides a summary table of main read count statistics. Sequence data was
made available from GEO repository (accession number: GSE43865). The TopHat
suite [Trapnell et al., "TopHat: discovering splice junctions with RNA-Seq".
Bioinformatics doi:10.1093/bioinformatics/btpl20] was used to map reads to the
A . thaliana TAIR10 reference genome [The Arabidopsis Genome Initiative 2000].
Along with the pre-built A . thaliana index, the reference genome was downloaded
from ENSEMBL (December 2012). Default values for TopHat parameters were
used with the exception of maximun intron length parameter, that was set to a
value of 5000 nt following estimated values reported in [Hong et al., Mol. Biol.
Evol. 2006 23:2392-2404]. Transcript abundances were estimated using Cufflink
[Trapnell et al., Nature Protocols 7:562-578 (2012)] with default parameter
setting.
RNA-seq data processing and differential expression analysis
[0278] The normalization and statistical analysis of count data was performed
using the package edgeR (version 3.04) [M.D. Robinson, et a/.,"edgeR: a
Bioconductor package for differential expression analysis of digital gene
expression data", Bioinformatics. 2010 January 1:26(1): 139—140] from the
Bioconductor library (version 2.11) of the R (version 2.15) statistical analysis
framework. The package easyRNAseq [N. Delhomme et al., "easyRNASeq: a
Bioconductor package for processing RNA-Seq data.", Bioinformatics, 2012] was
used to generate read count tables at the gene level. A non-specific prefiltering step
was conducted in order to filter out genes with less than two counts per million
reads in at least three samples resulting in 2 1143 (22628) - out from 33602 genes -
that were considered for further analysis, in the Col vs linkllink2 (time-course)
experiment. Differences in the RNA composition for each library, was taken into
account through a normalization step using the trimmed mean of M-values (TMM)
methodology. Estimates of the dispersion parameter for each transcript were
obtained in a two-step procedure: a first trended dispersion estimation - that
depends on transcript abundances -was further refined with an empirical Bayes
procedure for each transcript, with expression levels specified by a log-linear
model [Robinson et al., "Moderated statistical tests for assessing differences in tag
abundance", Bioinformatics 23:2881-2887]. In order to assess for differential
expression a negative binomial generalized log-linear model was fitted to the read
counts for each gene. We found 806 genes differentially expressed between
linkl;link2 and WT Col conditions (Benjamini-Hochberg FDR adjusted p-value <
0.05). On the other hand, for t e more complex time-course experiment, statistical
significance tests were performed for mean differences between WT Col and
linkl;link2 mutant timecourses, along with genotype-time interaction contrasts for
time points: 6hs, lOhs, 14hs, 18hs, and 22hs. We focused on genes that
simultaneously fulfilled the following two conditions. Transcripts should present
large (fold-change larger than 50%) and significant (Benjamini-Hochberg FDR
adjusted p-value less than 0.0001) linkl;link2 vs WT Col mean expression level
differences along the time-course, and at least one significant (Benjamini-
Hochberg FDR adjusted p-value less than 0.0001) genotype-time interaction
contrast. In this way, a subset of 387 transcripts were identified and considered for
follow-up analysis.
Expression profile clustering
For each transcript, concatenated WT Col and linkl;link2 time course
profiles were considered. Clusters of similar expression patterns could be detected
using a correlation based distance metric and a hierarchical clustering (complete
linkage) procedure followed by a hybrid adaptive dendrogram cut step [Langfelder
et al., "Defining clusters from a hierarchical cluster tree", Bioinformatics 2008] in
order to identify well-defined clusters.
EXAMPLE 2
LNK genes integrate light and clock signaling networks at core of
Arabidopsis oscillator
[0280] Light signaling pathways and the circadian clock interact to help organisms
synchronize physiological and developmental processes with periodic
environmental cycles. The plant photoreceptors responsible for clock resetting
have been characterized but signaling components that link the photoreceptors to
t e clock remain to be identified. Here we describe a family of night-light
inducible and clock regulated genes (LNK) that play a key role in the control of
daily and seasonal rhythms in Arabidopsis thaliana. A genome-wide transcriptome
analysis revealed that most light induced genes respond more strongly to light
during the subjective day, which is consistent with the diurnal nature of most
physiological processes in plants. However, a handful of genes, including t e
homologous genes LNK1 and LNK2, are more strongly induced by light in the
middle of the night, when the clock is most responsive to this signal. Further
analysis revealed that the morning phased LNK1 and LNK2 genes control circadian
rhythms and photomorphogenic responses. In addition, because they regulate the
expression of a subset of clock and flowering time genes in the afternoon, they are
required for photoperiodic dependent flowering. LNK1 and LNK2 themselves are
directly repressed by members of the TIMING OF CAB1 EXPRESSION
(TOCiyPSEUDO RESPONSE REGULATOR (PRRI) family of core-clock genes
in the afternoon and early night. Thus, LNK1 and LNK2 integrate early light
signals with temporal information provided by core oscillator components to
control the expression of afternoon genes, allowing plants to keep track of seasonal
changes in day-length.
[0281] The rotation of the earth around its own axis along with its movement
around the sun cause daily and seasonal oscillations in light intensity on our planet.
The profound impact of these environmental changes on biological processes
strongly contributed to the evolution of circadian clocks (1). Therefore, it is not
surprising that circadian and light signaling networks are intimately connected.
Indeed, while circadian rhythms normally persist in the absence of environmental
cues with a period of approximately 24h, light/dark cycles entrain the clock and
thereby ensure appropriate phasing of circadian rhythms in relation to changing
sunrise and sunset throughout t e year (2).
[0282] The effect of light on the clock is mediated by specific photoreceptors, such
as phytochromes, cryptochromes and members of the ZEITLUPE protein family in
plants (3-5), cryptochromes in flies (6), or melanopsin in mice (7). In mammals,
cryptochromes are central clock components rather than circadian photoreceptors
(8,9). In contrast, neither cryptochromes nor phytochromes are essential for
circadian oscillations in plants (10-12), but circadian regulation of
phototransduction pathways generates tight links between these two signaling
networks (13, 14). This phenomenon, known as gating, was originally described
for the light regulated activity of the promoter of the CHLOROPHYLL A/B
BINDING PROTEIN II (CABII) gene (15). CABII expression is acutely induced by
red light pulses, but the effectiveness of this treatment oscillates during a 24-hr
day, with maximal effects when photosynthetic activity is expected to be at its
peak during the day, and minimal effects during the night (15-17). Clock
regulation of light signaling also influences physiological processes such as
germination (18), stem elongation (19, 20), and the clock itself (16, 21, 22). In
plants grown under light/dark cycles and then transferred to constant darkness,
brief light pulses are most effective in resetting the phase of circadian rhythms
during the night rather than during the subjective day (i.e. the phase that would
have been illuminated if the plants were kept under light/dark cycles) (21-23). This
phenomenon is shared across kingdoms suggesting that it is critical for the
appropriate adjustment of circadian rhythms to the environment (24).
[0283] Despite the importance of the interactions between light and the circadian
clock in the control of biological activities in plants, a comprehensive analysis of
these interactions has been lacking. Light signaling and circadian networks operate
primarily by transcriptional control (13, 25-28). In order to characterize
transcriptional interactions in Arabidopsis we employed a genomics approach.
This analysis allowed us to identify a new family of light and clock regulated
morning genes. These genes control both the pace of circadian rhythms and the
photoperiodic regulation of flowering time, apparently by promoting the
expression of a subset of core-clock and clock-output genes in t e afternoon.
RESULTS
Light treatments are more effective during the subjective day
[0284] To investigate if and how time of day affects light regulation of gene
expression at a global level, we evaluated t e response of the Arabidopsis
transcriptome to a lh light treatment given either in the middle of the subjective
day or in the middle of the night (Figure 1A). The effect of a brief light pulse in the
middle of the subjective day should reveal genes acutely regulated by light on a
daily basis throughout the year. In contrast, the night-light treatment simulates
either the earlier sunrise or later sunset that plants normally experience on a typical
spring day at high latitudes, and may reveal genes involved in clock resetting
and/or seasonal adjustment.
[0285] Many light-regulated genes showed a stronger response to the light pulse
given during the subjective day compared to a similar treatment given during the
night (Figure IB). Among a total of 2237 light induced genes, 1537 responded at
least twice as strongly to the light pulse given in the middle of the subjective day,
and only 65 genes showed a stronger response during the night (data not provided).
Thus, almost 70% of light-induced genes behaved similarly to what had been
reported for CABII (15). This group was enriched in genes associated with
metabolism, chloroplast components, responses to environmental stimuli, as well
as with abiotic and biotic stress responses (data not provided). The influence of
time of day was less pronounced for light-repressed genes. Among a total of 1672
light-repressed genes, only 607 responded at least twice as much during the
subjective day compared to the night, and 78 showed the opposite response (data
not provided). The group more strongly repressed by light during the subjective
day was mostly enriched in genes involved in amino acid catabolism, while those
more responsive to light during the night were associated with hormonal
regulation, among other processes (data not provided).
Night-light is more effective in inducing the expression of a subset of core-clock
genes
[0286] Clock entrainment is most sensitive to light pulses given during the night, a
treatment that simulates seasonal changes in day-length. Consistent with this, t e
subset of 65 genes responding at least twice as strongly to the night-light treatment
was significantly enriched in clock genes, a phenomenon that was specific for this
particular class of light regulated genes (data not provided). Clock genes are also
enriched among those with oscillations that are robust to different experimental
conditions, such as continuous light, continuous darkness, short days, long days,
temperature cycles, etc. (26). Thus, we reasoned that the list of genes that are more
effectively induced by night-light and also cycle under multiple conditions should
contain new candidate clock regulators. Thirteen genes fulfilled both criteria, a 30-
fold enrichment over what would have been expected by chance (p < 1 x 10 15,
hypergeometric distribution) (Figure 1C). This group included the clock genes
CIRCADIAN CLOCK ASSOCIATED 1 (CCA1), PRR7, and GIGANTEA (GI), six
genes involved in the control of stem elongation, flowering time or photosynthesis,
as well as four genes that constitute a new family of plant specific proteins, which
we named LNK 1-4, for night-light inducible and clock regulated genes 1-4
(Figure ID).
[0287] LNK1 (AT5G64170) and LNK2 (AT3G54500) proteins are of medium
size, about 66 kDa, with 35% sequence similarity across their entire length. LNK3
(AT3G12320) and LNK4 (AT5G06980) proteins are smaller, with 60% sequence
similarity, and with a third of conserved positions also shared with LNK1/LNK2
(Figure 6). LNK homologs can be found throughout land-plants, including non
vascular plants. LNK3 and LNK4 appear to be the result of a recent duplication
event within the Brassicaceae. (Figure 7). Since LNK1 responded most strongly to
the night-light treatment (Table 6), we focused on LNK1 and its closest homolog,
LNK2. qRT PCR analyses of wild-type (WT) and mutants indicated that these two
genes were induced by a light pulse in the middle of the night through the
phytochrome family of red/far-red light photoreceptors, and that they were
rhythmically expressed with maximum levels in the subjective morning (Figure 1
E and F). Although LNK1 and LNK2 expression is highly correlated, a close
inspection of their expression patterns across different conditions using publicly
available microarray data revealed some differences. In particular, the phase of
LNK1 expression is delayed by four hours in comparison to that of LNK2 under 8
or 12 hour photoperiods, with LNK1 reaching maximum levels in the middle rather
than the beginning of the photoperiod under these conditions (Figure 8).
LNK1 and LNK2 regulate light signaling and biological timing
[0288] To determine if LNK1 and LNK2 affect light and clock regulated
developmental and physiological processes, several mutants with T-DNA
insertions in these two genes were identified and characterized in detail (Figure 9).
An early developmental phenomenon under control of light and the circadian clock
is the elongation of the hypocotyl, the embryonic stem. No significant differences
in hypocotyl length were observed among WT plants and linkl, link2 or Unkl;link2
mutants grown in complete darkness (Figure 10). In contrast, linkl mutants had
longer hypocotyls than WT plants under continuous white light (Figure 2A), under
continuous red light or under 8 hr white-light/ 16 hr dark cycles (Figure 10). Unk2
mutants also had longer hypocotyls than WT plants in red light (Figure 10), whilst
the differences in hypocotyl length were not statistically significant under most
other light conditions (Figures 2A and 10). The linkl ;link2 double mutant had
significantly longer hypocotyls than either single mutant or WT seedlings under
most light conditions tested, and the phenotype was stronger under red or white
light than blue- light (Figures 2A and 10). Taken together, these results indicate
that LNK1 and LNK2 mediate light inhibition of hypocotyl elongation, in
particular that triggered by the phytochrome family of red/far-red light
photoreceptors.
[0289] Another physiological process that depends on interactions between light
signaling and the circadian clock is photoperiod dependent flowering (29).
linkl ;link2 double mutant flowered later than WT plants, linkl or Unk2 single
mutants under long days (LD; 16 hr light/8 hr dark) (Figure 2B and 2C). Under
short days (SD; 8 hr light/16 hr dark), no delay in flowering was observed (Figure
2D), confirming that LNK1 and LNK2 are indeed only required for long-day
acceleration of flowering, rather than the transition to flowering per se.
[0290] To observe circadian behavior directly, we monitored the circadian rhythm
of leaf movement in WT plants, linkl, Unk2, and linkl ;link2 mutants by time lapse
photography. Leaf movement of Hnk2 mutants had longer circadian period than
WT or single linkl mutant plants (Figures 2E and 11), and t e linkl ;link2 double
mutant was even more strongly affected (Figures 2F and 11). Similar
photomorphogenic and circadian phenotypes were observed in two additional
mutant alleles of LNK1 and LNK2 (Figure 11), confirming that these two genes
play important and partially redundant roles controlling light and clock regulated
processes in Arabidopsis .
LNK1 and LNK2 activate clock controlled genes with afternoon peak
[0291] LNK proteins lack known functional domains, but transiently expressed
LNKLYFP localized to the nuclei of Nicotiana benthamiana cells, suggesting a
role in the regulation of gene expression (Figure 3A). To identify genes controlled
by LNK1 and LNK2, we compared the transcriptome of WT and linkl ;link2
mutant plants using RNA-seq. In plants grown under constant light and
temperature, we found 806 genes differentially expressed using an FDR adjusted
p-value of 0.05 as cut-off (data not provided). Genes down-regulated in linkl ;link2
mutants were significantly enriched for genes that peak in LD at Zeitgeber time 10
(ZT10), i.e. 10 h after lights-on. Up-regulated genes were slightly enriched for
genes that peak late at night (Fig 3B).
[0292] To learn more about LNK1/LNK2 target genes, we characterized the daily
transcriptome of LD-grown WT and Unkl;link2 mutant plants. Using stringent
criteria aimed at identifying genes with altered overall mRNA levels, and not
simply changed temporal patterns of expression, we identified 387 genes that
differed between WT and Unkl;link2 mutant plants. A cluster analysis revealed
that most of the genes down-regulated in Unkl;link2 mutant oscillated in WT
plants with peak expression in the afternoon or early night (Figure 12), with the
largest cluster peaking at ZT10 (Figure 3C), providing independent support for the
initial phase enrichment analysis, which had suggested that LNK1/LNK2 activity
is maximal in the afternoon (Figure 3B).
[0293] To identify genes likely to be responsible for the phenotypic defects in
linkl ;link2 mutants, we focused our analysis on the 113 down-regulated and the 47
up-regulated genes in both RNA-seq data-sets. Down-regulated genes included
two core-clock genes, PRR5 (Figure 3E) and EARLY FLOWERING 4 (ELF4;
Figure 3F), which were present in the cluster of genes with peak expression in WT
plants at ZT10 (Figure 3C), and might be primary targets of LNK1/LNK2 activity.
Other clock and light signaling genes were also miss-regulated in linkl ;link2
mutants (data not shown). However, these genes were affected more subtly,
suggesting that they are possibly secondary targets of LNK1/LNK2 activity.
Down-regulated genes also included the flowering time genes FLAVINBINDING
KELCH REPEAT F-BOX 1 (FKF1; Figure 3D), which was also present in the
cluster of genes with peak expression at ZT10 (Figure 3C), as well as
FLOWERING LOCUS T (FT) and SUPPRESOR OF CONSTANS
OVEXPRESSION 1 (SOCI) (Figure 13). All three genes are positive regulators of
flowering time, with FKF1 acting upstream of FT and SOCI. Therefore, the late
flowering of linkl ;link2 mutants under LD is likely due to reduced FKF1
expression, which in turn leads to reduced and SOCI mRNA levels (Figure 13).
PRR5 expression is severely affected in linkl ;link2 mutants under free-running
conditions
[0294] To investigate the effect of LNK1 and LNK2 on the central clock in more
detail, we analyzed the expression of clock components in plants that had been
entrained under 12h light/ 1 h dark cycles at 22°C and were then transferred to
constant light and temperature (i.e. free-running) conditions. The plant circadian
clock is based on interlocking transcriptional feedback loops in which the morning
clock factors CCA1 and LATE ELONGATED HYPOCOTYL (LHY) repress the
expression of evening clock genes such as TOC1/PRR1 (30). In addition, CCA1
and LHY also promote the expression of PRR9 and PRR7(3\) which, sequentially
with PRR5 and TOC1/PRR1 , repress CCA1 and LHY expression throughout the
remaining of the day and early night(32-34). Finally, ELF4, ELF3 and LUX
ARPvHYTHMO(LUX) proteins form a complex during the evening that represses
TOC1 expression, allowing CCA1 and LHY mRNA levels to start rising again in
t e late part of the night (19).
[0295] We observed a substantial delay in t e phase of CCAl, LHY, PRR9 and
PRR7 expression during the second day in continuous light. The delay increased to
eight hours on the third day, consistent with a lengthening of circadian period by
approximately 2.5 hours in t e linkl;link2 mutant compared to WT plants (Figure
4 A-D). In contrast, the phase of CCAl expression was delayed less than four
hours in nk2 single mutants on the third day (Figure 14), consistent with an
increase in period length of rhythmic leaf movement of approximately one hour
(Figure 2E).
[0296] In spite of the strong effect of LNKl and LNK2 on the period and/or phase
of circadian oscillations, the overall mRNA levels of morning and early afternoon
clock components were largely unaffected in Unkl;link2 mutants. In contrast,
significant down-regulation coupled with a much longer delay in the phase of
expression, i.e. close to 12 hours on the third day, was observed for PRR5, which
is normally expressed in the afternoon (Figure 4E). A similar phase delay, but
without differences in the overall mRNA levels, was observed for the TOCl/PRRl
gene that is expressed slightly after PRR5 (Figure 4F). Taken together, these
results suggest that LNKl and LNK2 act initially as activators of a subset of genes
with peak expression in the afternoon, such as PRR5 (Figures 3F and 4E), ELF4
(Figure 3F) and FKFl (Figure 3D), which later affect the rhythmic expression of
other core-clock and clock-output genes.
LNKl and LNK2 are repressed by members of the TOCl/PRRl family of clock
genes
[0297] Many clock-regulated genes with peak expression in the morning are
repressed throughout the day and during the early night by members of the
TOCl/PRRl family of clock proteins. To determine if the LNKs were regulated by
members of this protein family, we reexamined data describing TOCl/PRRl and
PRR5 binding sites in the Arabidopsis genome using chromatin
immunoprecipitation followed by sequencing (ChlP-seq) (33, 35). Indeed, we
found that the regulatory region of LNK3 was directly bound by TOCl/PRRl (33).
Furthermore, PRR5, PRR7 and PRR9 were also found to bind directly to the
regulatory regions οΐ ΣΝΚ1-4 (35).
[0298] To evaluate t e functional consequence of t e binding of these factors to
LNKl -4 promoters, we compared the expression patterns of LNKl and LNK2 in
WT, tocl, or prr9;prr7 mutant plants, entrained under light/dark cycles and then
transferred to constant light conditions. In addition to progressively larger delays
in the phase of the circadian oscillations of LNKl and LNK2, their mRNA levels at
the trough of the circadian oscillations were increased in the prr9;prr7 double
mutant (Figure 5A and B). A larger overall increase in LNKl and LNK2 mRNA
levels, coupled with progressive phase advances, was observed in the short period
mutant tocl over the entire time course (Figure 5C and D), indicating that TOC1 is
a direct repressor of these genes.
DISCUSSION
[0299] Light and the circadian clock interact to regulate many biological processes
in plants, such as flowering time (29) and stem growth (19, 20). In addition, this
interaction is also required for robust functioning of the circadian clock itself (16,
21, 22). Our genome-wide analysis revealed that these physiological interactions
are mirrored by global interactions at the transcriptional level. In particular, we
found that 70% of light induced genes responded more strongly to a light pulse
during the subjective day than at night, most likely optimizing the energy spent on
light-dependent biological processes that have maximal activity at midday, when
light intensity is at its peak under natural conditions. At the same time, a light
stimulus during the night preferentially promoted the expression of certain key
clock components, consistent with the general observation that light present at the
beginning or end of the photoperiod adjusts the circadian clock to seasonal
changes in day-length (2, 24).
[0300] The characterization of genes that are preferentially induced by light at
night and are also rhythmic across multiple conditions led to the identification of
LNK genes, a partially redundant family of plant-specific genes that control
photomorphogenic and photoperiodic responses, as well as circadian rhythms.
LNKl and LNK2 are regulated by the phytochrome photoreceptors and
predominantly affect responses to red light, pointing to an important role in
phytochrome signaling. In turn, they are expressed rhythmically with peak
expression in the morning or at noon, most likely as a result of their repression by
members of the TOC1/PRR1 family of core clock regulators during the afternoon
and early night. Thus, LNKl and LNK2 link phytochrome and circadian signaling
to regulate many physiological processes, including time keeping by the clock
itself.
[0301] A comparison of LNK genes with other morning expressed clock genes is
informative. Like LNK genes, CCAl and LHY are light induced genes whose
mRNAs reach peak levels in t e early morning. CCAl and LHY, however,
lengthen the period of circadian rhythms, while LNKl and LNK2 shorten it (36,
37). In contrast, PRR9 and PRR7 are similar to LNKl and LNK2 in that they are
expressed during the morning and early afternoon, are induced by light, and that
they decrease period length and promote flowering (31). However, different from
LNKl and LNK2, which at least under constant light do not seem to be required for
normal CCAl and LHY expression (Figure 4), PRR9 and PRR7 are repressors of
CCAl and H7(31).
[0302] LNKl and LNK2 are plant-specific proteins without recognizable
functional domains. This is reminiscent of the clock components ELF3 and ELF4,
which only very recently were shown to participate in an evening phased protein
complex that represses the expression of TOC1 and PRR9 (19). We note that LNKl
and LNK2 mRNAs reach maximum levels in the morning or at noon, but that their
positive effects on gene expression appear to be concentrated in the afternoon.
Together with the nuclear localization of LNKl, this suggests that LNKl and/or
LNK2 are regulatory proteins under post-transcriptional and/or post-translational
control, similar to several other clock proteins.
[0303] In summary, our work together with previous results support a model in
which light perceived through phytochromes activates the expression of the CCAl
and LHY transcription factors (40), as well as that of the LNKs, in the early
morning. CCAl and LHY then promote the expression of PRR9 and PRR7 (31),
while LNKl and LNK2 act at later during the day to activate clock genes with
peak expression in the afternoon, such as PRR5 and ELF4. Simultaneously,
members of the TOC1/PRR family repress these morning genes throughout the
afternoon and beginning of the night (32-34, 41). Finally, the progressive reduction
in TOC1/PRR levels due to the evening complex (19) leave CCA1, LHY and the
LNK genes poised to respond again to light signals that reset t e clock every
morning (Figure 5E).
EXAMPLE 3
Identification of LNK homologs in Oryza sativa
[0304] Ortholog proteins to each of the 4 known Arabidopsis thaliana LNK
proteins (LNKl, At5g64170; LNK2, At3g5400; LNK3, At5g06980; LNK4,
At3g 12320) were searched in rice using t e OsGDB BlastP service of PlantGDB
The protein query
sequences were obtained from the longest isoform of each gene from The
Arabidopsis Information Resource, release 10 (TAIR10,
http://-wwvv'.arabidopsis.orpJ . The coding sequences of the OsLNK genes and the
corresponding proteins are the following:
[0305] >OsLNKl_gnl|OsGDB|LOC_Os03g27019.2 (SEQ ID NO: 17)
ATTCTTTTACTTGCTGGCTACTACTACTACTTGCACTCCACGCCCTCATC
CCATCGACCCACCCATCTCTCCTATTCTCTCTTCAAAAAAAAATCAGGA
AATTTAATCGCGAGGAGGAGAGAGAAAAGAAAAAAAAAAGGAAATTC
GCAGGAGAAATCCCTGGAAGCCTCTAGAGACCGCGCGAACAGGAGAC
CCCGAGGAGCAGAGCAGAGCAGAGCAGAGGCGGCGCCAGCTTTGGGA
GCTCTCGGATTGATCAAGAACTGGGGATCCTGAGTTGAATATGATATC
AAATCCGGTGAATTGGTACAGTTTCGGTCCCGGATAGAATTTGTAGTGA
TGCCAGATTGGAGGGTGGGCGAGTTTGAAGGTAAGCTCAAGGATGGAT
TTGCTCGGAGCAATAATAGCGAACATGAAAATGGAGCCGGGACTGTGA
GTATATCCAGCAAGAAGTCGAAGCATCGGGTTGACAGTGAAAAAAAAC
CCCATGTTGACATCTCTGGAGTGATTGATTCAGATTCGCAGAAATGTAA
TTCAGAGCAAATCCATTCAGCTAATGGGATAGTATCCCGGGATGTCAA
CCATGATCACATAGAAAACTGCAAAGTTGAATCAAATGATTTTCCCTTG
AATACTATCTCTGAAACAAGATATCCAACAGACAATTGGAACAGTTCT
CAGTTTGCTCTGAGCAATGATGGTTCACCTGTTCTCAATAATCAGAGTA
CTCCACAAACTGGTCATGGCTATGGAGATAATGATCTAACCTACATTGA
TTGGCCTGCTATTGATAATTTTGAGGACGTCGACAACTTATTCAGGAGG
TGTGATTCCACGTACGGTCAGCAGCAACTTCCGAACACGGATGAACTG
TCATGGATTCCTTCTTCAGATGCCATGTACTCTTCTGATGTTGCTATGCA
ACCAGGGTTTGAATCCTCGTATTCTGATTATGGTATCCTGGATGACCTC
TCCGCATTCAATTGTACGGAAGATAAATCCCTGACAACAGCTGATCCTT
CAAGTGCTGTATGTGACGAGCAATTCGATGACTCTTATCTGTTCAATGA
GCAAAAACCTGAAGATGTTTATGGCGAACAGGCTTACCAAAGGGATGC
GATGGAATTGTTGTCCAGCGACCAGATATGCACTGGGCAGGAAAACCT
AGATATGATTGGAAATCGATATTCATCGGAAAATGCCATGGAACAGCC
TGAAGATCAGAAGTTTTCTATAGCTTCAGGTTCTCAACTAAGCTCTTCT
CAGAATTTATTGAACCAAAAGAACCACTTGGATTCAACTTCACCAAGT
AACATAACTTCTGAGTCCTATCCAGAAAGAAATTGCCAGATCATTCCAT
CTGGGGCTTCCTTTGCAGAGAGAAACTTGAAGGTGCAGAAGAAAGTGG
CCAGTTCGGCATCAGGACAACTTATCAGTGATAATGTGACTGGACATC
CTGGTCATCAAACATTGACAAGAAGGGCTTCATATCCTTGTGAGAATC
ATGAAATTGGAAAGAGGTCCTTAGGAAAAAGAGGTTTGGGTCATTCTG
ATGTTGCAATGGGCACCTCAATGGTAGTTGATGGGTCCTTCGTATCGTC
TATTTCTTCTGATAACTCAGTTGAAGAGAACAGCTTTCGGCAGCTTCAG
GATGCAGTTAGTCAGTTGGATGTGAAAACAAAAATGTGCATTCGAGAT
GGGTTATACCGCCTGGCAAGAAGTGCGCAGAATAGGCAAGTCTTCCCA
AATACAATGAACAACAATGGAGATAGCCACAATGTAAAGGACATGCA
AAATGCAGAAACTTCGGGAAAGTTTGTTGATCCTGGGAGCATCGAGAC
ACAGACAAATCCAATTGATCGGTCCATAGCTCTGTTGCTTTTCCATCAG
CCATCAGAGCATGTCACTGGAGCTGTTGATGAAGCGGCTTCACTAAAG
TCACATAATGATAACCACCAGGCTGCTGCTAAAAACCAAAGAGTGATG
CATGCTTCATCTGTACATTCACCAAGAGGGCAGGGAGACCCCATGGAT
GCAAAATCTTGCAGAAACAACTGAAGTTATCTCATGAAGCTTCAACAA
CTGTGACTGTTAATATTGTACTTGTTGCTGCAAACCTTTCTCCGTTTTGA
TCCGATCATGCAGTTAGCAGCTGTGTAGTGTGTACTACTACTCTAGTCG
ATTAGTCAGGTACAGGCAAACTTGTAACACCAATTTAACAAGTTAGAT
TGGCTTTTGACCATTAGCTTTGTATCTTAATTATTGAGAAGGTCGTCTGT
GCCGTGGCCATTCGTGTCTGTTCTCACTCACATTTTGTGTAATCTCAAAC
CACCATTTCATGTTGTTAAAACAAGCCAACTCTGTACTTCTGTTTTAAA
TGATTGCTGGGGTGTGTTACATGTCAGTCATTC
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ATGCGCCCCCTCCACACGTGGCCCTCCCGCACCTCAACCCCGACCGCCC
GCCCAATCATCTTGCACCACGCGTCCGCCCCTCCCTGGACTCCTCTCGG
TGGGTGGGAAGGGAGAGGAGAGAGGGAGAGGGGGGAGAGGGAAGCG
CAGACGACGACAACACAGGTCGCGAGTGGAGGAGGAGGAGAAGCGAG
CAAGCGCAACGCGATTCTCCGCCGCGTCACCGAATTGGAGGATTTTCTG
CCCTTCCCTTTTGCCGTGGCTGGAGATGCAACCGTCGGGACCCGGGGG
GCAGCGCGTATCGGGCTCTCGTTCGGGTGCGGCGCCAGCGGCGGCCGC
CACCTGAGGAGGATGTTCGAGTGGAACGACGACCAGCAGCAGGGGATT
TTAGTGCTCGAAGAAGCAGCTGATGATTGTGAGCGAGCGAGCGAGGAT
GATAGGATTATTTCCAAGGAGGCTCACCTAGCAGAGAGAGTCTTGTGG
GCATTTAGATGCTACCGCGTGCGGTTGGGTTGTGCTAGGTCTCATAAGG
TGGGAGATGCAATATGGGCTGAGTTCAATGAGAATGAAGACCATATTG
TGCCTTACCCTAAGGATACAGAGGATAGTGCATTAGTAAGTGTTGGAG
ACCAGAAGAAGAATGATGAAGAAACTGATAATATTCCTGGCCTTACTG
AACGAAGTTCAAGTGGTCAAACTGAGTTTCCAGTTTTGGAAAAGCAGC
CTGCCTCTCAGGCTAGTGAACATTATTCAGCTACACAACTTGACGTTGA
ATCCTGGCCTGACTTGCCTTCTTTGAATGCCACACTTGATAGAAACTAC
AGCGATGATAATATAGCATCTACATATTTGGATTTCAGTTCTGCACCTA
GTTTAGAGAAGGTCACAGGAAACACAACAGTGCAGCTGGATGGTGAA
ACTGAAGTGTTTGGTAATGATCATGAAGAAAAGAGTAACAGCTTCCTT
GATTGTGACTGGGGTAATATCGGAGATTTTGATGATTTTGACCGCTTAT
TTAGCAATGGTGACTCCATATTTGGTAATGAGATGGTTGCTGATGGCAG
TAATTTTCTCTCAGCATCTTCAGATCTGGTGGATACTACTGTACAATCA
ATCCCCTTTCCACATATACCACTGAATAAACAACTATCTTCTGATCATG
GATCTTCGCTTCTGATTAATGAAACATCTGGTGGAACTACCGAACAAG
AAAGCAAGGGAGATGTGCAGAAGAAGTCAGTGAGGTCACGGAGAAGA
ACAGAAGAAAGAGGCAAAAGTAAAATGTCCAATAGTACAAGTGGCTT
CTCCCAGAACCAAGGACAGCATCGACCAGCCAGTTCGCATTCATTGGC
CAAAGCCCCTGCGCAACCCCTTCAGACTCCTCAATACTTGCTATTACAT
GATAACAAGAACATGGGACAACTTCAGCAGGCTAATCAGTTTATTTTC
CCTGACTATGGATATCCTTCATATCAATTTCCTGGCATTCCTCTGATGTC
AAATGTTCAGGCTGAAAGCCATCAAACAAAGCCAGCTACTACAAATTA
CCGAACTTCAATAGATTCCCCAAAACAGTCAAGTTCCGCAGAAAAGTC
ACAAGATATACCATCAAGACCATTGATGATGACACCCCAAGAAAAGAT
TGAAAAGCTTAGGCGTCGACAGCAAATGCAAGCACTGATAGCTATTCA
GCAGCAGCAGCAGCAGTTTGGTCAAGATGGTTCTGGCAGCGATACCAT
GGTACCTCAAGCGTACTCACCAAAGAGCAAAAATCCAGATTCCTTAGG
GAGTTCTGTTGTCATAGATGATAATGCAAATAAAGTTTTCTCACTAGAG
CTGATTCCAACTGGCCATGAAGAGATTCAGAAGAGTTCTGGGATTCCT
GATGACCCCTTTATAGAAGAAAAAATATATTATCAGCTTCAAGATGCTC
TTGCGAAGTTGGATACCAGAACTCGGCGTTGTATTCGAGACAGTTTACT
CCGTTTGGCCCATAGTGTCTCAGAGAGACAAATTACTAGTGACAGAAG
TAGTGCTAACAAGAGTAATAAAGATGATGATGAAGTTTCAGAAGACAC
ATCTAAAAGAAGATCTCCAGCAAGTGAAGCAGAAACAAACACAAATC
CAATCGACCGCATTGTGGCACATTTACTGTTTCATAAGCCTTGTTCAAA
GGTTTCAACACCTGCAAAAGAAGAGATCAAATCCTCAACTCCATTGCC
AACTGAACCTGATTCGAAGATTCCTACAGACGCACCTGGGGGACCATC
AGAAAATCACCAGAATGGGCAAGAAATGACACTGCAGCCTTCACTGTA
ATAGTATGTGGCAGGGGACCAATGAATTGCTCAACATCAACATGGTTA
GCTGCCTCTAAAGATGGCCATTGCCAGTCCGCTGATCACCTCCACTGTC
AGAGATCATTACGTGATGTATCCTGCTGTATCAGTTTCACCATCCTAGT
GCCTTGTGTCATATCCCAAAAAAAAAAAAAAAAACAACACTGTACAGT
TTAGACTGGATTCATGCCGAGGTGACACTTTGGGTGTGTATGTTAGAGT
TCACTGAAAGAGAGCGAACATTTGGCTCTAGAAATACTTTTGTCGTTGG
AAATTCCTCGATCTTATTCCCCAGAAAATGTCCTGTTCC
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GTCTTCTCCCTTGCCATCTCTGCGCTCCGATCCTTGGTTGAGCTGCTGTC
TTGTTTGTTTGGCTGGATCAATAATGCATGCGTCCGTGGGGAGGAGATG
GGGGTTTGATCCTTGCGACGAGGTCACCCACGTTGTTATGAATGACTTT
GCTCTGATGAATGACCACACCGTGCTGCTTCAAGGCCATGACAAGTCA
AGGATCAGCCCAGCTGGTTATTTGACAAGGTCAGGACCTACACAGGGC
GGTGGCATCAGAAACAATATTGGATATTGTGACGGGAGATCCATCAAT
GAATCCTGCGGTAAAAGAAGCACTTATCCACCAACTTACAAGAAAGAT
GTCACTGTTCCAAAAAGTACAAAACCAAGCATTTTTGATGCTGATGAAT
ATGTCAGTGTTAGCAATGTTTCAGACGTTCCTTCGTCAGAAGGCAATAC
TATGCAGGATGAGCACAGGAACAAAGGGAAAGATTTGTTATACTGTGA
TTGGTCTGAACTGCTCAACTTGGATGACCTCGAAGCAGATCTGAGAAG
TTTCGAGTCCACGTTTGAGATAGGAAGTAATCACTTTGAAGATCCACTG
TGGTCTTCAGTTTGCTTACCAGATGCCCAGCTAGTACCAAGCAGCTGTC
TCTTGGACAATACCAATTTGTCAACTGTTTCGAATGAGAGCACAACAA
AGTCTATATTATCATCAGTTTCAGTTTCCGATACTACTAGTGCTGAACC
ATTGTTCCTTGATCAGAATAATATGGCAAATCCTATCAACATACAACAA
CCACCCAGCAAAGGAAGAAGTTCGGCAACTTTGAATCATGAAGCACTT
GCCTGTTCTTCCGGGGAAATCGAGCGATTTTCACAACATTCAGATGTTG
ATGTTTTCTACCCATTTGACAATGTAACAAGCTCGGAACGCATAAGTGG
CTGTGAGGGACTAGAGGCTATCTTTTGCACAAATCAGGAAATGCTAGC
CCCAACAACATCAAGCATCATGTGTGATGATGAAATTGTATCTTCATCG
ACTTTCTCAGCACCGGATCTCGTTGCAACCTACGTTCCGCGTTCGATGA
AGAGATCTCATGATCCACTGAATGGAACTCCAGACATGATCCTCGACG
AAATGGCTGGAAATCCACTAGAGATGTATTTCCCTCCATCATTGACTGC
ATATGAACACCCAGAACATCTGAATAACGTTACTTTGACACAAACACA
CCAGTTTCCTGAAGGATTTGCAGGTGACGATGTTCTGAAAAGTGCAGA
CTTACAGTTCCTCTCGAAGGGAAAGACTTCAGCAGACTTATGTGTGAAC
CCTTGCTCACCACTGATTCTAGAAGCTGTGCCAGTTAAGGATCTTGGCT
TCCATAAGCTTCAGGAAGGCATGAATCAGTTGGACGTGGCATCCAAAG
CTCGCATAAGAGATGCCTTGTATCGATTGGCCAATTGTGTTGAGCATAG
GCATCGCATTGCTAGTACAACAGAGACCGTTAACCAACTTGGAGTTAT
GGAATCATCAGCTTCAAAGAGGTGGAGAGAAATTCAGATGATGAACCC
TATGGATCGCTCAGTGGCACAGCTGCTTCTCCAGAAACCGCTCCACCAT
AAATCTCCACCTGATTCGGCGCTCGGCATTGGTCCCTGAATTGTACTGC
ACCGTGAAAAACACGTAGGAGTGGCTGCTGATGCGATGTGGTTTTTTTT
ACTGCACATGTCTGATCGATTGAGCATTCTAGGTCCGGCAATTTTTTTT
CCCTCTCGGTTCCGGTACGCATGTATATACAGTAATCACTAAAGAGTAC
AGACTTACTAGATGAAATGTAATGTGATAGCAACGCTTTGCTGTTCAGA
GATGTGATTCTAAATAGAAACTACAGTGTTTTTTTTTTGTTGTCTTCAGC
ATTTACCTGTGACTTGTCAGATGCCCCATTGTACCGTCCAAAAATTTCC
TCTATTGACGGTTACCCCTTGGTCGCAGA
[0308] >osLNKl_(Os03g27019.2)
MPDWRVGEFEGKLKDGFARSNNSEHENGAGTVSISSKKSKHRVDSEKKPH
VDISGVIDSDSQKCNSEQIHSANGIVSRDVNHDHIENCKVESNDFPLNTISET
RYPTDNWNSSQFALSNDGSPVLNNQSTPQTGHGYGDNDLTYIDWPAIDNF
EDVDNLFRRCDSTYGQQQLPNTDELSWIPSSDAMYSSDVAMQPGFESSYS
DYGILDDLSAFNCTEDKSLTTADPSSAVCDEQFDDSYLFNEQKPEDVYGEQ
AYQRDAMELLSSDQICTGQENLDMIGNRYSSENAMEQPEDQKFSIASGSQ
LSSSQNLLNQKNHLDSTSPSNITSESYPERNCQIIPSGASFAERNLKVQKKV
ASSASGQLISDNVTGHPGHQTLTRRASYPCENHEIGKRSLGKRGLGHSDVA
MGTSMVVDGSFVSSISSDNSVEENSFRQLQDAVSQLDVKTKMCIRDGLYR
LARSAQNRQVFPNTMNNNGDSHNVKDMQNAETSGKFVDPGSIETQTNPID
RSIALLLFHQPSEHVTGAVDEAASLKSHNDNHQAAAKNQRVMHASSVHSP
RGQGDPMDAKSCRN
[0309] >osLNK2_(Os01g3 1360.3)
MRPLHTWPSRTSTPTARPIILHHASAPPWTPLGGWEGRGERERGEREAQTT
TTQVASGGGGEASKRNAILRRVTELEDFLPFPFAVAGDATVGTRGAARIGL
SFGCGASGGRHLRRMFEWNDDQQQGILVLEEAADDCERASEDDRIISKEA
HLAERVLWAFRCYRVRLGCARSHKVGDAIWAEFNENEDHIVPYPKDTED
SALVSVGDQKKNDEETDNIPGLTERSSSGQTEFPVLEKQPASQASEHYSAT
QLDVESWPDLPSLNATLDRNYSDDNIASTYLDFSSAPSLEKVTGNTTVQLD
GETEVFGNDHEEKSNSFLDCDWGNIGDFDDFDRLFSNGDSIFGNEMVADG
SNFLSASSDLVDTTVQSIPFPHIPLNKQLSSDHGSSLLINETSGGTTEQESKG
DVQKKSVRSRRRTEERGKSKMSNSTSGFSQNQGQHRPASSHSLAKAPAQP
LQTPQYLLLHDNKNMGQLQQANQFIFPDYGYPSYQFPGIPLMSNVQAESH
QTKPATTOYRTSIDSPKQSSSAEKSQDIPSRPLMMTPQEKIEKLRRRQQMQ
ALIAIQQQQQQFGQDGSGSDTMVPQAYSPKSKNPDSLGSSVVIDDNANKV
FSLELIPTGHEEIQKSSGIPDDPFIEEKIYYQLQDALAKLDTRTRRCIRDSLLR
LAHSVSERQITSDRSSANKSNKDDDEVSEDTSKRRSPASEAETNTNPIDRIV
AHLLFHKPC SKVSTPAKEEIKSSTPLPTEPDSKIPTDAPGGP SENHQNGQEM
TLQPSL
[0310] >osLNK3_(Os02g5 1760.1)
MHASVGRRWGFDPCDEVTWVMNDFALMNDHTVLLQGHDKSRISPAGY
LTRSGPTQGGGIRNNIGYCDGRSINESCGKRSTYPPTYKKDVTVPKSTKPSI
FDADEYVSVSNVSDVPSSEGNTMQDEHRNKGKDLLYCDWSELLNLDDLE
ADLRSFESTFEIGSNHFEDPLWSSVCLPDAQLVPSSCLLDNTNLSTVSNEST
TKSILSSVSVSDTTSAEPLFLDQNNMANPINIQQPPSKGRSSATLNHEALAC
SSGEIERFSQHSDVDVFYPFDNVTSSERISGCEGLEAIFCTNQEMLAPTTSSI
MCDDEIVSSSTFSAPDLVATYVPRSMKRSHDPLNGTPDMILDEMAGNPLE
MYFPPSLTAYEHPEHLNNVTLTQTHQFPEGFAGDDVLKSADLQFLSKGKT
SADLCVNPCSPLILEAVPVKDLGFHKLQEGMNQLDVASKARIRDALYRLA
NCVEHRHRIASTTEWNQLGVMESSASKRWREIQMMNPMDRSVAQLLLQ
KPLHHKSPPDSALGIGP
EXAMPLE 4
Phylogenetic analysis of LNK genes in monocots
[0311] In addition to the AtLNK homologs in Oryza sativa, we also searched for
orthologs in Sorghum bicolor and Glycine max using the BlastP algorithm of
PlantGDB for sorghum (http://www.plantgdb.org/SbGDB/cgi-bin/blastGDB.pl )
and soy (http://www.plantgdb.org/GmGDB/cgi-bin/blastGDB.pl ). respectively.
[0312] The sets of ortholog proteins from Arabidopsis thaliana, Oryza sativa,
Sorghum bicolor and Glycine max were aligned by MEGA6. The evolutionary
history of taxa was inferred by the neighbor-joining method according to Saitou N
and Nei M . (Saitou N . and Nei M . (1987). The neighbor-joining method: A new
method for reconstructing phylogenetic trees. Molecular Biology and Evolution
4:406-425). The bootstrap consensus tree inferred from 1000 replicates
[Felsenstein J . (1985). Confidence limits on phylogenies: An approach using the
bootstrap. Evolution 39:783-791] is taken to represent the evolutionary history of
t e taxa analyzed. Branches corresponding to partitions reproduced in less than
50% bootstrap replicates are collapsed. The evolutionary distances were computed
using the Poisson correction method [Zuckerkandl E . and Pauling L. (1965).
Evolutionary divergence and convergence in proteins. Edited in Evolving Genes
and Proteins by V. Bryson and H.J. Vogel, pp. 97-166. Academic Press, New
York] and are in the units of the number of amino acid substitutions per site. The
rate variation among sites was modeled with a gamma distribution (shape
parameter = 0.05). The analysis involved 23 amino acid sequences. All ambiguous
positions were removed for each sequence pair. There were a total of 1028
positions in the final dataset. Evolutionary analyses were conducted in MEGA6
[Tamura K., Stecher G., Peterson D., Filipski A., and Kumar S. (2013). MEGA6:
Molecular Evolutionary Genetics Analysis version 6.0. Molecular Biology and
Evolution 30: 2725-2729]. (Figure 15).
EXAMPLE 5
LNK function is conserved in dicots and monocots
To determine if the function of LNK genes is conserved between monocots
and dicots, we compared the regulation and function of LNK genes in rice, a
model monocot species, and Arabidopsis, a model eudicot species. For this, wild
type rice plants and a rice mutant line with a T-DNA insertion in OsLNK2
(PGF_2C-50209.L, developed by Gynheung An, see Jeong et al. and Jeon et. al
2000) and gene expression patterns of rice LNKl and LNK2 homologs under a
long day (LD, 16 h light /8 h darkness) cycle were characterized. Fresh leaves
were harvested every 4 hours on days 30 and 3 1 after germination for a total of 9
time points, starting at ZT2 (2 hours after lights on). Leaves were immediately
frozen in liquid Nitrogen and stored at -80°C until sample processing. All samples
were processed on t e same day. Total RNA was extracted using the Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
Total RNA ( 1 µg) was amplified with the dT18 primer by using the MMLV
Reverse Transcriptase (Invitrogen) according to t e manufacturer's instructions.
The reaction product (2 µΐ aliquot) was then diluted 1/50 and used for qRT-PCR
analysis. We carried out qRT-PCR in a total volume of 10 µΐ containing 2 µΐ of the
reverse-transcribed product above, 0.25 mM gene-specific primers, and 5 µΐ
FastStart Universal SYBR Green Master Mix Rox (Roche) on a Stratagene
Mx3005P Real-Time PCR System according to the manufacturer's instructions.
The measurements were obtained using the relative quantification method (Livak
and Schmittgen, 2001) using the rice ubiquitin gene (OsUBQ) as an internal
control. The expression of OsUBQ, OsLNKl, OsLNK2 and OsLNK3 was
measured by qRT-PCR. As observed previously in Arabidopsis, OsLNKl and
OsLNK2 rice genes display diurnal oscillations in gene expression with peak
levels in the early morning (Figure 16). Thus, similarly to what we observed in
Arabidopsis, the expression of the rice LNK gene orthologs is regulated by the
circadian clock.
Next we examined the molecular function of OsLNK2 in the control of the
rice circadian clock as well as in the regulation of flowering time in this species
using wild type rice plants and the mutant line PGF_2C-50209.L (Figure 17).
Then, we grew plants from this mutant background side by side with wild-type
plants under LD conditions (16 h light /8 h darkness). In Arabidopsis, LNK1 and
LNK2 genes regulate flowering time under long day conditions promoting the
expression of the flowering time gene FKF1. In rice, we found lower mRNA levels
of OsFKFl in the Oslnk2 mutant, indicating that OsLNK2 also functions
promoting the expression of this gene. Thus, LNK genes have a conserved
function in the control of FKF1, a key flowering time gene in rice and Arabidopsis.
Finally, we analyzed the role of OsLNK2 in the regulation of rice clock
genes. In Arabidopsis, LNKl and LNK2 genes accelerate the pace of the circadian
clock activating the expression of clock genes peaking in the afternoon or early
evening, such as PRR5. In rice, we found lower mRNA levels of OsPR95 in the
Oslnk2 mutant, indicating that OsLNK2 also functions promoting the expression
of this gene (Figure 17). Thus, LNK genes have a conserved function in the control
of OsPR95, a key core clock gene in rice and Arabidopsis, indicating that t e role
of LNK genes in t e control of the plant circadian clock is conserved between
monocots and dicots.
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LNK1 cDNA, genomic and protein sequence accessible at AT5G64170
(last modified April 27, 2007. The start codon (atg) at position 302 is double-
underlined and in bold. LNK1 cDNA sequence (AT5G64170.2; SEQ ID NO: 1):
1 GTCAAAAAAA AAAAAATAGG AAGCCTTCAT CGTCTTCTGC CGAACATCTC
51 TAGAAAGTCC TACACAGTTT TTTTTTTCGA TCTAGCTTCG A GAAT GAT
101 ACAATCTCTT CTATCTGCTG AGTTTTTTGT TTTCTGGTAA ACAATTTTAT
151 CTGTGGAGTT TTCTGGAGTT GCTAGTGGAA GAATCTGTCT CACAGAACCA
201 GAAATAGTGT TTGTGGGAGT TACATGTTTT GCAATAGAGA TGACATATCG
251 GGGTAATGTG CATGATTTTA GTGGTGATTA AAGAGTCTGA AGTTGGGAGG
301 AATGTCGGAC TTGTACATTC ATGAGCTAGG CGATTATCTT TCGGATGAAT
351 TTCATGGGAA CGATGATGGT ATAGTGCCAG ACTCAGCGTA TGAGGATGGA
401 GGTCAGTTTC CAATTCTAGT TAGTAACAGG AAGAAAC GAA GAAATGATGA
451 TATGGGTAGT GGAACAAACC ATCTAAAGAG TAATACTTTT ATCAAGAGAG
501 AGGCAAACAT GTTAGGAAAA AATCCATGGC CTGAGAAAGA TAGTGGTGGC
551 TCTTCGGTTT CTCGTGATAC GGGAACAGGA AAAGATGTTC AGGATATGAC
601 ATTGGAGGAT ACAAATACTT CAGATCATGG TTTCAATGGT GGCCACGTAG
651 ATGTGGTTGA AAATTTCTCC ACTGGGGATC CCATGTTGTG TGACACTTCC
701 GCTGCAACGA ATGATGGCGT ATATAATTAT TCCCTCAACA GCATTCCGGA
751 TGCTGAAAAT GATCTTAGCT TTTTCGACAA TGGAGATAAA GAAAAAAATG
801 ATCTCTTCTA TGGCTGGGGT GACATAGGAA ATTTTGAGGA TGTGGACAAC
851 ATGCTTAGGA GTTGTGATTC AACATTCGGC TTGGATAGTC TTAATAATGA
901 AGGTGACTTA GGGTGGTTCT CTTCTGCCCA GCCAAATGAG GAGACAGCAG
951 GCGCGATGAC AGATGATCTC AAACCAGACA AAATGTTGGA AAAT CAAAGA
1001 ACCGCTATGT TGCAGGTTGA AGACTTTTTG AACAACAGT G AGCCCAACCA
1051 TGCTGTTGAA GATGAGTATG GATATACTAT TGAGGACGAT TCAGCTCAAG
1101 GAAAATCATC ACAAAAT GTA TTCGATACAA GTTTGCAAAA GAAGGATATA
1151 TTGATGCTGG ATGTAGAGGC AAAT CTTGAG AAGAAGCAGA CTGATCATCT
1201 TCATCATCTG GATGGGAAAA GTGATGGGTT CTCGGAGAAC AGTTTTACTT
1251 TACAGCACAG TGGTATTTCA AGGGAAATAA TGGATACCAA CCAGTATTAC
1301 CCTCCCTCCG CATTCCAACA GCGAGATGTG CCATACTCGC ATTTCAATTG
1351 TGAGCAGCCT TCCGTTCAAG TATCAGCATG TGAAAGTAAA TCTGGTATTA
1401 AATCTGAGAA CAAACCCAGT CCTTCCTCTG CTTCAAATGA GTCATACACA
1451 TCAAAT CATG CACAATCAAT CGAGAGCTTA CAAGGTCCAA CTGTTGATGA
1501 TCGGTTTAGG AAGGTCTTTG AAAC GAGAGC CAACTTGCTG CCTGGGCAAG
1551 ATATGCCTCC TTCTTTTGCT GCAAATACCA AGAAGAGTAG TAAGACAGAC
1601 TCCATGGTGT TTCCTGATGC TGCTCCTATC CAGAAGATTG GGCTTGAGAA
1651 TGACCACAGA AAAGCTGCAA CTGAATTGGA AACATCAAAT ATGCAGGGAA
1701 GTTCTTGTGT TAGCTCTGTT GTGGATGACA TTTCACTGGA AGCAACAAGT
1751 TTTCGCCAGC TTCAACAAGT TATAGAACAG TTGGATGTTA GGACAAAGCT
1801 TTGCATAAGA GACAGCTTAT ACCGATTAGC AAAAAGTGCG GAACAGAGAC
1851 ATCATGGTGG AAACAGACCG GAGAAAGGCG CAGGCTCGCA TCTCGTGACT
1901 GGTGAAGCAG ACAAGTATGC TGGATTCATG GATA CGAAA CTGATACAAA
1951 CCCGATAGAT CGATCGATAG CTCATTTGCT GTTTCACAGG CCCTCAGACT
2001 CATCTCTTTC ATCCGATAAC AATGTTCTGT CTTATAAATC TCATCCAATG
2051 ATTCCTCAGC CCAATAGTAG TCCGAGCCTG AGGATAGAGA AACAAGAGGA
2101 AACTACAGAA CTTAGACCCG AAGCAGAAGT TGTAACAAGT GACAACAATT
2151 AATGATGTCA AATAAAACTG GCTCTTTCAT TGCTGAAGCA TTCGAGATAT
2201 TGTTGTTAAC ACTAATCTCG ATTTTGGCTA AGCGAAATTG CTCAGGTTAG
2251 TTACTAAAAT CCTGACTGCT TCTTCATTAG AAT CATGGAT TTTGTAACAC
2301 AGTTGTATTT ATGTGTTGAG ATAACTTTCT GGTCTAGATT TCGGTTCGAA
2351 CCTGATTGTA CACCTGGTTG CTCGAACCTG ATTGTACACC TGGTTGCTCG
2401 AACCAGGTCT TTAAGATATG TTCTTTACCT TTGTAATCTG TTCAAGTTGT
2451 TAAGTAGAGG AAGAAGTAGA GACATAGCAA TTCTGTAGAT AAAGATGTTA
2501 GTTCGTTTTG TAATGCGATA AAATATTCTG CTGTGTATTT ACTCTCTTTT
2551 TTTCAAAATA GCGAATTTTA GGGTTTTATT TTCCAATAAA
[0317] LNKl polypeptide sequence (AT5G64170.2; SEQ ID NO:2):
1 MSDLYIHELG DYLSDEFHGN DDGIVPDSAY EDGGQFPILV SNRKKRRNDD
51 MGSGTNHLKS NTFIKREANM LGKNPWPEKD SGGSSVSRDT GTGKDVQDMT
01 LEDTNTSDHG FNGGHVDWE NFSTGDPMLC DTSAATNDGV YNYSLNSIPD
51 AENDLSFFDN GDKEKNDLFY GWGDIGNFED VDNMLRSCDS TFGLDSLNNE
01 GDLGWFSSAQ PNEETAGAMT DDLKPDKMLE NQRTAMLQVE DFLNNSEPNH
51 AVEDEYGYTI EDDSAQGKSS QNVFDTSLQK KDILMLDVEA NLEKKQTDHL
01 HHLDGKSDGF SENSFTLQHS GISREIMDTN QYYPPSAFQQ RDVPYSHFNC
51 EQPSVQVSAC ESKSGIKSEN KPSPSSASNE SYTSNHAQSI ESLQGPTVDD
01 RFRKVFETRA NLLPGQDMPP SFAANTKKSS KTDSMVFPDA APIQKIGLEN
51 DHRKAATELE TSNMQGSSCV SSWDDISLE ATSFRQLQQV lEQLDVRTKL
01 CIRDSLYRLA KSAEQRHHGG NRPEKGAGSH LVTGEADKYA GFMDIETDTN
51 PIDRSIAHLL FHRPSDSSLS SDNNVLSYKS HPMIPQPNSS PSLRIEKQEE
01 TTELRPEAEV
[0318] LNKl cDNA sequence (AT5G64170. 1; SEQ ID NO:5):
1 GTCAAAAAAA AAAAAATAGG AAGCCTTCAT CGTCTTCTGC CGAACATCTC
51 TAGAAAGTCC TACACAGTTT TTTTTTTCGA TCTAGCTTCG ATGAATTGAT
101 ACAATCTCTT CTATCTGCTG AGTTTTTTGT TTTCTGGTAA ACAATTTTAT
151 CTGTGGAGTT TTCTGGAGTT GCTAGTGGAA GAATCTGTCT CACAGCTAGG
201 CGATTATCTT TCGGATGAAT TTCATGGGAA CGATGATGGT ATAGTGCCAG
251 ACTCAGCGTA TGAGGATGGA GGTCAGTTTC CAATTCTAGT TAGTAACAGG
301 AAGAAAC GAA GAAATGATGA TATGGGTAGT GGAACAAACC ATCTAAAGAG
351 TAATACTTTT ATCAAGAGAG AGGCAAACAT GTTAGGAAAA AATCCATGGC
401 CTGAGAAAGA TAGTGGTGGC TCTTCGGTTT CTCGTGATAC GGGAACAGGA
451 AAAGATGTTC AGGATATGAC ATTGGAGGAT ACAAATACTT CAGATCATGG
501 TTTCAATGGT GGCCACGTAG ATGTGGTTGA AAATTTCTCC ACTGGGGATC
551 CCATGTTGTG TGACACTTCC GCTGCAACGA ATGATGGCGT ATATAATTAT
601 TCCCTCAACA GCATTCCGGA TGCTGAAAAT GATCTTAGCT TTTTCGACAA
651 TGGAGATAAA GAAAAAAATG ATCTCTTCTA TGGCTGGGGT GACATAGGAA
701 ATTTTGAGGA TGTGGACAAC ATGCTTAGGA GTTGTGATTC AACATTCGGC
751 TTGGATAGTC TTAATAATGA AGGTGACTTA GGGTGGTTCT CTTCTGCCCA
801 GCCAAATGAG GAGACAGCAG GCGCGATGAC AGATGATCTC AAAC CAGACA
851 AAATGTTGGA AAATCAAAGA ACCGCTATGT TGCAGGTTGA AGACTTTTTG
901 AACAACAGT G AGCCCAACCA TGCTGTTGAA GATGAGTATG GATATACTAT
951 TGAGGACGAT TCAGCTCAAG GAAAATCATC ACAAAAT GTA TTCGATACAA
1001 GTTTGCAAAA GAAGGATATA TTGATGCTGG ATGTAGAGGC AAAT CTTGAG
1051 AAGAAGCAGA CTGATCATCT TCATCATCTG GATGGGAAAA GTGATGGGTT
1101 CTCGGAGAAC AGTTTTACTT TACAGCACAG TGGTATTTCA AGGGAAATAA
1151 TGGATACCAA CCAGTATTAC CCTCCCTCCG CATTCCAACA GCGAGATGTG
1201 CCATACTCGC ATTTCAATTG TGAGCAGCCT TCCGTTCAAG TATCAGCATG
1251 TGAAAGTAAA TCTGGTATTA AATCTGAGAA CAAACCCAGT CCTTCCTCTG
1 3 0 1 CTTCAAATGA GT CATACACA TCAAATCATG CACAATCAAT CGAGAGCTTA
1 3 5 1 CAAGGTCCAA CTGTTGATGA TCGGTTTAGG AAGGTCTTTG AAACGAGAGC
1 4 0 1 CAACTTGCTG CCTGGGCAAG ATATGCCTCC TTCTTTTGCT GCAAATACCA
1 4 5 1 AGAAGAGTAG TAAGACAGAC TCCATGGTGT TTCCTGATGC TGCTCCTATC
1 5 0 1 CAGAAGATTG GGCTTGAGAA TGACCACAGA AAAGCTGCAA CTGAATTGGA
1 5 5 1 AACAT CAAAT ATGCAGGGAA GTTCTTGTGT TAGCTCTGTT GTGGATGACA
1 6 0 1 TTTCACTGGA AGCAACAAGT TTTCGCCAGC TTCAACAAGT TATAGAACAG
1 6 5 1 TTGGATGTTA GGACAAAGCT TTGCATAAGA GACAGCTTAT ACCGATTAGC
1 7 0 1 AAAAAGTGCG GAACAGAGAC ATCATGGTGG AAACAGACCG GAGAAAGGCG
1 7 5 1 CAGGCTCGCA TCTCGTGACT GGTGAAGCAG ACAAGTATGC TGGATTCATG
1 8 0 1 GATATCGAAA CTGATACAAA CCCGATAGAT CGATCGATAG CTCATTTGCT
1 8 5 1 GTTTCACAGG CCCTCAGACT CATCTCTTTC ATCCGATAAC AATGTTCTGT
1 9 0 1 CTTATAAATC TCATCCAATG ATTCCTCAGC CCAATAGTAG TCCGAGCCTG
1 9 5 1 AGGATAGAGA AACAAGAGGA AACTACAGAA CTTAGACCCG AAGCAGAAGT
2 0 0 1 TGTAACAAGT GACAACAATT AATGATGTCA AATAAAACTG GCTCTTTCAT
2 0 5 1 TGCTGAAGCA TTCGAGATAT TGTTGTTAAC ACTAATCTCG ATTTTGGCTA
2 1 0 1 AGCGAAATTG CTCAGGTTAG TTACTAAAAT CCTGACTGCT TCTTCATTAG
2 1 5 1 AATCATGGAT TTTGTAACAC AGTTGTATTT ATGTGTTGAG ATAACTTTCT
2 2 0 1 GGTCTAGATT TCGGTTCGAA CCTGATTGTA CACCTGGTTG CTCGAACCTG
2 2 5 1 ATTGTACACC TGGTTGCTCG AACCAGGTCT TTAAGATATG TTCTTTACCT
2 3 0 1 TTGTAATCTG TTCAAGTTGT TAAGTAGAGG AAGAAGTAGA GACATAGCAA
2 3 5 1 TTCTGTAGAT AAAGATGT TA GTTCGTTTTG TAAT GCGATA AAATATTCTG
2 4 0 1 CTGTGTATTT ACTCTCTTTT TTTCAAAATA GCGAATTTTA GGGTTTTATT
2 4 5 1 TTCCAATAAA
[0319] LNK1 polypeptide sequence (AT5G64170.1; SEQ ID NO:6):
1 MGSGTNHLKS NTFIKREANM LGKNPWPEKD SGGS SVSRDT GTGKDVQDMT
5 1 LEDTNTSDHG FNGGHVDWE NFSTGDPMLC DTSAATNDGV YNYSLNS I P D
1 0 1 AENDLS FFDN GDKEKNDLFY GWGDI GNFED VDNMLRSCDS TFGLDSLNNE
1 5 1 GDLGWFS SAQ PNEETAGAMT DDLKPDKMLE NQRTAMLQVE DFLNNSEPNH
2 0 1 AVEDEYGYTI EDDSAQGKS S QNVFDTSLQK KDI LMLDVEA NLEKKQTDHL
2 5 1 HHLDGKSDGF SENS FTLQHS GI SREIMDTN QYYPPSAFQQ RDVPYSHFNC
3 0 1 EQPSVQVSAC ESKSGI KSEN KPS P S SASNE SYTSNHAQS I ESLQGPTVDD
3 5 1 RFRKVFETRA NLLPGQDMPP SFAANTKKS S KTDSMVFPDA APIQKIGLEN
4 0 1 DHRKAATELE TSNMQGS SCV SSWDDI SLE ATS FRQLQQV I EQLDVRTKL
4 5 1 CI RDSLYRLA KSAEQRHHGG NRPEKGAGSH LVTGEADKYA GFMDI ETDTN
5 0 1 P I DRS IAHLL FHRPSDS SLS SDNNVLSYKS HPMI PQPNS S PSLRI EKQEE
5 5 1 TTELRPEAEV VTSDNN
[0320] LNK1 promoter sequence (SEQ ID NO: 7):
CCCAAGCCTGTTAAACCTTTTGATTTAGTTGCCACGTGTTGATATCATGGTCACTTGTC
TTTTGATTCT CCCGAAACAAAAACAATAGTTTAATTAAAATTTAAAATGT TTGT CAAAA
AAAAAAAAATAGGAAGCCTTCATCGTCTTCTGCCGAACATCTCTAGAAAGTCCTACACA
GTTTTTTTTTTCGATCTAGCTTCGATGAATTGATACAATCTCTTCTATCTGCTGAGTTT
TTTGTTTTCTGGTAAACAATTTTATCTGTGGAGTTTTCTGGAGTTGCTAGTGGAAGAAT
CTGTCTCACAGGTGAGCTTATTTCGTTCGGCTTTGATGGAATCTATTTCGATTGAATTT
AATTAGAAAATTTGGTTCTTATCCTCAGTGTTTCCATAGCAGCGGTAGCTGAGGATTTC
TCAGATTTGATTGTTTTTTTTTTTGTTGCAGTTAGTTTCATTGAATGCCTCATTTCACT
GGATTTTAGTTGTTTTTGTAAACTCTCGGTTTAATAATGATAGTTTAACTCGATTTTGC
TAGAAATTACGAGCATAAAATGGTTGAATCCTACTATCTGATTTTTCTCCTACTTTGTT
TTTGTGCTACTTGCTATGAGATTTGACTTTTTGGCTGTAGAATTTGAGTCTAATTTCTG
GAATTCATGAATAGTTGAAAGAATGGGT TAACTCTTAGGGTTTG GATTACATGTATTTC
GGGTTTCATGGGATTTGATTCTGGATAAGAAAAGTCAAGTTTTCTTATATGCTGGGTTC
GATTTCTCTATTAT TGGAAGCTGT TTAATATATTTATATTTCCTATCCAGAACCAGAAA
TAGTGTTTGTGGGAGTTACATGTTTTGCAATAGAGATGACATATCGGGGTAATGTGCAT
GATTTTAGT GGT GATTAAAGAGTCT GAAGTTGGGAGGAATG
LNK2 cDNA, genomic and protein sequence accessible at AT3G54500.
LNK2 cDNA (splice variants): including splice variants e.g., AT3G54500.2;
AT3G54500.1 or AT3G54500.4: LNK2 cDNA sequence (AT3G54500.3; SEQ ID
NO:3). The start codon (atg) is double-underlined and in bold:
1 AAAAAAAACT CTTTTTTCTT TTTTCCACTG TAACTCCTTT CTCTTCCCAT
51 ATCCTTTGAG CACGAAGGAG GATTCTGCTG AATCAAGGTT TTTCAAAGCT
101 TGTTGCTTTT TCAGTTTAAT ATTCTTTTAT TTATCGTTTT TTCCACTTTA
151 TTATTGTGTG TGGATTTACG TTATCCGATT TGTTGATCTT GTTGTTTTTT
201 CCTGGATTTT TTTCGTTGTG GAGCTGGCGA TGTGTGGAGC AATCAGGGAG
251 CTTGATTTTG GGTCTGTGAT TCGATTTTGT TTCTCCAGTC ATGTTTGATT
301 GGGAAGAAGA AGAGCTTACT AATATGATAT GGGGTGATGA TGCTGAGACA
351 GGCGACCATA TTGTGCCTTT AAAGT CAGA AGT GAACAAC TTAACAAAAA
401 GGAACAGATT GAGGAATCTA AGACAGCTGA GCAAAAGATA ACTGGGACTA
451 AAATTGACCT CCATGATAAA AATTTGGGGA GCAGTTCGAG CCATAATGTT
501 GATGAGGGGC TTCCTCAGCC AGATTTCTGT ATGAGCTCAT GGCCTGACAC
551 GTCGCTAACT AATGCTACAA AGGTTGATCA AGATTTGAGT GCGACTGAAC
601 TTTCAAAATG CTTAGCTGAG CCAGTCAGAT ATGATTCAAC AAGAGGTGGT
651 GCGTTTCTCT TGAAACAGTC ATGTTTTACT TGGGTACGTT CTTTCCAATC
701 TAATCATTTT AAAAGTTGTG TGCTCACTCT GTTTTTACCA GAGAAAACGT
751 CTGAACTTGG GAAAGGCCCT GATATTTTTC ATAGCTCTGA TGAGAGTAAA
801 GAGCAAGGTG ATTTTGATGA CTACAGCTGG GCCAACATTG GTAGTTTTGA
851 TGATCTTGAT CGAATGTTCA GCAATGATGT CCCTATATTT GGTGATGGCA
901 GTCTCAGCGG TGGTGATGAG TTATGGTCAT CTTCTAAAGA TGTATCCAAT
951 AGCCCAAAAT CATTATCATC AATGTTGGAC TCTCAAGATC TAGGATTGGA
1001 TATTAGAACT GAGTTTGAGC AACAAGAGAA CCAGCAATTT CCATTGACTG
1051 GAAAAGCCAA TGGTCTGTCA TCCCAAAGTG TCCCAAGTGT ACGTGTAACT
1101 CTTAAGGCTG ACCAATATCG TGAGCATAAG GGTCAACCCT CAGTTGAGGA
1151 CCAGCCATAT CAACAAAATA AAATGATGAA GTTTTCGAAA ATGCCTGGGA
1201 CTTCTGAGGC AAGGCCCTTT CAAGAGCTGT ACGGTCAGAG GATTCCATTT
1251 AGTAATTCAG CTGGAAAATG TGTAAATCAG TTGGCACCGC CACAATCGTC
1301 TCTGATGGCT GTTAATCTCC TGAGTGAGTC TGAGGGGTCT GGGACATCAC
1351 ACTATTCACA TATGCCAAAC CAATACATGG CTAATTCTGC TTTTGGTAAT
1401 CTTGCAAATC CATATTCTAG TGTGCCTGTA ATTTCGGCCG TCCAACATCC
1451 TGATGTTAGG AATCAGTTGA TGCATCCTTC CTACAATCCT GCTACTGCTA
1501 CCTCAGTAAA CATGGCAACA GATGCCTCTG CACGGCCTTC AACAATGACA
1551 CCACAGGAAA AACTAGAAAA ACTTAGACGC AGACAGCAAA TGCAGGCAAT
1601 GCTTGCCATT CAGAGACAAC AGCAGCAATT TTCTCATCAG GTGCCTGTAG
1651 CAGATCAATC CATTACTCAA AACTGTCTCC AAGATATTCC ACTCCAGCTT
1701 GTCGACAAAA CTAATCTCCA AGGGCTAACT GCAATGCCTT CCTTTGATCC
1751 TAGTTCATCT TTGGAACAAG ATGATTCTGG CAAATTTGCT GCTGCTGTTG
1801 ATAATTCAGC AGAATTCGCA GTTCTTTATC GGCTTCAGGA TGTTGTAGCA
1851 AAGTTGGATA TGGGAACACG GACTTGTATA CGGGATAGCT TATTCCGGTT
1901 GGCTGGTAGT GCAGCTCAGA GACATTACAC TAGT GATACA TCCCACAGTA
1951 ACAAGACTAG CCAGGATGAC CAGGAAGTCA TTCCCAGAGA AGAATCCAGA
2001 TATAGATATG CTGGGATGCC AGATACAGAA GCAGTGACCA ACCCCACAGA
2051 CAGAACTGTG GCTCATTTGC TCTTTCATAG GCCTTTTGAT ATGTTGGCGG
2101 CAAAGCGAAT GGAAGGACCA GAATCACCCG CTTCTTCGAA GATGGGAACT
2151 GAAGAAAAAG GGAATTTTCC TAAATGCAGC ATACGAGAGA CTCACTTAAC
2201 TAAGCAGAAA GCTCAAAAGG AAGAAGGACC TGCAGATTCA CTTGCTTTGG
2251 GGAATGCACC CAACTCTGGA TCTAGTAGTA CTGTTGGTGA GAGGGTTGTT
2301 GAAGCATCCC AAGGAAACAA AAGAAAATTG TGAAATTTAG AAGTTTAGGT
2351 TGCCGTGTTA GAGAGGAGCT TTGGGTATTT CTGCAGACTA GACAGCATCT
2401 TTCTGCGTCT CTTGAAACAA TCTCCTGACT GCTCCTTTCT TGTGAAGCTC
2451 TTATTCTTGT AATTAGATTT TTTTTTTTTT GTTACTTTTC GAAAACCTCT
2501 TTTGTTATAC GTATCTCCAT GACAACTACA TTTTGGAAAA CGTGTAGTTT
2 5 5 1 GCAATGTTTT TCCCCCATTC GAAACCAGAT TCAATCTCTT AATACAATTG
2 6 0 1 AAGCACACA CCAAGGACAC ATAAAGTACT GTTTTGAGG
[0322] LNK2 polypeptide sequence (AT3G54500.3; SEQ ID NO:4):
1 MIWGDDAETG DHIVPFKVRS EQLNKKEQI E ESKTAEQKIT GTKI DLHDKN
5 1 LGS SS SHNVD EGLPQPDFCM SSWPDTSLTN ATKVDQDLSA TELSKCLAEP
1 0 1 VRYDSTRGGA FLLKQSCFTW VRS FQSNHFK SCVLTLFLPE KTSELGKGPD
1 5 1 I FHSSDESKE QGDFDDYSWA NI GS FDDLDR MFSNDVPI FG DGSLSGGDEL
2 0 1 WS S SKDVSNS PKSLS SMLDS QDLGLDIRTE FEQQENQQFP LTGKANGLS S
2 5 1 QSVPSVRVTL KADQYREHKG QPSVEDQPYQ QNKMMKFSKM PGTSEARPFQ
3 0 1 ELYGQRI PFS NSAGKCVNQL APPQS SLMAV NLLSESEGSG TSHYSHMPNQ
3 5 1 YMANSAFGNL ANPYS SVPVI SAVQHPDVRN QLMHPSYN PA TATSVNMATD
4 0 1 ASARPSTMTP QEKLEKLRRR QQMQAMLAI Q RQQQQFSHQV PVADQSITQN
4 5 1 CLQDI PLQLV DKTNLQGLTA MPS FDPSS SL EQDDSGKFAA AVDNSAEFAV
5 0 1 LYRLQDWAK LDMGTRTCI R DSLFRLAGSA AQRHYTSDTS HSNKTSQDDQ
5 5 1 EVI PREESRY RYAGMPDTEA VTNPTDRTVA HLLFHRPFDM LAAKRMEGPE
6 0 1 S PASSKMGTE EKGNFPKCS I RETHLTKQKA QKEEGPADSL ALGNAPNSGS
651 S STVGERWE ASQGNKRKL
[0323] LNK2 cDNA sequence (AT3G54500.1; SEQ ID NO:8). The start codon
(atg) is double-underlined and in bold:
1 CCCATATCCT TTGAGCACGA AGGAGGATTC TGCTGAATCA AGCTGGCGAT
5 1 GTGTGGAGCA ATCAGGGAGC TTGATTTTGG GTCTGTGATT CGATTTTGTT
1 0 1 GGAAGAAGAA GAGCTTACTA ATATGATATG
1 5 1 GGGTGATGAT GCTGAGACAG GCGACCATAT TGTGCCTTTT AAAGTCAGAA
2 0 1 GTGAACAACT TAACAAAAAG GAACAGATTG AGGAATCTAA GACAGCTGAG
2 5 1 CAAAAGATAA CTGGGACTAA AATTGACCTC CATGATAAAA ATTTGGGGAG
3 0 1 CAGTTCGAGC CATAATGTTG ATGAGGGGCT TCCTCAGCCA GATTTCTGTA
3 5 1 TGAGCTCATG GCCTGACACG TCGCTAACTA ATGCTACAAA GGTTGATCAA
4 0 1 GATTTGAGTG CGACTGAACT TTCAAAATGC TTAGCTGAGC CAGTCAGATA
4 5 1 TGATTCAACA AGAGAGAAAA CGTCTGAACT TGGGAAAGGC CCTGATATTT
5 0 1 TTCATAGCTC TGATGAGAGT AAAGAGCAAG GTGATTTTGA TGACTACAGC
5 5 1 TGGGCCAACA TTGGTAGTTT TGATGATCTT GATCGAATGT TCAGCAATGA
6 0 1 TGTCCCTATA TTTGGTGATG GCAGTCTCAG CGGTGGTGAT GAGTTATGGT
6 5 1 CATCTTCTAA AGATGTATCC AATAGCCCAA AATCATTATC ATCAATGTTG
7 0 1 GACTCTCAAG ATCTAGGATT GGATATTAGA ACTGAGTTTG AGCAACAAGA
7 5 1 GAACCAGCAA TTTCCATTGA CTGGAAAAGC CAATGGTCTG TCATCCCAAA
8 0 1 GTGTCCCAAG TGTACGTGTA ACTCTTAAGG CTGACCAATA TCGTGAGCAT
8 5 1 AAGGGTCAAC CCTCAGTTGA GGACCAGCCA TAT CAACAAA ATAAAATGAT
9 0 1 GAAGTTTTCG AAAATGCCTG GGACTTCTGA GGCAAGGCCC TTTCAAGAGC
9 5 1 TGTACGGTCA GAGGATTCCA TTTAGTAATT CAGCTGGAAA ATGTGTAAAT
1 0 0 1 CAGTTGGCAC CGCCACAATC GTCTCTGATG GCTGTTAATC TCCTGAGTGA
1 0 5 1 GTCTGAGGGG TCTGGGACAT CACACTATTC ACATATGCCA AACCAATACA
1 1 0 1 TGGCTAATTC TGCTTTTGGT AATCTTGCAA ATCCATATTC TAGTGTGCCT
1 1 5 1 GTAATTTCGG CCGTCCAACA TCCTGATGTT AGGAATCAGT TGATGCATCC
1 2 0 1 TTCCTACAAT CCTGCTACTG CTACCTCAGT AAACATGGCA ACAGATGCCT
1 2 5 1 CTGCACGGCC TTCAACAATG ACACCACAGG AAAAACTAGA AAAACTTAGA
1 3 0 1 CGCAGACAGC AAATGCAGGC AATGCTTGCC ATTCAGAGAC AACAGCAGCA
1 3 5 1 ATTTTCTCAT CAGGTGCCTG TAGCAGATCA ATCCATTACT CAAAACTGTC
1 4 0 1 TCCAAGATAT TCCACTCCAG CTTGTCGACA AAACTAATCT CCAAGGGCTA
1 4 5 1 ACTGCAATGC CTTCCTTTGA TCCTAGTTCA TCTTTGGAAC AAGATGATTC
1 5 0 1 TGGCAAATTT GCTGCTGCTG TTGATAATTC AGCAGAATTC GCAGTTCTTT
1 5 5 1 ATCGGCTTCA GGATGTTGTA GCAAAGTTGG ATATGGGAAC ACGGACTTGT
1 6 0 1 ATACGGGATA GCTTATTCCG GTTGGCTGGT AGTGCAGCTC AGAGACATTA
1 6 5 1 CACTAGTGAT ACATCCCACA GTAACAAGAC TAGCCAGGAT GACCAGGAAG
1 7 0 1 TCATTCCCAG AGAAGAATCC AGATATAGAT ATGCTGGGAT GCCAGATACA
1751 GAAGCAGTGA CCAACCCCAC AGACAGAACT GTGGCTCATT TGCTCTTTCA
1801 TAGGCCTTTT GATATGTTGG CGGCAAAGCG AATGGAAGGA CCAGAATCAC
1851 CCGCTTCTTC GAAGATGGGA ACTGAAGAAA AAGGGAATTT TCCTAAATGC
1901 AGCATACGAG AGACTCACTT AACTAAGCAG AAAGCTCAAA AGGAAGAAGG
1951 ACCTGCAGAT TCACTTGCTT TGGGGAATGC ACCCAACTCT GGATCTAGTA
2001 GTACTGTTGG TGAGAGGGTT GTTGAAGCAT CCCAAGGAAA CAAAAGAAAA
2051 TTGTGAAATT TAGAAGTTTA GGTTGCCGTG TTAGAGAGGA GCTTTGGGTA
2101 TTTCTGCAGA CTAGACAGCA TCTTTCTGCG TCTCTTGAAA CAATCTCCTG
2151 ACTGCTCCTT TCTTGTGAAG CTCTTATTCT TGTAATTAGA TTTTTTTTTT
2201 TTTGTTACTT TTCGAAAACC TCTTTTGTTA TACGTATCTC CATGACAACT
2251 ACATTTTGGA AAACGTGTAG TTTGCAATGT TTTTCCCCCA TTCGAAACCA
2301 GATTCAATCT CTTAATACAA TTGTAAGCAC
[0324] LNK2 polypeptide sequence (AT3G54500.1; SEQ ID NO:9):
1 MFDWEEEELT NMIWGDDAET GDHIVPFKVR SEQLNKKEQI EESKTAEQKI
51 TGTKIDLHDK NLGSSSSHNV DEGLPQPDFC MSSWPDTSLT NATKVDQDLS
101 ATELSKCLAE PVRYDSTREK TSELGKGPDI FHSSDESKEQ GDFDDYSWAN
151 IGSFDDLDRM FSNDVPI FGD GSLSGGDELW SSSKDVSNSP KSLSSMLDSQ
201 DLGLDIRTEF EQQENQQFPL TGKANGLSSQ SVPSVRVTLK ADQYREHKGQ
251 PSVEDQPYQQ NKMMKFSKMP GTSEARPFQE LYGQRIPFSN SAGKCVNQLA
301 PPQSSLMAVN LLSESEGSGT SHYSHMPNQY MANSAFGNLA NPYSSVPVIS
351 AVQHPDVRNQ LMHPSYNPAT ATSVNMATDA SARPSTMTPQ EKLEKLRRRQ
401 QMQAMLAIQR QQQQFSHQVP VADQSITQNC LQDI PLQLVD KTNLQGLTAM
451 PSFDPSSSLE QDDSGKFAAA VDNSAEFAVL YRLQDWAKL DMGTRTCIRD
501 SLFRLAGSAA QRHYTSDTSH SNKTSQDDQE VIPREESRYR YAGMPDTEAV
551 TNPTDRTVAH LLFHRPFDML AAKRMEGPES PASSKMGTEE KGNFPKCSIR
601 ETHLTKQKAQ KEEGPADSLA LGNAPNSGSS STVGERWEA SQGNKRKL
[0325] LNK2 cDNA sequence (AT3G54500.2; SEQ ID NO: 10). The start codon
(atg) is double-underlined and in bold:
1 CATATCCTTT GAGCACGAAG GAGGATTCTG CTGAATCAAG CTGGCGATGT
51 GTGGAGCAAT CAGGGAGCTT GATTTTGGGT CTGTGATTCG ATTTTGTTTC
101 TCCAGTCATG TTTGATTGGG AAGAAGAAGA GGCGACCATA TTGTGCCTTT
151 TAAAGTCAGA AGTGAACAAC TTAACAAAAA GGAACAGATT GAGGAATCTA
201 AGACAGCTGA GCAAAAGATA ACTGGGACTA AAATTGACCT CCATGATAAA
251 AATTTGGGGA GCAGTTCGAG CCATAATGTT GATGAGGGGC TTCCTCAGCC
301 AGATTTCTGT ATGAGCTCAT GGCCTGACAC GTCGCTAACT AATGCTACAA
351 AGGTTGATCA AGATTTGAGT GCGACTGAAC TTTCAAAATG CTTAGCTGAG
401 CCAGTCAGAT ATGATTCAAC AAGAG GTGAG AAAACGTCTG AACTTGGGAA
451 AGGCCCTGAT ATTTTTCATA GCTCTGATGA GAGTAAAGAG CAAGGTGATT
501 TTGATGACTA CAGCTGGGCC AACATTGGTA GTTTTGATGA TCTTGATCGA
551 ATGTTCAGCA ATGATGTCCC TATATTTGGT GATGGCAGTC TCAGCGGTGG
601 TGATGAGTTA TGGTCATCTT CTAAAGATGT ATCCAATAGC CCAAAAT CAT
651 TATCATCAAT GTTGGACTCT CAAGATCTAG GATTGGATAT TAGAACTGAG
701 TTTGAGCAAC AAGAGAAC CA GCAATTTCCA TTGACTGGAA AAGCCAATGG
751 TCTGTCATCC CAAAGTGTCC CAAGTGTACG TGTAACTCTT AAGGCTGACC
801 AATATCGTGA GCATAAGGGT CAACCCTCAG TTGAGGACCA GCCATATCAA
851 CAAAATAAAA TGATGAAGTT TTCGAAAATG CCTGGGACTT CTGAGGCAAG
901 GCCCTTTCAA GAGCTGTACG GTCAGAGGAT TCCATTTAGT AATTCAGCTG
951 GAAAATGTGT AAATCAGTTG GCACCGCCAC AATCGTCTCT GATGGCTGTT
1001 AATCTCCTGA GTGAGTCTGA GGGGTCTGGG ACATCACACT ATTCACATAT
1051 GCCAAACCAA TACATGGCTA ATTCTGCTTT TGGTAATCTT GCAAATCCAT
1101 ATTCTAGTGT GCCTGTAATT TCGGCCGTCC AACATCCTGA TGTTAGGAAT
1151 CAGTTGATGC ATCCTTCCTA CAATCCTGCT ACTGCTACCT CAGTAAACAT
1201 GGCAACAGAT GCCTCTGCAC GGCCTTCAAC AATGACACCA CAGGAAAAAC
1251 TAGAAAAACT TAGACGCAGA CAGCAAATGC AGGCAATGCT TGCCATTCAG
1301 AGACAACAGC AGCAATTTTC TCATCAGGTG CCTGTAGCAG ATCAATCCAT
1351 TACTCAAAAC TGTCTCCAAG ATATTCCACT CCAGCTTGTC GACAAAAC A
1401 ATCTCCAAGG GCTAACTGCA ATGCCTTCCT TTGATCCTAG TTCATCTTTG
1451 GAACAAGATG ATTCTGGCAA ATTTGCTGCT GCTGTTGATA ATTCAGCAGA
1501 ATTCGCAGTT CTTTATCGGC TTCAGGATGT TGTAGCAAAG TTGGATATGG
1551 GAACACGGAC TTGTATACGG GATAGCTTAT TCCGGTTGGC TGGTAGTGCA
1601 GCTCAGAGAC ATTACACTAG TGATACATCC CACAGTAACA AGAC AGCCA
1651 GGATGACCAG GAAGTCATTC CCAGAGAAGA ATCCAGATAT AGATATGCTG
1701 GGATGCCAGA TACAGAAG CA GTGACCAACC CCACAGACAG AACTGTGGCT
1751 CATTTGCTCT TTCATAGGCC TTTTGATATG TTGGCGGCAA AGCGAATGGA
1801 AGGACCAGAA TCACCCGCTT CTTCGAAGAT GGGAACTGAA GAAAAAGGGA
1851 ATTTTCCTAA ATGCAGCATA CGAGAGACTC ACTTAACTAA GCAGAAAGCT
1901 CAAAAGGAAG AAGGACCTGC AGATTCACTT GCTTTGGGGA ATGCACCCAA
1951 CTCTGGATCT AGTAGTACTG TTGGTGAGAG GGTTGTTGAA GCATCCCAAG
2001 GAAACAAAAG AAAATTGTGA AATTTAGAAG GTTGTTATTT CCATACTATA
2051 ACTCTATAAA TCGTTTCCAT GCCCTTTTGT ATACGTGCAT AGAGCTTGTA
2101 TACAGATTGT AACTAATACG CAGGTGTTGC TTTTGCTTTC AATCAGTTTA
2151 GGTTGCCGTG TTAGAGAGGA GCTTTGGGTA TTTCTGCAGA CTAGACAGCA
2201 TCTTTCTGCG TCTCTTGAAA CAATCTCCTG ACTGCTCCTT TCTTGTGAAG
2251 CTCTTATTCT TGTAATTAGA TTTTTTTTTT TTTGTTACTT TTCGAAAACC
2301 TCTTTTGTTA TACGTATCTC CATGACAACT ACATTTTGGA AAACGTGTAG
2351 TTTGCAATGT TTTTCCCCCA TTCGAAACCA GATTCAATCT CTTAATACAA
2401 TTGTAAGC
[0326] LNK2 polypeptide sequence (AT3G54500.2; SEQ ID NO: 11)
1 MSSWPDTSLT NATKVDQDLS ATELSKCLAE PVRYDSTRGE KTSELGKGPD
51 IFHSSDESKE QGDFDDYSWA NIGSFDDLDR MFSNDVPIFG DGSLSGGDEL
101 WSSSKDVSNS PKSLSSMLDS QDLGLDIRTE FEQQENQQFP LTGKANGLSS
151 QSVPSVRVTL KADQYREHKG QPSVEDQPYQ QNKMMKFSKM PGTSEARPFQ
201 ELYGQRI PFS NSAGKCVNQL APPQSSLMAV NLLSESEGSG TSHYSHMPNQ
251 YMANSAFGNL ANPYSSVPVI SAVQHPDVRN QLMHPSYN PA TATSVNMATD
301 ASARPSTMTP QEKLEKLRRR QQMQAMLAIQ RQQQQFSHQV PVADQSITQN
351 CLQDI PLQLV DKTNLQGLTA MPSFDPSSSL EQDDSGKFAA AVDNSAEFAV
401 LYRLQDWAK LDMGTRTCIR DSLFRLAGSA AQRHYTSDTS HSNKTSQDDQ
451 EVI PREESRY RYAGMPDTEA VTNPTDRTVA HLLFHRPFDM LAAKRMEGPE
501 SPASSKMGTE EKGNFPKCSI RETHLTKQKA QKEEGPADSL ALGNAPNSGS
551 SSTVGERWE ASQGNKRKL
[0327] LNK2 promoter sequence (SEQ ID NO: 12). The start codon (atg) is
double-underlined and in bold:
TTAATATTTTTATTTTATTTTGTATACAACATAATTTTTTTCTTGTACCAGTTTCTT
AGAAACATATTCTCTAGCGTCTTT CATGATTGTAGAT CACTAAAAT CTTGCGCATGTAAC
AAGTACAAATTTATCAAGTCAGCAATAACGGGTTTGTAG CACATTTCTATTTTTGATATA
TACACTAATTTGCTTTTGTCT CAGACTCACTCTATCTATGATCTATCACAAGCTAGCAAC
AATGTTTACTGCTTAATATGTGTCTAACGTAACTCGTGATCATTTCTGAAACAAGAGTAA
CCCCTACCAACAATTCGTTTTAATCTCGAAATACAAAGTACAAACACAAGATAAACAAAC
GCATAAACAAT CGAGGCACAAAG CCTATTAACAAGGTCTGAAAATTTTCAACCTAGT CAT
CAAGGACGAAAACGATTTCATTATAATTGAAAAATAAACACACTTATTAAAAAATATATA
TCAATTGCAACCATTTATATCCACTGTTTCGTTATGAACTGTTCAGGATAACGCATTAGT
TCCTTTTCAATAAACTGATCCAAGCAAATACTTTTGAAAAAGTGGATATCAATGAAAGCT
AAATTAGTTAAAACATATAAGATAAAAAT TGTGGTCGCTAT GAACTCAAACCCCACCAAA
TCTAAAAGTTGAACACT GGTTCCACTCTTT AAAAACATATTTACCCAATTGTGTGTCTC
TTCTTTTCTC GAACACTAATCCGATA AACATGAAAATATTAAAAAAAC GTCAACAAAAG
ACCACAGCCAGGGAAAGTCAAAATGAGCTGTCATGGAATCAAGTCGTGTTTACTCTCAGC
CACATGTTTAGATACGGCCTTCTCGTCTGACGTGGCAACCCGTTCTCTCTCAGCCACTCG
TTTGGCACGTGACCATTTCATACAAAAAAAAACTCTTTTTTCTTTTTTCCACTGTAACTC
CTTTCTCTTCCCATATCCTTTGAGCACGAAGGAGGATTCTGCTGAATCAAGGTTTTTCAAA
GCTTGTTGCTTTTTCAGTTTAATATTCTTTTATTTATCGTTTTTTCCACTTTATTATTGTG
TGTGGATTTACGTTATCCGATTTGTTGATCTTGTTGTTTTTTCCTGGATTTTTTTCGTTGT
GGAGCTGGCGATGTGTGGAGCAATCAGGGAGCTTGATTTTGGGTCTGTGATTCGATTTTGT
TTCTCCAGTCATGTTTGATTGGGAAGAAGAAGAG CTTACTAATATG
[0328] LNK3cONA, genomic and protein sequence accessible at AT3G12320:
LNK3 cDNA sequence (AT3G12320.1; SEQ ID NO: 13). The start codon
(atg) is double-underlined and in bold:
1 ACATTACAAC AAACACATTC GTCTTCTTCT CTCTCTCTTT CTCTTTGGTC
51 TTTTTTTTGC TTACTGTTGA AGAAAATTTA AACAAAGGCT TCTCTTGATT
101 TTTGAACCAA TCATCTTTAC TTCATCTGAG GGTTTCTGAT TTGGGTCTGA
151 TTCAAAACTC TCTCATCCGT TCACTACAAA GTTGATAGAT CGATCGATTG
201 ATTTTATG GA TTGTTATGCT GAAGAGCTTG TTGTGCCTAA TTATCAAGAA
251 TCATCATCAG AGACATACCC ATCTACTGGT ATGTGGGGTG GATGGAGCAT
301 GAGCTCCCCT GAAGCAGCTG AGAAATGTTT CGATTACGAT GGTTTCAATG
351 GAGAAGGAAT GATGTATAGT CAGATGAGTA TGAGGACTAG TGAAGAAGAA
401 GAAGAGTCTA AAAGAT CAAA GGCTTTCTAT GGTGCTTCTT CACTTCACGA
451 TTTCGAAGGC ATCGAACAGA TGGATGATAT GTTCTTAAGT TCAATTTTGG
501 AGGATGTTCC AGAGGATGAT GGAGATGTTC ACCGCGCGAC CAGTAGCAAT
551 AACAGTGTCG GTTCTTCTTC TATGTATGGT GGTGGTAGGG AAGTCCCTAT
601 GTTCCATTGT CATGACATGT CTTTCAAGGA GGAAGCTCCA TTTACAATCT
651 CGGATCTGTC TGAAGAGAAC ATGTTAGATT CAAACTATGG GGATGAACTG
701 TCTTCTGAAG AATTCGTGTT GCAGGATCTA CAAAGGGCTT CACAAAAGTT
751 GACTGATGAG ACACGCAAAT GTTTCCGGGA TACTTTTTAC CGACTTGCAA
801 GGAGCTCACA AGATAAATCT GATTCAGTCA GCCCCAACTC GGAAGAGCTG
851 CTTATGCAAA CGTCTAGATA TGATTATGGT GATGGAAACA GGTTTAGTAG
901 AGAGGAAGAG ATAGAATCTG AAAC GAATTC AAT CGATAGA GCTGTCGCAA
951 ACCTCACATT CAACAAAATG GAATCCAACA TAAGCAATTT TCCTCTGTCG
1001 GAAAGAGTAC AGTAGCTGCC GCTGATCAAG ATCAACCATT GGCGCCTCAT
1051 CATCTTCCTA TGAAGTTTTC TGTTACCATA TGTGTATAAA TGTGTGTATA
1101 TATAGTTGAC TTAATGTTGC AAGCTTCAGT TTTGATCTGT CAAAAGAATC
1151 TGGTCCCCTT TTTAATTCCT GCAGTATGCT TTCTACAAAC ACTACCTGAT
1201 GGCCTTGAGA CTTACTTT
[0329] LNK3 polypeptide sequence (AT3G12320.1; SEQ ID NO: 14):
1 MDCYAEELW PNYQESSSET YPSTGMWGGW SMSSPEAAEK CFDYDGFNGE
51 GMMYSQMSMR TSEEEEESKR SKAFYGASSL HDFEGIEQMD DMFLSSILED
101 VPEDDGDVHR ATSSNNSVGS SSMYGGGREV PMFHCHDMSF KEEAPFTISD
151 LSEENMLDSN YGDELSSEEF VLQDLQRASQ KLTDETRKCF RDTFYRLARS
201 SQDKSDSVSP NSEELLMQTS RYDYGDGNRF SREEEIESET NSIDRAVANL
251 TFNKMESNIS NFPLSERVQ
[0330] LNK4cDNA, genomic and protein sequence accessible at AT5G06980.
LNK4 cDNA sequence (AT5G06980.4; SEQ ID NO: 15). The start codon (atg) is
double-underlined and in bold:
1 GTGGACCAAT GAAAGAGTTG CTTTAGATGG AGGAGTAATC TAAGCCACAA
5 1 ATCTCGTTTG TGAATTCTAA GCCACTAACT AAAGTTCAAA CTCACGCGCT
1 0 1 CTCCACTTCC TCTCTTCAAC TTGCTTCTTT GTCTTCTCTC TCTTTCCTCC
1 5 1 TTCGCACTCA CAAATCTACA GAAGATAGAA GAAGATAGAC TCATAATCTT
2 0 1 TTGGATTTGG ATTTAGATCT GAT CATAAAG GTTAAAGTAT CATTC ATG GA
2 5 1 TCGTTATTCG AGGAGGAATT TAGAGGATCT TGTTGTGCCT AACTATCAAG
3 0 1 AGACATCAGA TTCGTACCCT TCTCCTGATA TGTGGGGTAC TGGATGGAGC
3 5 1 ATGAACTCTT CAGAAGCTGC TGAGAAATGT TTTGATTATG ATGTGATTCA
4 0 1 CAATGGTTTC AGTGGAGGAT TATACAGTCA GATGGAGATG GATATGGGAA
4 5 1 CTAGT GAACA AGTAGAAGAA GAAAC AAGA AGTTAAAGGC TAGTGGTTGT
5 0 1 TTTGACCGTT CGCTTCATGA TTTTGATGAA A CCAACA CA TGGATGACAT
5 5 1 GTTCTTTTCC ATTTTGGAGG ATGTTCCAGG GAAT GAGAAT TTTCTTTCTT
6 0 1 TCAAGGAGTC GGATAATAAC AACAGCTCCA GTTCCTCCTA TCTCGACACA
6 5 1 ACTGATGGCA GGGAAGTCCC TTTGTTCCAT TACAACTGGG AAACTTGTCA
7 0 1 AGATATGCCA CTTATGGAGG AGGATGCACC TAT GAATCTG TGTGAGGAGA
7 5 1 ACAAGGAGGA GGCATCTGCT GAAGAAGTTG TGTTGCAGGA TCTACAAAGG
8 0 1 GCTACAGAAA TGTTGACTGA TGATACCCGC AAGTGCTTCC GCGATACCTT
8 5 1 TTACCGGCTT GCAAAGAACT CACAACAGAA GTCAGACTCC AACTCGGATG
9 0 1 AGTTCCTTGA GGATAGAACC AGTTCTAATG ACTCATCACC ATCTATGACG
9 5 1 TTTTTGTCAG TAGGGAAACT GAATTTGAAA CCAAACTCAA TCGACAGAGC
1 0 0 1 CGTGGCCAAT CTCACATTCA ACAAGATGGA ATCCAACATG AGAAATAT GC
1 0 5 1 CTCCACCGAA GAGACTTTCT TCTGTTCAAG GATAAGAGAG TTTCATCATA
1 1 0 1 TTTGGTAATA CCATATGTGT ATATAATATA TATGTGTGTG TGTATGTGTG
1 1 5 1 CTTGGCTTGA CTTTTTCCAA GCTTCAGTTT TGATCTGTTT CATTAGACTC
1 2 0 1 TGACTCTGCT TCTGGATTTC CAATTTCTTA TGCTATATGT TATTTACCGA
1 2 5 1 GTGAACCTGT GAATGTACAT TACCCCATGT AGAATCTGTT GTTTCAATGT
1 3 0 1 ATCAAAAAAG ATATTCTTCA GAC
[0331] LNK4 polypeptide sequence (AT5G06980.4; SEQ ID NO: 16):
1 MDRYSRRNLE DLWPNYQET SDSYPS PDMW GTGWSMNS S E AAEKCFDYDV
5 1 IHNGFSGGLY SQMEMDMGTS EQVEEETKKL KASGCFDRSL HDFDEIQHMD
1 0 1 DMFFS I LEDV PGNENFLS F K ESDNNNSS S S SYLDTTDGRE VPLFHYNWET
1 5 1 CQDMPLMEED APMNLCEENK EEASAEEWL QDLQRATEML TDDTRKCFRD
2 0 1 TFYRLAKNSQ QKSDSNSDEF LEDRTS SNDS S PSMTFLSVG KLNLKPNS I D
2 5 1 PAVANLTFNK MESNMRNMPP PKRLS SVQG
[0332] All publications, patents, patent applications, internet sites, and accession
numbers/database sequences (including both polynucleotide and polypeptide
sequences) cited herein are hereby incorporated by reference in their entirety for all
purposes to the same extent as if each individual publication, patent, patent
application, internet site, or accession number/database sequence were specifically
and individually indicated to be so incorporated by reference.
WHAT IS CLAIMED IS:
1. A transgenic plant stably transformed with an isolated nucleic acid
encoding a polypeptide selected from the group consisting of:
(a) a polypeptide comprising the LNK1 amino acid sequence of SEQ ID NO:2;
(b) an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ
ID NO:2;
(c) an amino acid sequence comprising at least 50, 100, 150, 200, 250, 300,
350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of t e
amino acid sequence of SEQ ID NO:2;
(d) a polypeptide comprising the LNK2 amino acid sequence of SEQ ID NO:4;
(e) an amino acid sequence that is at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ
ID NO:4; and
(f) an amino acid sequence comprising at least 50, 100, 150, 200, 250, 300,
350, 400, 500, 600, 700, 800 or more contiguous amino acid residues of t e
amino acid sequence of SEQ ID NO:4.
2 . The transgenic plant of claim 1, wherein the nucleic acid sequence encodes
the LNK1 polypeptide of SEQ ID NO:2.
3 . The transgenic plant of claim 1, wherein the nucleic acid sequence encodes
the LNK2 polypeptide of SEQ ID NO:4.
4 . A transgenic plant stably transformed with an isolated nucleic acid
comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO: 1;
(b) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or
50 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:l or
t e complementary strand thereof;
(c) a nucleotide sequence comprising at least 100 consecutive nucleotides of
t e nucleotide sequence of SEQ ID NO:l or the complementary strand
thereof;
(d) the nucleotide sequence of SEQ ID NO: 3;
(e) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or
50 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:3 or
the complementary strand thereof;
(f) a nucleotide sequence comprising at least 100 consecutive nucleotides of
the nucleotide sequence of SEQ ID NO: 3 or the complementary strand
thereof;
(g) a nucleotide sequence having at least 95% sequence identity to the
nucleotide sequence of (a), (c), (d) or (f);
(h) a nucleotide sequence that hybridizes to the complete complement of the
nucleotide sequence of (a), (c), (d) or (f) under stringent hybridization
conditions; and
(i) a nucleotide sequence that differs from the nucleotide sequence of any of
(a), (c), (d) or (f)-(h) due to the degeneracy of the genetic code.
5 . The transgenic plant of claim 4, wherein the nucleic acid comprises at least
10, at least 15, at least 20, or at least 25 consecutive nucleotides of the nucleotide
sequence of SEQ ID NO: 1 or the complementary strand thereof.
6 . The transgenic plant of claim 4, wherein the nucleic acid sequence
comprises at least 10, at least 15, at least 20, or at least 25 consecutive nucleotides of the
nucleotide sequence of SEQ ID NO: 3 or the complementary strand thereof.
7 . The transgenic plant of any of claims 1-6, wherein the transgenic plant is
stably transformed with an expression cassette comprising the isolated nucleic acid
operably associated with a promoter.
8 . The transgenic plant of claim 7, wherein the promoter is a heterologous
promoter.
9 . The transgenic plant of any of claims 7-8, wherein the expression cassette
comprises a selectable marker.
10. An isolated nucleic acid selected from the group consisting of:
(a) a nucleic acid encoding a polypeptide comprising the LNKl amino acid
sequence of SEQ ID NO:2;
(b) a nucleic acid encoding a polypeptide having an amino acid sequence that
is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the amino acid sequence of SEQ ID NO:2;
(c) a nucleic acid encoding a polypeptide having an amino acid sequence
comprising at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700,
800 or more contiguous amino acid residues of the amino acid sequence of
SEQ ID NO:2;
(d) a nucleic acid encoding a polypeptide comprising the LNK2 amino acid
sequence of SEQ ID NO:4;
(e) a nucleic acid encoding a polypeptide having an amino acid sequence that
is at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
identical to the amino acid sequence of SEQ ID NO:4;
(f) a nucleic acid encoding a polypeptide comprising at least 50, 100, 150,
200, 250, 300, 350, 400, 500, 600, 700, 800 or more contiguous amino acid
residues of the amino acid sequence of SEQ ID NO:4;
(g) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or
50 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:l or
t e complementary strand thereof;
(h) a nucleotide sequence comprising at least 10, 15, 20, 25, 30, 35, 40, 45 or
50 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:3 or
t e complementary strand thereof;
(i) a nucleotide sequence comprising at least 100 consecutive nucleotides of
the nucleotide sequence of SEQ ID NO:l or the complementary strand
thereof;
(j) a nucleotide sequence comprising at least 100 consecutive nucleotides of
the nucleotide sequence of SEQ ID NO: 3 or the complementary strand
thereof;
(k) a nucleotide sequence having at least 95% sequence identity to the
nucleotide sequence of (a)- (i) or (j); and
(1) a nucleotide sequence that hybridizes to the complete complement of the
nucleotide sequence of (a)-(i) or (j) under stringent hybridization
conditions.
11. A method of modulating a circadian response of a plant, the method
comprising (a) stably transforming a plant cell with the isolated nucleic acid of claim 10.
12. A method of modulating the flowering time of a plant, the method
comprising (a) stably transforming a plant cell with the isolated nucleic acid of claim 10.
13. The method of claim 12 wherein the flowering time of the plant is
accelerated.
14. The method of claim 12 wherein the flowering time of the plant is delayed.
15. A method of modulating the biomass of a plant of a plant, the method
comprising (a) stably transforming a plant cell with the isolated nucleic acid of claim 10.
16. The method of claim 15 wherein the biomass of t e plant is increased.
17. The method of claim 15 wherein the biomass of t e plant is decreased.
18. The method of any of claims 11-17, which further comprises regenerating a
stably transformed plant from the stably transformed plant cell of (a); and expressing the
nucleic acid sequence in the plant.
19. An expression cassette comprising the isolated nucleic acid of claim 10.
20. The expression cassette of claim 19 wherein the nucleic acid is operably
associated with a promoter.
21. The expression cassette of claim 20, wherein the promoter is a
heterologous promoter.
22. The expression cassette of claims 19-21, wherein the expression cassette
comprises a selectable marker.
23. A plant comprising the expression cassette of any of claims 19-22.
24. The plant of any of claims 1-9 or 23, wherein the plant is a monocot.
25. The plant of any of claims 1-9 or 23, wherein the plant is a dicot.
26. The plant of any of claims 1-9 or 23-25 wherein the plant is sunflower,
wheat, maize, soybean, rice, sorghum, alfalfa or Arabidopsis.
27. A product harvested from the plant of any of claims 1-9 or 23-26.
28. A processed product produced from the harvested product of claim 27.
29. A crop comprising a plurality of the plant of any of claims 1-9 or 23-26.
30. A method of introducing a nucleic acid into a plant, plant part or plant cell,
the method comprising transforming the plant, plant part or plant cell with the expression
cassette of any of claims 19-22.
31. A stably transformed transgenic plant produced by the method of any of
claims 11-18.
32. Seed produced from the transgenic plant of any of claims 1-9 or 23-26,
wherein t e seed comprises the isolated nucleic acid stably incorporated in its genome.

































